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Abstract
The aims of the study reported in this thesis were to develop and utilise mass spectrometry 
imaging techniques (MALDI-MSI), in combination with conventional proteomic methodologies, 
to investigate protein induction in vascular-targeted strategies.
Proteins thought to be involved in tumourigenesis and drug treatment resistance were 
observed along with the responses from proteins identified via the techniques used, in this 
global analysis study. MALDI-MSI, LC-ESI-MS/MS, LC-MALDI-MS/MS with iTRAQ labelling and 
immunohistochemistry intended to provide cross validation of the effects post administration 
of vascular disrupting agent CA-4-P. Two mouse fibrosarcoma models (expressing VEGF120/ 
VEGF188 isoforms only) following treatment with the tubulin-binding tumour vascular 
disrupting agent, combretastatin A-4-phosphate (CA-4-P) have been studied.
The gross haemorrhagic pharmacological response elicited by CA-4-P was visible by MALDI-MSI 
throughout the fibrosarcoma 120 time course. The latter encouraged the prospect that other 
proteins could potentially be observed induced via a dose response relationship. The 
haemoglobin time course using the resistant 188 tumour model gave quite different results to 
those previously seen in the MALDI-MSI of the fibrosarcoma 120 data set. The first indication 
of the 'switch back to tissue viability' concept was revealed.
The experimental work using LC-ESI-MS/MS revealed many proteins connected with necrosis, 
apoptosis, cell structural reorganisation, polymerisation, tumour survival and stress induced 
molecular chaperones. The inverse correlation of structural proteins, haemoglobin and heat 
shock molecular chaperones gave the required validation and identification to relate these 
responses to those seen in MALDI-MSI. The relationship pathways generated by using STRING
9.0 proteomic network software gave an invaluable insight into the activity of the active 
tumour milieu and provided a means of linking the identified proteins to their functional 
partners. Protein-protein interactions could be observed to help interpretation of the MALDI- 
MSI, LC-ESI-MS/MS and iTRAQ LC-ESI-MS/MS response graphs.
Overall, the dose relationships observed in the iTRAQ data by the proteins involved in 
haemorrhaging, structural remodelling, were in good agreement with the other techniques 
employed here.
It could be said that MALDI-MSI could potentially forge a place in the workflow of clinical 
diagnostics. Targeted approaches for the observation of disease biomarkers could be visualised 
using MALDI-MSI and serve as a complimentary technique to standard clinical imaging. A 
novel method reported here using a multi-peptide recombinant standard could prove an 
important diagnostic tool for the analysis of patient biopsies and tissue micro-arrays. The 
exciting prospect is the diversity of a multi-peptide recombinant standard, an artificial 
construct that can be engineered to include any prospective biomarkers for both research and 
diagnostic screening applications.
Table of Contents
Table of Contents.......................................................................................................................................1
List of Figures.............................................................................................................................................. 6
Chapter 1 ................................................................................................................................................ 6
Chapter 2 .................................................................................................................  7
Chapter 3 ................................................................................................................................................ 8
Chapter 4 .............................................................................................................................................. 10
Chapter 5 .............................................................................................................................................. 11
Abbreviations........................................................................................................................................... 13
Chapter 1 ...................................................................................................................................................17
General Introduction...............................................................................................................................17
1.1 Cancer............................................................................................................................................. 18
1.1.1. Statistical information, incidence/ prevalence............................................................... 18
1.1.2 Tumour types........................................................................................................................ 22
1.1.3 Overview of current anti-cancer therapies.......................................................................23
1.1.4 Vascular targeted strategies................................................................................................ 30
1.1.5 Vascular disrupting agents.................................................................................................. 33
1.1.6 Biomarker Discovery............................................................................................................ 39
1.1.7 Considering Vascular disrupting agents for anti-cancer therapeutics..........................41
1.2 The Role of Mass Spectrometry in Biomarker Discovery....................................................... 41
1.2.1. Overview of mass spectrometry as an analytical tool.................................................... 41
1.2.2. Basic principles of mass spectrometry............................................................................. 42
1.2.3. Ionisation techniques and Mass analysers.......................................................................46
1.3 Mass spectrometry instrumentation........................................................................................ 49
1.3.1 LC-MS.................................................................................................................................... 49
1.3.2. Electrospray ionisation (ESI)............................................................................................... 51
1.3.3. Matrix assisited laser desorption ionisation (MALDI)................................  52
1.3.4. Quadrupole Time of flight mass spectrometry (QqToF)................................................54
1.3.5. Synapt HDMS -  travelling wave ion mobility separation............................................... 56
1.3.6. MALDI-mass spectrometry imaging.................................................................................. 59
1.3.7. Quantitative Proteomics............................   60
1.3.8. Aims of the study.................................................................................................................. 63
References...............................................................................................   66
2.1 Introduction.................................................................................................................................75
2.2 Materials and Samples................................................................................................................ 76
2.2.1 Chemicals and Materials..................................................................................................... 76
2.2.2 Tissue samples.......................................................................................................................77
2.2.3. Experimental groups...........................................................................................................77
2.2.4 Tissue preparation................................................................................................................ 77
2.2.5 In situ tissue digestion and trypsin deposition................................................................. 77
2.3Methods and instrumentation.................................................................................................... 78
2.3.1 Matrix deposition................................................................................................................. 78
2.3.2 Instrumentation....................................................................................................................78
2.3.3 Haematoxylin and eosin staining....................................................................................... 79
2.3.4 Data pre-processing using SpecAlign and Marker View software................................ 79
2.3.5 Statistical analysis..................................................................................................................79
2.3.6 Data pre-processing usingWaters MassLynx™ Software and MATLAB®...................... 79
2.4 Results and Discussion.............................................................................................................. 80
2.4.1 Initial MALDI profiling and imaging of in situ tissue tryptic digests in mouse 
fibrosarcoma 120 models.............................................................................................................. 80
2.4.2 Haematoxylin and Eosin staining of fibrosarcoma 120 tissue........................................83
2.4.3 Initial imaging of proteins according to theoretical digests using MALDI-MSI ......86
2.4.4 Principle component analysis-discriminant analysis (PCA-DA).................................. 88
2.4.5. Employment of Ion Mobility MALDI-Mass Spectrometry to study//? situ tryptic 
digestion in fibrosarcoma 120 models........................................................................................ 91
2.4.6 Rho GTPases: a target to help understand resistance to CA-4-P?................................ 99
2.4.7.Statistical analysis of mouse fibrosarcoma 120 tumour tissue using MATLAB® 107
2.4.8 Region of interest (ROI) study for the analysis of tumour rim and necrotic regions 
within fibrosarcoma 120 tissue................................................................................................... 112
2.4.9 Concluding Remarks........................................................................................................... 118
References.......................................................................................................................................... 120
3.1 Introduction................................................................................................................................. 124
3.2 Materials and Samples...............................................................................................................126
3.2.1 Chemicals and Materials....................................................................................................126
3.2.2 Tissue samples..................................................................................................................... 126
3.2.3. Experimental groups......................................................................................................... 126
3.2.4 Tissue preparation...............................................................................................................126
3.2.5 In situ tissue digestion and trypsin deposition............................................................... 127
3.3 Methods and instrumentation..................................................................................................127
2
3.3.1 Matrix deposition............................................................................................................... 127
3.3.2 Instrumentation..................................................................................................................127
3.3.3 Haematoxylin and eosin staining.....................................................................................128
3.3.4 Statistical analysis............................................................................................................... 129
3.3.5 Data pre-processing using Waters MassLynx™ Software and MATLAB®...................129
3.3.6Protein network analysis.................................................................................................... 129
3.3.7 Immunohistochemical staining........................................................................................ 129
3.3.8 Protein precipitation and digestion................................................................................ 130
3.3.9 Protein estimation -  BCA assay....................................................................................... 131
3.4 Results and Discussion...........................................................................................................132
3.4.1 MALDI-MSI of fibrosarcoma 188 CA-4-P treated tumour tissue................................ 132
3.4.2 Statistical analysis of mouse fibrosarcoma 188 tumour tissue using MATLAB® 150
3.4.3 Label free LC-ESI -MS/MS for the identification of proteins in a CA-4-P treated 
fibrosarcoma 188 mouse model............................................................................................... 159
3.4.4 Protein relationship mapping of fibrosarcoma 188 LC-ESI-MS/MS data using String
9.0................................................................................................................................................... 182
3.4.5 Concluding remarks........................................................................................................... 186
References......................................................................................................................................... 188
4.1 Introduction................................................................................................................................ 194
4.2 Materials and Samples..............................................................................................................195
4.2.1 Chemicals and Materials...................................................................................................195
4.2.2 Tissue samples....................................................................................................................195
4.2.3. Experimental groups..................................................................................................... 196
4.2.4 Tissue preparation............................................................................................................. 196
4.2.5 Tissue homogenisation and precipitation of protein................................................... 196
4.2.6 Protein Digestion................................................................................................................197
4.2.7 Preparation of samples for column loading.................................................................. 197
4.2.8 C18 bond-elute preparation.............................................................................................197
4.2.9 Sample re-suspension.......................................................................................................198
4.2.10 iTRAQ labelling.................................................................................................................198
4.2.11 SCX..................................................................................................................................... 199
4.3Methods and instrumentation................................................................................................. 199
4.3.1 Sample fractionation and matrix deposition................................................................. 199
4.3.2 Instrumentation................................................................................................................ 199
4.3.3 Data pre-processing..........................................................................................................200
4.3.4 Statistical analysis.............................................................................................................. 201
3
4.3.5 Protein network analysis................................................................................................... 201
4.4 Results and discussion - Fibrosarcoma 120............................................................................ 202
4.4.1. HPLC UV profiles of fibrosarcoma 120 tumour fractions............................................ 202
4.4.2 Frequency of unique peptides identified........................................................................203
4.4.3. Analysis using excel...........................................................................................................203
4.4.4. Analysis with Scaffold Q + .................................................................................................207
4.4.5 Protein relationship mapping of fibrosarcoma 120 data using STRING 9.0.............. 218
4.5 Results and discussion - Fibrosarcoma 188............................................................................ 224
4.5.1. HPLC UV profiles of fibrosarcoma 188 tumour fractions............................................ 224
4.5.2 Frequency of unique peptides identified........................................................................225
4.5.3. Analysis using excel........................................................................................................... 225
4.5.4. Analysis with Scaffold Q + ................................................................................................. 231
4.5.5 Protein relationship mapping of Fibrosarcoma 188 data using STRING 9 .0 ............. 242
4.5.6 Protein dose response relationship analysis using String 9 .0 ......................................247
4.5.7 Relation of MALDI-MSI to iTRAQ proteomic response.................................................256
4.5.8 Concluding Remarks........................................................................................................... 259
References..........................................................................................................................................260
5.1 Introduction................................................................................................................................. 266
5.2 Materials and Methods............................................................................................................. 267
5.2.1 Peptide sequences chosen for a recombinant protein standard based on MALDI-MSI 
and conventional proteomic analysis of fibrosarcoma 120 and 188 tissue.........................267
5.2.2 Bacterial culture..................................................................................................................268
5.2.3 Plasmid preparation........................................................................................................... 269
5.2.4 E. coli- transformation........................................................................................................269
5.2.5 Protein Purification............................................................................................................ 269
5.4.6 Digestion...............................................................................................................................270
5.4.7 MALDI-MSI - Chemicals and Materials............................................................................ 271
5.4.8 Methods and instrumentation..........................................................................................272
5.3 Results and Discussion.............................................................................................................. 273
5.3.1 MALDI-IMS-MS Peptide mass fingerprint of the digested recombinant DNA construct 
.............................................................................................................................   273
5.3.2 MALDI-IMS-MSI of fibrosarcoma 188 tumour tissue, Control and post CA-4-P 
treatm ent.......................................................................................................................................275
5.3.3 Recombinant MALDI-IMS-MSI visualised through HDI 1.1 software..........................280
5.3.4 Cross validation of Plectin and HSP-90 response in fibrosarcoma 188 tissue 
employing a multimodal proteomic strategy............................................................................292
4
5.4 Concluding Remarks................................................................................................................295
References..........................................................................................................................................297
Appendices.............................................................................................................................................304
Appendix 1: Publications................................................................................................................. 305
Appendix 2: Oral presentations..................................................................................................... 306
Appendix 3: Poster presentations..................................................................................................307
5
List of Figures
Chapter 1
Figure 1.1: Percentage of all deaths due to cancer in the different regions of the world (WHO)
Regions of the World............................................................................................................................... 19
Figure 1. 2: Cancer incidence worldwide map.....................................................................................20
Figure 1.3 : The 20 Most Common Causes of Cancer Death, UK..................................................... 21
Figure 1.4 : Diagrammatical representation of the possible routes of cell division..................... 22
Figure 1. 5 : Proposal of adding CSC specific predictive tests to therapy regimes for potential
increase in tumour control probability.................................................................................................26
Figure 1. 6 : Images to illustrate the substandard tumour vasculature.......................................... 33
Figure 1. 7 : Chemical structures of vascular disrupting agents....................................................... 34
Figure 1. 8 : Proposed mechanism of action of Combretastatin A-4-3-0-phosphate...................35
Figure 1. 9 : Fluorescent staining of Human umbilical vein endothelial cells, Control and post
CA4P administration................................................................................................................................ 36
Figure 1 .10 : CA-4-P and its effect on hypoxia induction and vascular shutdown........................37
Figure 1 .1 1 : Exploitation of tumour vasculature by antiangiogenic treatment and vascular
disrupting agents......................................................................................................................................37
Figure 1.12 : Therapeutic targeting of the hallmarks of cancer...................................................... 40
Figure 1 .13:The cells of the tumour microenvironment...................................................................40
Figure 1 .14 : Basic principles of a mass spectrometer...................................................................... 43
Figure 1.15 : Basic ionisation techniques............................................................................................ 46
Figure 1.16 : Mass analysers used in mass spectrometers...............................................................47
Figure 1.17 : Protein identification methods......................................................................................48
Figure 1.18 : Schematic representation of a liquid chromatography mass spectrometer.........50
Figure 1.19 : Schematic of Electrospray ionisation............................................................................ 51
Figure 1. 20 : Ionisation using MALDI....................................................................................................52
Figure 1. 21: Diagrammatical representation of a tandem QqTOF mass spectrometer........... 55
Figure 1. 22 : Schematic representation of a ToF modulator............................................................56
Figure 1. 23 : SYNAPT™ G2 HDMS system............................................................................................57
Figure 1. 24 : Stacked ring ion guide.....................................................................................................57
Figure 1. 25 : Travelling wave ion guide- schematic representation................................................58
Figure 1. 26 : MALDI-MSI workflow diagram...................................................................................... 60
Figure 1. 27 :The concept of area peptide measurement coupled with a specific time
domain,visualisedthrough Progenesis LC- MS software....................................................................61
Figure 1. 28 : Simple workflow using Isobaric Tags for Relative and Absolute Quantitation
(iTRAQ).......................................................................................................................................................62
Figure 1. 29 : VEGF isoform expression and exon structure..............................................................64
6
Chapter 2
Figure 2.1: Representative peptide mass fingerprint (PMF) arising from an on-tissue digest of a
VEGF120 tumour 24 h after dosing with 100 mg/kg i.p, CA-4-P...................................................... 80
Figure 2. 2: Peptide mass fingerprints obtained from the fibrosarcom 120 tumour tissue
sections treated with saline or 100 mg/kg i.p..................................................................................... 81
Figure 2. 3: MALDI-MS images for the distribution of m/z 1274throughout a fibrosarcoma 120
timecourse................................................................................................................................................ 82
Figure 2 .4  : Haematoxylin and eosin stained sections...................................................................... 84
Figure 2. 5: Higher magnification images of the H&E staining of the tumour rim in the VEGF120
tumour sections....................................................................................................................................... 85
Figure 2. 6: MALDI-MSI of peptides from tumour 5:1 (24hrs CA-4-P).............................................86
Figure 2. 7: PCA-DA of fibrosarcoma 120 tumour in situ tryptic digests.........................................88
Figure 2. 8: Representative peptide mass fingerprint (PMF) arising from an on-tissue digest of a
VEGF120 tumour 6 h after dosing with 100 mg/kg i.p, CA-4-P.........................................................92
Figure 2. 9: IMS-MS/MS data obtained from the peak observed in Figure 2.8 at m/z 1819....... 93
Figure 2 .10  a: A Drift scope plot of a tumour section 24 h post CA-4-P showing the ion mobility
separation as a function of drift time................................................................................................... 94
Figure 2.11: The distribution of two known peptides in tumour 5_6, i.e. a tumour 24 h after
treatment with CA-4-P........................................................................................................................... 97
Figure 2.12: Overlaid MALDI MSI images showing differing spatial distribution and co­
registration of peptides...........................................................................................................................98
Figure 2.13: Major Functions of Rho GTPases in vitro.................................................................... 100
Figure 2.14: Peptide mass fingerprints obtained from the fibrosarcom 120 tumour tissue
30min post CA-4-P(100 mg/kg i.p.) with peak of interst at m/z 844......................   101
Figure 2.15: IMS-MS/MS data obtained from the peak observed in Figure 2.14 at m/z 844.5.
 102
Figure 2.16: Mascot score histogram detailing the results in the identification of N-chimaerin.
 102
Figure 2.17: Zoomed in Driftscope plot showing ion of interest, arrow indicating the peak
originally selected.................................................................................................................................. 103
Figure 2.18: PMF's throughout a fibrosarcoma 120 time course with putative peptide of 
interest N-chimaerin visible in early time points .Control (saline), 0.5 h post CA-4-P, 6 h post
CA-4-P and 24 h postCA-4-P................................................................................................................. 104
Figure 2.19: MALDI-MSI throughout a fibrosarcoma 120 time course of the putative peptide
Rho GTPase activating protein 2 m/z 844 (183-189, RLTSLVR).......................................................105
Figure 2. 20 : PCA of fibrosarcoma 120 tumour tissue in situ tryptic digests............................... 108
Figure 2. 21: Partial least squares discriminant analysis (PLSDA) regression vector plot 
comparing MALDI "on-tissue" digest data from samples of fibrosarcoma 120 Control/Saline 
and 30 min post combretastatin-4-phosphate (CA-4-P) (a vascular disrupting agent), treatment
tumour samples......................................................................................................................................110
Figure 2. 22: HDI software displaying MALDI-MSI from a fibrosarcoma tumour section 24h post
CA-4-P.......................................................................................................................................................113
Figure 2. 23: PLSDA regression vector plot showing fibrosarcoma 120 Control necrotic regions 
versus fibrosarcoma 120 necrotic regions post 24h CA-4-P............................................................114
7
Figure 2. 24: PLSDA regression vector plot showing fibrosarcoma 120 Control rim regions
versus spectra from rim regions post 24h CA-4-P............................................................................ 115
Figure 2.25: VIP scores for the Control fibrosarcoma 120 tumour rim regions...........................116
Figure 2.26: VIP scores for the 24h post CA-4-P fibrosarcoma 120 tumour rim regions........... 117
Chapter 3
Figure 3.1: Diagrammatical cross section of the region present at the end of growing long
bones showing the areas involved in epiphysis and metaphysis................................................... 124
Figure 3. 2: Screen shot of protein delocalisation in MALDI-MSI, visualised using BioMap
imaging software................................................................................................................................... 133
Figure 3. 3: Screen shot of an on tissue tryptic digest using MALDI-MSI, visualised using BioMap
imaging software................................................................................................................................... 135
Figure 3.4: PMF's of a fibrosarcoma 188 time course study. Spectra shown are Control, 0.5h,
6h, 24h and 72h post CA-4-P treatment.............................................................................................137
Figure 3. 5: Zoomed in region of fibrosarcoma 188 PMF's. The blue arrows indicate the gross 
differences visible in the 24h and 72h time points, m/z 1416 being Hb and an unknown species
at m/z 1577............................................................................................................................................. 138
Figure 3.6: Comparison control tissue peptide mass fingerprints from fibrosarcoma 120 and
188 on tissue digests............................................................................................................................. 139
Figure 3. 7: MALDI-MSI multi image of a fibrosarcoma 188 time course..................................... 141
Figure 3. 8: Fibrosarcoma 188 MALDI-MSI multi image showing spatial distribution of HSP-90.
MALDI images showing spatial distribution of HSP-90 alpha at m/z 1168................................... 143
Figure 3. 9: Immunohistochemical staining of a fibrosarcoma 188 time course.........................144
Figure 3.10: Immunohistochemical staining of HSP-90 in Fibrosarcoma 188 tissue..................145
Figure 3.11: SYNAPT G2 MALDI imaging plate indicating tissue image regions..........................147
Figure 3 .1 2 :40pm MALDI-MSI of 24h post CA-4-P fibrosarcoma 188 tumour tissue   148
Figure 3 .1 3 :40pm MALDI-MSI of m/z 944.5 in fibrosarcoma 188 tumour tissue..................... 148
Figure 3 .1 4 :40pm MALDI-MSI of a on tissue trytic digest and corresponding H and E
histological section................................................................................................................................ 149
Figure 3.15: 30 pm MALDI-MSI of a Control fibrosarcoma 188 tumour on tissue tryptic digest
.................................................................................................................................................................. 149
Figure 3.16: PCA score plot of fibrosarcoma 188 tumour tissue in situ tryptic digests.............150
Figure 3.17: PCA loadings plot fibrosarcoma 188 tumour tissue in situ tryptic digests............ 151
Figure 3.18: Partial least squares discriminant analysis (PLSDA) regression vector plot 
comparing MALDI "on-tissue" digest data from samples of fibrosarcoma 188 Control and 0.5h
post combretastatin-4-phosphate (CA-4-P), treatment tumour samples....................................152
Figure 3.19: Partial least squares discriminant analysis (PLSDA) regression vector plot for the
comparison of Control and 6h post CA-4-P fibrosarcoma 188 on tissue digests.........................153
Figure 3. 20: Partial least squares discriminant analysis (PLSDA) regression vector plot for the
comparison of Control and 24h post CA-4-P fibrosarcoma 188 on tissue digests...................... 154
Figure 3. 21: Partial least squares discriminant analysis (PLSDA) regression vector plot for the
comparison of Control and 72h post CA-4-P fibrosarcoma 188 on tissue digests.......................155
Figure 3. 22: VIP scores for the 0.5h post CA-4-P fibrosarcoma 188 on tissue digest................ 156
8
Figure 3. 23: VIP scores for the 6h post CA-4-P fibrosarcoma 188 on tissue digest....................156
Figure 3. 24: VIP scores for the 24h post CA-4-P fibrosarcoma 188 on tissue digest................. 157
Figure 3. 25: VIP scores for the 72h post CA-4-P fibrosarcoma 188 on tissue digest................. 157
Figure 3. 26: Scaffold proteomic tool software used for LC-ESI-MS/MS analysis....................... 160
Figure 3. 27: Graph A - Fibrosarcoma 188 treatment time course results, exported from
Scaffold 3.................................................................................................................................................161
Figure 3. 28: Graph B - Fibrosarcoma 188 treatment time course results, exported from
Scaffold 3.................................................................................................................................................162
Figure 3. 29: Graph C - Fibrosarcoma 188 treatment time course results, exported from
Scaffold 3.......................................................  163
Figure 3. 30: Graph D - Fibrosarcoma 188 treatment time course results, exported from
Scaffold 3.................................................................................................................................................164
Figure 3. 31: Graph E - Fibrosarcoma 188 treatment time course results, exported from
Scaffold 3.................................................................................................................................................165
Figure 3. 32: Graph F - Fibrosarcoma 188 treatment time course results, exported from
Scaffold 3.................................................................................................................................................166
Figure 3. 33: Graph G - Fibrosarcoma 188 treatment time course results, exported from
Scaffold 3.................................................................................................................................................167
Figure 3. 34: Fibrosarcoma 188 time course results post CA-4-P treatment using LC-ESI-MS/MS.
 168
Figure 3. 35: MS/MS spectrum and normalised intensity graph of Alpha-2-macroglobulin in
fibrosarcoma 188 LC-ESI-MS/MS results............................................................................................. 170
Figure 3. 36: Immunohistochemical staining of macrophage cell surface marker F4/80 using
fibrosarcoma 188 tissue lOx................................................................................................................ 172
Figure 3. 37: MS/MS spectrum and normalised intensity graph of Plectin in fibrosarcoma 188 
LC-ESI-MS/MS results. Insert displays the normalised spectral counts for Plectin throughout the
time course post CA-4-P........................................................................................................................174
Figure 3. 38: Fibrosarcoma 188 MALDI-MSI multi image showing spatial distribution of Plectin.
MALDI images showing spatial distribution of Plectin at m/z 977.................................................174
Figure 3. 39: Immunohistochemical staining of Plectin in Fibrosarcoma 188 tissue post CA-4-P
treatment................................................................................................................................................ 175
Figure 3.40: Optical scans of anti-Plectin and HSP-90 Immunohistochemical staining in
fibrosarcoma 188 serial sections, 72h post CA-4-P treatm ent...................................................... 177
Figure 3.41: Example MS/MS spectrum and normalised intensity graph of IQGAP1 in
fibrosarcoma 188 LC-ESI-MS/MS results............................................................................................ 178
Figure 3.42: Example MS/MS spectrum and normalised intensity graph of Tenascin C in
fibrosarcoma 188 LC-ESI-MS/MS results............................................................................................ 179
Figure 3.43: Example MS/MS spectrum and normalised intensity graph of Alpha-enolase in
fibrosarcoma 188 LC-ESI-MS/MS results............................................................................................ 180
Figure 3.44: Example MS/MS spectrum and normalised intensity graph of Transforming 
growth factor-beta-induced protein ig-h3 (Tgfbi) in fibrosarcoma 188 LC-ESI-MS/MS results.
 181
Figure 3.45: LC-ESI-MS/MS proteins of interest from fibrosarcoma 188, visualised through
proteomic pathway software STRING 9.0.......................................................................................... 182
Figure 3.46: Proteomic network from LC-ESI-MS/MS fibrosarcoma 188 data............................ 184
9
Chapter 4
Figure 4 .1: The principles of multiplex tagging chemistry............................................................ 194
Figure 4.2: UV profiles from the fibrosarcoma 120 fractions after SCX...................................... 202
Figure 4. 3: Frequency of detection of unique peptides by LC-MALDI-MS/MS......................... 203
Figure 4 .4 : iTRAQ results from fibrosarcoma 120 fixed filtered search......................................204
Figure 4. 5: iTRAQ ratio response relative to the control (113), normalised to an average of 1.
................................................................................   205
Figure 4. 6: Scaffold proteomic software used for iTRAQ analysis................................................ 208
Figure 4 .7: Scaffold proteomic software with the employment of 'Q+' function for iTRAQ ratio
analysis....................................................................................................................................................209
Figure 4. 8: iTRAQ fold change ratio using fibrosarcoma 120 tumour digest samples.............. 210
Figure 4. 9: Vimentin peptides identified, response bar graph and related MS/MS spectrum
from iTRAQ LC-MALDI-MS/MS Fibrosarcoma 120 tissue................................................................ 212
Figure 4.10: Haemoglobin subunit beta-1 peptides identified, response bar graph and related
MS/MS spectrum from iTRAQ LC-MALDI-MS/MS Fibrosarcoma 120 tissue................................ 213
Figure 4.11: Peroxiredoxin-1 (Macrophage 23kDa stress protein) peptides identified, response 
bar graph and related MS/MS spectrum from iTRAQ LC-MALDI-MS/MS Fibrosarcoma 120
tissue......................................................................................................  214
Figure 4.12: Tubulin beta-5 chain peptides identified, response bar graph and related MS/MS
spectrum from iTRAQ LC-MALDI-MS/MS Fibrosarcoma 120 tissue.............................................. 215
Figure 4 .13: Annexin A5 peptides identified, response bar graph and related MS/MS spectrum
from iTRAQ LC-MALDI-MS/MS Fibrosarcoma 120 tissue................................................................ 216
Figure 4.14: Keratin -1 (type II skeletal 1) peptides identified, response bar graph and related
MS/MS spectrum from iTRAQ LC-MALDI-MS/MS Fibrosarcoma 120 tissue................................ 217
Figure 4.15: Fixed modification search showing proteins from iTRAQ using Fibrosarcoma 120
tumours, visualised by STRING 9.0 (Confidence view).....................................................................219
Figure 4.16: Fixed modification search of iTRAQ fibrosarcoma 120 proteomic data, complied
using STRING 9.0, evidence view.........................................................................................................220
Figure 4.17: Zoomed in region of a fixed modification search, iTRAQ fibrosarcoma 120 samples.
 221
Figure 4.18: Zoomed in region of a fixed modification search, iTRAQ fibrosarcoma 120 samples.
 222
Figure 4.19: UV profiles from the fibrosarcoma 188 fractions after SCX..................................... 224
Figure 4. 20: Frequency of detection of unique peptides by LC-MALDI-MS/MS........................225
Figure 4. 21: iTRAQ results from fibrosarcoma 188 fixed filtered search.................................... 226
Figure 4. 22: a iTRAQ ratio response relative to the control (113), normalised to an average of 1.
..........................................................................................................................................................................227
Figure 4. 23: Scaffold proteomic software used for iTRAQ analysis.............................................232
Figure 4. 24: Scaffold proteomic software with the employment of 'Q+' function for iTRAQ
ratio analysis........................................................................................................................................... 233
Figure 4. 25: iTRAQ fold change ratio using fibrosarcoma 188 tumour digest samples............ 234
Figure 4. 26: Vimentin peptides identified, response bar graph and related MS/MS spectrum
from iTRAQ LC-MALDI-MS/MS Fibrosarcoma 188 tissue.................................................................237
Figure 4. 27: Haemoglobin subunit beta-1 peptides identified, response bar graph and related 
MS/MS spectrum from iTRAQ LC-MALDI-MS/MS Fibrosarcoma 188 tissue  .................... 238
10
Figure 4. 28: Pyruvate kinase isozymes M 1/M 2 peptides identified, response bar graph and
related MS/MS spectrum from iTRAQ LC-MALDI-MS/MS Fibrosarcoma 188 tissue.................. 239
Figure 4. 29: Tenascin peptides identified, response bar graph and related MS/MS spectrum
from iTRAQ LC-MALDI-MS/MS Fibrosarcoma 188 tissue................................................................ 240
Figure 4. 30: Fibronectin peptides identified, response bar graph and related MS/MS spectrum
from iTRAQ LC-MALDI-MS/MS Fibrosarcoma 188 tissue................................................................ 241
Figure 4. 31: iTRAQ Fixed modification search using Fibrosarcoma 188 tumours, visualised by
STRING 9.0 (Confidence view)............................................................................................................. 243
Figure 4. 32: iTRAQ Fixed modification search using Fibrosarcoma 188 tumours, visualised by
STRING 9.0 (Evidence view)..................................................................................................................244
Figure 4. 33: Zoomed in region of a fixed modification search, iTRAQ fibrosarcoma 188 samples,
visualised through STRING 9.0.............................................................................................................245
Figure 4. 34: iTRAQ fibrosarcoma 188 zoomed in region of a fixed modification search,
visualised through STRING 9.0.............................................................................................................246
Figure 4. 35: iTRAQ fibrosarcoma 188 zoomed in region of a fixed modification search,
visualised through STRING 9.0.............................................................................................................247
Figure 4. 36: iTRAQ proteomic response results using a Fibrosarcoma 120 treatment
timecourse.............................................................................................................................................. 248
Figure 4. 37: Fibrosarcoma 120 proteomic response using String 9.0.......................................... 250
Figure 4. 38: iTRAQ combinations of fibrosarcoma 120 increased and decreased proteins.... 251 
Figure 4. 39: iTRAQ proteomic response results using a Fibrosarcoma 188 treatment time
course...................................................................................................................................................... 252
Figure 4.40: iTRAQ proteomic response results using a 24h post CA-4-P Fibrosarcoma 188
treatment................................................................................................................................................ 253
Figure 4.41: iTRAQ proteomic response results using a 0.5h post CA-4-P Fibrosarcoma 188
treatment................................................................................................................................................ 254
Figure 4.42: iTRAQ combinations of fibrosarcoma 188 increased and decreased proteins. ...255 
Figure 4.43: Bar graph showing protein response relative to the control (113) normalised to an
average of 1, using fibrosarcoma 188 tissue..................................................................................... 256
Figure 4.44: MALDI-MSI multiple Fibrosarcoma 188 sample on tissue digest of Plectin at m/z
977............................................................................................................................................................257
Figure 4.45: MALDI-MSI multiple Fibrosarcoma 188 sample on tissue digest of Hb subunit 
alpha at m/z 1416.................................................................................................................................. 258
Chapter 5
Figure 5.1: pETBIue-1 vector and sequence used for the synthesis of the recombinant protein
standard.................................................................................................................................................. 268
Figure 5. 2: The final sequence of the recombinant standard........................................................ 268
Figure 5. 3: PMF of a novel recombinant standard for MALDI-IMS-MSI validation.................... 274
Figure 5.4: MALDI-MSI of on tissue tryptic digests and digested recombinant standard in 72h
treated tissue..........................................................................................................................................275
Figure 5. 5: MALDI-MS images for the distribution peptides in fibrosarcoma 188 72h tissue,
employing a DNA artificial construct for image validation..............................................................276
Figure 5. 6: MALDI-MS images displaying peptides distribution in fibrosarcoma 188 6h treated 
tissue, employing a DNA artificial construct for image validation. The spatial distribution of 
peptides; Actin (m/z 1198) with arrow indicating position of the spotted recombinant standard,
11
Histone HB (m/z 1032)showing the absence of the standard and CHCA peak at 1066 to show
inverse image correlation.....................................................................................................................277
Figure 5. 7: MALDI-MS images for the distribution peptides in fibrosarcoma 188 Control tissue,
employing a DNA artificial construct for image validation............................................................. 278
Figure 5. 8: HDI visualisation of Actin at m/z 1198.7. Arrow indicates the ion of interest
separated by drift time and yellow square denotes the ROI for exportation..............................281
Figure 5. 9: HDI visualisation of m/z 1198.6 to display the differentiation in tissue and standard
image due to separation in drift time compared to m/z 1198.7....................................................283
Figure 5.10: HDI visualisation of HSP-90a at m/z 1168.5. Arrows indicates the ion of interest
separated by drift time, and yellow ROI square is shown..............................................................284
Figure 5.11: HSP-90 a at m/z 1168.5 after exportation to Mass Lynx software from the
selected ROI in HDI 1.1......................................................................................................................... 285
Figure 5.12: HDI visualisation of Histone H3 at m/z 1032.7. The arrow indicates the ion of
interest separated by drift time and no signal apparent in the standard.....................................286
Figure 5.13: HDI visualisation of Actin at m/z 1198.7. The arrow indicates the ion of interest
separated by drift time......................................................................................................................... 287
Figure 5.14: HDI visualisation of Histone 2A at m/z 944.5. The arrow indicates the ion of
interest separated by drift time.......................................................................................................... 288
Figure 5.15: HDI software with image correlation filter for Plectin m/z 1032 displaying fellow
Histones...................................................................................................................................................290
Figure 5.16: HDI software with image correlation filter for Plectin m/z 1350 showing no
discrimination between other peaks.............................................................   291
Figure 5.17: MALDI-MSI of fibrosarcoma 188 on tissue tryptic digests for the spatial
distribution of Plectin at m/z 1385......................................................................................................292
Figure 5.18: MALDI-MSI and conventional proteomic techniques to asses a dose relationship in
Plectin......................................................................................  293
Figure 5.19: MALDI-MSI and conventional proteomic techniques to asses a dose relationship in
HSP-90..................................................................................................................................................... 294
Figure 5. 20: Issues and factors to consider when performing on tissue digestion for MALDI 
imaging experiments............................................................................................................................. 296
List of Tables
Table 1: Cancer incidence throughout the regions of the w orld.................................................... 18
Table 2: Current anti-cancer treatments..............................................................................................29
Table 3: Categorisation of vascular targeted therapies.....................................................................30
Table 4 : Example of drugs within each category................................................................................31
Table 5 : Inhibiting the process of angiogenesis.................................................................................32
Table 6 : Mass spectrometers for proteomics.................................................................................... 45
Table 7 : Common matrices used in UV- MALDI..................................................................................54
Table 8: Identities and Mascot scores from the IMS-MS/MS analyses of peptide signals...........91
Table 9: Twelve peptides from target proteins chosen for positive identification..................... 267
12
Abbreviations
ACN: acetonitrile
Aldoartl: Fructose-bisphosphate aldolase A 
AL022784: alpha-enolase 1 (Enol)
ANI: aniline
APCI: atmospheric pressure chemical ionisation 
APPI: atmospheric pressure photoionisation 
BCA: bicinchoninic acid assay 
Calr: Calreticulin
CHCA: a-cyano-4-hydroxycinnamic acid 
CHCI3: chloroform 
CID: collision-induced dissociation 
CA-4-P: combretastatin A-4 -3-0 phosphate 
CSC: cancer stem cell 
dH20: deionised water
DMXAA: 5,6-Di-methylxanthenone-4-acetic acid 
Eeflal: Elongation factor 1-alpha 1 
ESI: electrospray ionisation
ESI-LC-MS: electrospray ionisation-liquid chromatograpgy-mass spectrometry 
ESI-LC-MS/MS: electrospray ionisation-liquid chromatograpgy-tandem mass spectrometry 
EtOH: ethanol
FFPE: formalin fixed paraffin embedded
GAPDH: Glyceraldehyde-3-phosphate dehydrogenase
13
Gpil: Glucose-6-phosphate isomerase 
GRP-78: glucose- regulated protein 78 (Hspa5)
HE: haematoxylin and eosin
HIF-1 a: hypoxia- inducible factor 1 alpha
HPLC: high performance liquid chromatography
HSP: heat shock protein
IHC: immunohistochemistry
IMS: ion mobility separation
IQGAP1: Ras GTPase-activating-like protein
iTRAQ: isobaric tag for relative absolute quantitation
KTR1: Keratin-l(type II skeletal-1)
LC: liquid chromatography
LC-MALDI: liquid chromatography-matrix assisted laser desorption ionisation
LC-MALDI-MS/MS: liquid chromatography-matrix assisted laser desorption ionisation-tandem 
mass spectrometry
LC-MS/MS: liquid chromatography -mass spectrometry tandem mass spectrometry 
Lgalsl: Galectin-1
MALDI: matrix assisted laser desorption ionisation
MALDI-MS: matrix assisted laser desorption ionisation-mass spectrometry
MALDI-IMS-MS: matrix assisted laser desorption ionisation-ion mobility separation-mass 
spectrometry
MALDI-IMS-MSI: matrix assisted laser desorption ionisation-ion mobility separation-mass 
spectrometry imaging
MALDI-MSI: matrix assisted laser desorption ionisation- mass spectrometry imaging 
MALDi-ToF: matrix assisted laser desorption ionisation-time of flight
Mcm5: DNA replication licensing factor MCM5 
MS: mass spectrometry 
m/z: mass- to -charge ratio 
MeOH: methanol
MudPIT: multidimensional protein identification technology 
N2 laser: nitrogen laser
Nd: YAG: neodymium-doped yttrium aluminium garnet
Nd:YV04: yttrium ortho-vanadate
NH4HC03: ammonium bicarbonate
NHS: N-hydroxysuccinimide
OcGIc: Octyl-a/p-glucoside
PCA: principle component analysis
PCA-DA: principle component analysis-discriminant analysis 
PLSDA: partial least squares discriminant analysis 
PMF: peptide mass fingerprint 
PRDX1: Peroxiredoxin-1 
Q: quadrupole
QqTOF: quadrupole time of flight 
ROI: region of interest 
S100a6: Calcylin 
SMA: smooth muscle actin 
TAA: tumour associated antigen 
TFA: trifluoroacetic acid
Tgfbi: Transforming growth factor-beta-induced protein ig-h3
15
Tnc: Tenascin C 
TOF: time of flight
TOF MS: time of flight mass spectrometry
Tpil: Triosephosphate isomerase
TSP: thermospray
TWIGS: travelling wave ion guides
VDA: vascular disrupting agent
VEGF: vascular endothelial growth factor
VEGFR: vascular endothelial growth factor receptor
VIP: variable importance in projection
VTS: vascular targeted strategy
VTT: vascular targeted therapy
16
Chapter 1
General Introduction
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1.1 Cancer
1.1.1. Statistical information, incidence/ prevalence
At the time that this account was written the latest official current world population estimate 
was ~7,094,391,160. This approximation was made based on population figures on the 
27thJanuary 2013 (Worldometers 2013). Demographic predications state that by 2028 the 
number of our planet's inhabitants will exceed 8 billion (Cancer Research UK 2007).
The current population is described as 'aging', the relevance of this from a cancer perspective 
is that the disease has been known to predominantly affect the older generations (Cancer 
Research UK 2007). Worldwide life expectancy is increasing, people are living longer and the 
average lifetime expectancy at birth is said to be 65yrs possibly escalating to 76yrs by the year 
2050. Throughout the world there are still ~12.7 million people who are annually diagnosed 
with cancer with estimations likely to increase to ~26 million by 2030 (World Cancer Research 
Fund 2010). The UK has the 22nd highest overall cancer rate in the world.
Africa 715,571 6
Asia 6,092,359 48
Europe 3,208,882 25
Latin America & 906,008 7
Caribbean
North America 1,603,870 13
Oceania 135,864 1
Developed regions 5,555,281 44
Developingregions 7,107,273 56
World 12,662,554 100
Table 1 :  Cancer incidence throughout the regions o f the world (Adapted from Cancer 
Research UK 2011).
It is evident from Table 1 that Asia has the largest proportion of new cases diagnosed but this 
is understood to be a reflection of the magnitude of population size within that particular 
continent.
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On a global scale the mortality rate is such that in 2008 there were an estimated 7.6 million 
deaths as a result of cancer, the bar graph below shows the proportion of deaths due to cancer 
in the regions of the world (World Health organisation 2012).
25
Western Europe Amencas World South-East Eastern Africa 
Pacific Asia Mediterranean
Area
Figure 1 .1 : Percentage of all deaths due to cancer in the different regions o f the world 
(WHO) Regions of the World, 2008 Estimates (Cancer Research UK 2007).
The following map (Figure 1.2) entitled 'Cancer Incidence Worldwide' (Cancer Research UK 
2011) represents the most frequently diagnosed cancers within the areas shown in 2008. The 
cancer types which account for the largest proportion of cases diagnosed are found to be; lung, 
breast, bowel, stomach and prostate.
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It is stated that 47% of all cancer related death are from lung, bowel, breast and prostate 
cancers (Cancer Research UK 2011). Figure 1.3 displays the 20 most common causes of death 
from cancer in the UK.
Male ■  Female
Lung 
Bowel* 
Breast 
Prostate 
Pancreas 
Oesophagus 
Stomach 
Bladder 
Leukaemia 
Non-Hodgkin Lymphoma 
Ovary 
Kidney
Brain and Central Nervous System
Liver
Other Digestive Organs 
Myeloma 
Mesothelioma 
Malignant Melanoma 
Oral 
Uterus 
Other Sites**
0 5.000 10,000
Number of Deaths
15,000 20,000
Figure 1.3 : The 20 Most Common Causes of Cancer Death, UK, 2010 (Cancer Research UK 
2011).
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1.1.2 Tumour types
There are over 200 different kinds of cancer which can be classified by cell of origin (Cancer 
Research UK 2009). Tumours are generally classified as benign or malignant to illustrate that 
not all are cancerous (Medline Plus 2010). Malignant is the term used to describe an abnormal 
neoplasm which is cancerous and benign is a non-cancerous growth. The cells which constitute 
the cancerous tumour types have metastatic capabilities and are able to reach other regions of 
the body to form secondary tumours whilst benign tumour types do not metastasize.
Figure 1 .4 : Diagrammatical representation o f the possible routes o f cell division (National 
Cancer Institute 2009).
The cancer cell has the ability to elicit morphological changes as depicted in Figure 1.4., to 
ultimately disregard the usual signals for cell suicide or apoptosis.
It is possible to divide solid tumours into 3 broad categories these being; carcinomas which 
originate from altered epithelial cells which function as linings of a body surface region i.e. skin, 
gut, cervix, mouth, lung, sarcomas occur in connective tissue i.e. bone, muscle, cartilage and 
lymphomas/ leukaemia which describes cancers that arise from lymphoid organs (lymph nodes, 
spleen) and cells from bone marrow (http://www.chemotherapy.com/ 2011).
Loss of Normal Growth Control
Normal 
cell division
CeB SujckV  or ApoptoiH
Cancer 
cell division
Flrct Second 
mutation mutation
TTWd Fourth Of 
mutation later mutation
Uncontrolled growth
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1.1.3 Overview of current anti-cancer therapies
Pre-treatment clinical assessment of patient tumours is generally based on tumour size, 
through histological staining, tumour grade and is regularly coupled with the employment of 
various imaging techniques (Koch et al 2010). The tumour grading is a system that is used as a 
reference in order to classify cancer cells. Analysis of the abnormalities exhibited by cancer 
cells are visualised by microscopy, here the aggressiveness of the tumour can be determined. 
Although factors used for tumour grading vary in cancer type the cellular architecture and 
growth patterns are studied (National Cancer Institute 2009). The outcome of these 
evaluations will then determine the appropriate treatment route.
An example of a grading system commonly used by Doctors is the TNM system. This grading 
system is an accepted method by the International Union against Cancer (UICC) and the 
American Joint Committee on Cancer (AJCC) (National Cancer Institute 2009). In brief the 
rationale behind the TNM method is that the T  refers to the extent of the tumour, the 'N' 
amount of colonisation in the lymph nodes and 'M ' the presence of metastasis. A number is 
assigned to the T /N /M  indicative of size and metastatic status. The TNM system is further 
annotated, details are as follows:
Primary Tumours (T); TX - Primary tumour cannot be evaluated, TO - no evidence of primary 
tumour, Tis - Carcinoma in situ and T l, T2, T3, T4 refer to the size/ severity of the primary 
tumour.
Regional Lymph Nodes (N); NX-regional lymph nodes cannot be evaluated, NO - no regional 
lymph node involvement and N l, N2, N3 depicts the involvement of regional lymph nodes and 
to what extent.
Distant Metastasis (M) -  MX distant metastasis cannot be evaluated, M0 - no distant 
metastasis and M l distant metastasis is present.
Further categorisations of the above TNM combinations are then graded as follows;
Stage 0 - Carcinoma in situ, Stage I, Stage II, and Stage III Higher are indicative of the extent 
ofcancer: Larger tumour size and/or spread of the cancer beyond the organ in which it first 
developed to nearby lymph nodes and/or organs adjacent to the location of the primary 
tumour.Stage IV - the cancer has metastasised to another organ(s).
The above information regarding the TNM system was taken from (National Cancer Institute 
2009, http://www.cancer.gov/cancertopics/factsheet/detection/staging).
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Currently the main course of action for the treatment of tumours is by surgical removal, 
chemotherapy, radiotherapy, systemic adjuvant treatments and in recent times some agents 
have been used to achieve a more targeted approach (Koch et al 2010).
A brief account follows which considers the history of how both chemotherapy and 
radiotherapy have been implemented as anticancer therapies within the clinical setting. 
Secondly, a compilation anticancer therapies in table format aims to summarise the range of 
treatments available with an overview of how they are administered, anti-cancer mechanisms 
and possible side effects.
It is documented that work by German scientist Paul Ehrlich lead to the adoption of the widely 
used term 'chemotherapy' (DeVita and Chu 2008). During turn of the 20th century, the focus 
of his work was the discovery and advancement of drugs to combat infectious disease. 
Amongst Ehrlich's achievement was the use of animal models to enable assessment of 
potential anticancer agents.
With reference to a cancer chemotherapy timeline by DeVita and Chu 2008, it took 
approximately 40 years to develop a suitable experiment model (DeVita and Chu 2008). 
Although this period included the revolutionary success of transplantable tumour rodent 
models by New Yorker George Clowes a surgeon/ researcher from the Roswell Park Memorial 
Institute.
With regard to early anticancer therapeutics, 1908 saw the use of arsenicals which had been 
originally used to eradicate Syphilis (DeVita and Chu 2008). 'Fowlers solution1 (arsenicals) as it 
was known, was used to treat leukaemias and apparently a common practice well into the 
1930's (Papac 2001).
Optimism arising from these early triumphs in cancer therapy was dampened following work 
investigating the use of nitrogen mustard (1943) to eradicate lymphomas. (DeVita and Chu 
2008). Reports stated that patients suffering from lymphomas experienced only short-lived 
remission and thus began a decline of confidence in the concept of 'a drug to cure cancer'.
It was not until the opening of the Cancer Chemotherapy National Service Centre (CCNSC) in 
1955 that a possible future for cancer drug development was confirmed (DeVita and Chu 2008). 
This change of heart was said to be encouraged by the positive response to the drug 
methotrexate in children with acute leukaemia. Since the 1960s, the development of anti­
cancer drugs has been aided by many advances. Experimental models which employ 
xenografts and novel cell culture methods have been used. Adjuvent therapy (chemotherapy, 
radiation therapy, hormone therapy, targeted therapy, or biological therapy) given in addition
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to the primary treatment was developed and investments into molecular biology have been 
made. From the beginning of the 21st century, there seems to have been a different approach 
in anticancer therapeutics emerging (DeVita and Chu 2008). Completion of sequencing of the 
genome appears to have led to a more targeted approach to cancer treatment. Through 
advancements in chemotherapy a major decrease in mortality is seen by 2007, the latter 
considering knowledge of prevention and improvements in diagnostics.
Radiotherapy/ Radiation Oncology are terms which are commonly associated with cancer 
treatment with an estimated 50% of patients receiving this form of anticancer therapy for both 
palliative and therapeutic means (Delaney et al 2005). In combination with other forms of 
management, radiation therapy features in approximately 40% of those patients who are 
cured of their disease (Shariq et al 2009).
After the German physicist Wilhelm Roentgen discovered x-rays in 1895, the concept of using 
x-rays as a therapeutic aid was not long to follow, assisted greatly through work on radioactive 
elements (radium, polonium) by Marie Curie and husband Pierre (Connell and Heilman 2009). 
There have been numerous clinical, technological and biological advances in radiotherapy 
since Roentgen's breakthrough over 115 years ago. Examples of key clinical advances are Henri 
Coutard using fractionated external beam radiotherapy (XRT) in 1928 to cure head/ neck 
malignancies, the use of the proton beam (1961) and the high precision accuracy of 
stereotactic body radiotherapy (1995) (Connell and Heilman 2009).
A large proportion of patients, however, still exhibit metastasising cancers even after 
treatments such as combination radiotherapy. (Koch et al 2010). One explanation could be the 
inadequate targeting of cancer stem cells (CSCs), i.e. CSCs could be sheltered by hypoxic 
tumour environments enabling them 'radio-resistant'. Therefore increased doses of radiation 
could be concentrated to these specific resistant areas. The following proposal (Figure 1.5) by 
Koch et al (2010) suggested how CSC-predictive test regime and radiotherapy could be 
implemented.
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Current therapy
Entity I  Histology 
Tumour volume 
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Metabolic imaging (PET)
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Figure 1. 5 : Proposal of adding CSC specific predictive tests to therapy regimes fo r potential 
increase in tumour control probability (Koch et a 12010).
Table 2 gives a list of current anti-cancer therapies, administration routes, mechanism and 
possible side effects related to the particular therapy.
26
Anti-cancer Therapy Administration Route Anti-cancer Action Examples of Possible 
Side Effects
Biological therapy Orally, in jected, 
in travenous, 
in tra d e rm a l/ 
in tram uscu la r
Targets th e  im m une 
system, re ta rd a tio n  o f 
cancer cells, e.g. IL-2, 
In te rfe ro n  alpha,
Rashes, nausea, flu  like 
sym ptom s, hypotension
Chemotherapy Orally, in jected, Targets cells o f high Hair loss, rashes,
in travenous, in tra - p ro life ra tive  na tu re  d ia rrhoea , nausea/
a rte ria lly , in su ffla tio n  a lte ring  DNA synthesis/ vom iting , d igestion
fun c tion , in te rfe rence  issues, fa tigue
w ith  cell cycle e.g.
a lky la ting
agents(C isplatin),
an tim e tab o lite s
(m e tho trexa te ),
a n titu m o r an tib io tics
(B leom ycin),
anthracyclines
(Idarubic in), p lan t
alkalo ids (V inblastine),
taxanes (Paclitaxel),
m onoclona l an tibod ies
(Bevacizumab),
Radiation Therapy Patient exposure to  E xp lo ita tion  o f rap id Hair loss, rashes.
source o f rad ia tion , d iv id ing  cell types, d ia rrhoea , nausea/
localised beam exposure o f rad ia tion  to  vom iting , d igestion
tu m o u r regions issues, fa tigue ,
ne u trop en ia
Targeted Therapies O rally (small m olecu le Target high Nausea/ vom iting ,
inh ib ito rs ), p ro life ra tive  cells, rashes, d ia rrhoea , skin
In travenously Inh ib ito rs  o f d isco lo ra tion ,
(m onoclona l angiogenesis, ty ros ine  dyspepsia, flu c tu a tio n s
an tibodies), kinase rece p to r in b lood pressure
in h ib ito rs , to  im pede
tu m o u r en la rgem ent 
and survival
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Proton Beam Therapy Patient exposure to  
source o f rad ia tion , 
h igh ly specific localised 
beam
Based on s tab ility  o f 
p ro tons enabling 3D 
m an ipu la tion  o f beam. 
Highly specific to  
tu m o u r region w ith  
m in im al exposure to  
norm al tissue
Hair loss, rashes, 
d ia rrhoea , nausea/ 
vom iting , d igestion  
issues, fa tigue , 
neu tropen ia
Surgical Oncology Perform ed by Surgeon 
p re /p o s t chem othe rapy 
or rad io the rapy  if 
m alignan t
Surgical rem oval o f 
tu m o u r tissue plus 
som e hea lthy  tissue 
fro m  periphery, 
transp la n ta tio n  o f bone 
m arrow
Risk o f in fe c tion , ha ir 
loss, by 'p rep a ra tive  
reg im en ' (bone m arro w  
transp la n t 
surgery)d iarrhoea , 
nausea/ vom iting , 
fa tigue
Gene Therapy A fte r transduc tion  cells 
are re in troduced  in to  
pa tien t by in travenous 
in fusion, insu ffla tion , 
d irec tly  in to  tu m o u r if 
accessible
Cancer cells th a t have 
taken up transduced 
cells are said to  have 
increased suscep tib ility  
to  chem othe rapy  and 
o th e r anticancer 
tre a tm e n ts
Long te rm  side effects 
unknow n, f lu -like  
sym ptom s,
hypo tens ion , vom iting , 
nausea
Hormone Therapy O rally, in jec tion , 
surgical in te rve n tio n
In te rfe rence  w ith  
ho rm one cell surface 
receptors to  block 
activa tion  o f a
Flu-like sym ptom s, 
w e igh t gain, th rom b os is  
in rare cases, a lopecia, 
m u s c le / jo in t pain
pa rticu la r horm one 
th o u g h t to  encourage 
tu m o u r g ro w th , e.g. 
Tam oxifen -  a n ti­
oestrogen, Fulvestrant 
-  oestrogen recep to r 
an tagon ist
Vaccine Therapies Presently tria lled  on Aim  to  induce tu m o u r Long te rm side e ffec ts
pa tien ts  w ith  advanced im m unogen ic ity unknow n, flu - like
illness, no t ye t am ongst sym ptom s, vo m itin g ,
the  m ainstay o f nausea
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anticancer trea tm e n ts , 
the  search fo r  novel 
tu m o u r associated 
antigens is underw ay
Complementary /  Various rou tes 
Alternative Medicine ad m in is tra tion
o f Num erous categories Advice requ ired  fo r  the
some w h ich include; p a tien t to  consider
sp iritua l healers, poss ib ility  o f cross
d ie ta ry  in te rven tion , rea c tiv ity  w ith
herbal m edicines conven tion  means o f
psychological m ethods, tre a tm e n t
cu ltu ra l techniques 
based on tra d itio n
Table 2: Current anti-cancer treatments (Oncolink 2010., National Cancer Institute 2009).
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1.1.4 Vascular targeted strategies
Targeting the tumour vasculature is a promising anticancer strategy and drugs of this nature 
are in various stages of clinical trials. Here, the types of vascular -targeted therapies (VTTs) will 
be discussed looking at pitfalls, limitations and future aspirations regarding this kind of 
approach to anticancer medicine. Firstly a brief overview will describe the targets and 
mechanisms of VTTs focusing then on the vascular disrupting agent Combretastatin A-4-3-0- 
phosphate (CA-4-P/ ZybrestatTM/ Fosbretabulin).
The importance of angiogenesis in the development and rejuvenation of tumour tissue was 
initially suggested by Folkman in 1971 (Folkman 1971). In vivo experiments using rodent 
models carried out by Denekamp, showed that blocking and interference of the tumour blood 
supply resulted in deterioration of tumour tissue (Denekamp 1990). Denekamp then proposed 
the tumour endothelium as a therapy target by exploiting its high proliferative fragile nature to 
ultimately interfere and/or destroy the tumour vasculature.
Vascular targeted agents can be divided in to two main categories (Table 3) i.e. those which 
inhibit formation of new blood vessels (antiangiogenic) and the vascular disrupting agents 
which take advantage of the substandard micro-architecture of the tumour vasculature 
(Siemann et al 2005). Examples of VTTs and targets are shown in Table 4.
Vascular-targeted therapy
Antiangiogenic agents Vascular disrupting agents
Stop new  vessel fo rm a tio n  (neovascularisa tion) D isrupt a rch itec tu re  o f  tu m o u r b lood vessels
Continual tre a tm e n t Acute tre a tm e n t
Early stage -  asym ptom atic  metastases Established disease, e ffec tive  against large
tu m o u r masses, cause cen tra l necrosis
Table 3: Categorisation of vascular targeted therapies (Siemann 2005).
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Vascular-targeted strategies
Antiangiogenic Vascular disrupting
Target
VEGF/VEGFR 1-3
inhibition
Tie-2/angiopoietin
Av03 integrin
Endogenous inhibitors
VE-cadherin
Unknown
Example
Bevacizumab, VEGF- 
Trap, ZD6474
A422885.66
V itaxin , c ileng itide
Ang iosta tin
E4G10
Thalidom ide
Target
Tubulin
Cytokine induction 
Ab Toxin 
Av|33 integrin
Unknown
Example
C-A-4-P, AVE8062A
DMXAA
VEGF-gelonin
Gene the rapy , pep tide  
ta rge ting
PDT
Table 4 : Example o f drugs within each category (Siemann 2005).
The design hypothesis of antiangiogenic agents is to hamper the cascade of biochemical events 
that result in new vessel development (Siemann 2005). Amidst the complex array of signals 
and receptors which govern the latter process, vascular endothelial growth factor (VEGF) is 
thought to be an important target for impeding antiangiogenesis. An example of anti 
angiogenic therapy is Bevacizumab/ Avastin, this uses monoclonal antibodies to target VEGF or 
its' receptors, as does ZD6474 a tyrosine kinase inhibitor. (Wedge et al 2002). One treatment 
success story of Bevacizumab was when it was used in fluorouracil based combination 
chemotherapy to treat colorectal cancer. (Hurwitz et al 2004).
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Table 5 illustrates the stages of angiogenesis and goals of the 'antiangiogenic 'approach. 
(Siemann et al 2005).
The steps 
towards 
Angiogenesis
Antiangiogenisis
approach
Endothialc«ll
proliferation
Angiogenic switch
Upre gulation of factors 
and docking of 
endothelialcell receptors 
which promote 
angiogenesis
Matrix metalloproteinase 
activation and 
degradation of basement 
membrane
* \
Endothelial cell migration 
and tube formation
t ......
Inhibition of 
proangioge me factors
k I I II III I I IMI
Inhibition of stimulus 
amplification of 
e ndoge nous suppre ssors 
of angiogenesis
Receptor antagonists 
signal transduction 
inhibitors
Ihibition of matrix 
breakdown
f ............
Inhibition of tube 
formation
Table 5 : Inhibiting the process o f angiogenesis (Siemann et al 2005).
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1.1.5 Vascular disrupting agents
Vascular disrupting agents (VDAs) exploit the characteristic tumour vasculature (Figure 1.6) 
which is notoriously sinusoidal and leaky, and is hence susceptible to vascular disruption. 
(Tozer et al 2008). Shortly after administration of VDAs major shutdown occurs of the tumour 
vascular network.
Healthy vasculature, m ature blood 
vessels, smooth muscle and pericyte  
support
Tum our vasculature, im m ature blood  
vessels, lack o f support by smooth 
muscle and pericytes
Figure 1. 6 :  Images to illustrate the substandard tumour vasculature (Oxigene 2010).
Flavanoids (e.g. DMXAA) and tubulin-binding agents (e.g. CA-4-P) are VDAs, both are designed 
to disrupt tumour blood vessels but work in different ways as the chemical structures suggest 
in Figure 1.7.
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CA-4-P (Fosbretabulin)
HoCO
O— P— ONa
ONaOCH
H
DMXAA (Vadimezan)
O
CH, c h 2c o o h
CA-l-P (Oxi4503)
H3CO.
h 3CO
OCH
ONa 
0 \  | ONa
I
, 0
o/ /'O — P — ONa\
OCH3 0Na AVE8062 (Ombrabulin)
H3CO.
H3C 0 ‘
OCH
NHF.HCI
OCH
Figure 1. 7 :  Chemical structures o f vascular disrupting agents (Kanthou and Tozer 2007).
The mechanism of 5,6-dimethylxanthnone-4-acetic acid (DMXAA/ ASA404) is still not yet fully
understood but it is thought to operate via the induction of TNF-a. (Thorpe et al 2003).
Through the action of DMXAA it is suggested that TNF-a is retained within the tumour
microenvironment thus stimulating additional amounts of TNF-a amongst other cytokines.
The tumour blood vessels are weakened with the subsequent changes in morphology leading
to haemorrhagic necrosis (Kanthou and Tozer 2007). In Phase I clinical trials DMXAA showed
the drug had a well tolerated anti-tumour action, Phase II involved combination with
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conventional chemotherapy agents with positive outcomes when used in non-small cell lung 
cancer patients. DMXAA then moved into Phase III clinical trials which unfortunately did not 
produce the same effects as in its early trial success (Buchanan 2012).
Microtubule depolymerising agents have a destructive effect on the architectural integrity of 
3D capillary composition (Bayless and Davies 2004). The following diagrammatical 
representation (Figure 1.8) from a paper by Kanthou and Tozer (2007) details the proposed 
mechanism of action of a microtubule depolymerising agent (e.g. Combretastatin A-4-3-0- 
phosphate).
H I V '
A< m \ IV
Untreated endothelial cells
•  intact micronjbulss
•  non-contractile cells
•  tight VE-cadherin junctions
•  low permeability
•  low RhoA-GTPase activity
•  low Rho kinase activity
Microtubules 
— Actin stress fibers
%% Cell surface actin blebs 
VE-cadherin junctions
VDA-treated endothelial cells
•  disrupted microtubules
•  contractile cells
•  actin stress fibers
•  strong fecal adhesions
•  disrupted VE-cadherin junctions
•  high permeability
•  high RhoA-GTPase activity
•  high Rho kinase activity
•  high SAPK-2'p3d activity
•  high ERK activity?
VDA-treated endothelial cells
•  disrupted microtubules
•  conlractile-blebbrng cells
•  actin-lined surface blebs
•  (Disassembled focal adhesions
•  lost VE-cadherm junctions
•  high permeability
•  necrotic celts
•  high RhoA-GTPase activity
•  high Rho kinase activity
•  high SAPK-2/p38 activity
•  low ERK activity?
Dug Dacmvry Today S‘rat*yes
Figure 1. 8 :  Proposed mechanism of action o f Combretastatin A-4-3-0-phosphate (Kanthou 
and Tozer 2007).
It is suggested that increased permeability post CA-4-P administration is a major factor in the 
disruption of endothelial organisation; this is evident from Figure 1.8 (Kanthou and Tozer
2007). Interference in vascular integrity due to abnormality in the cytoskeleton, subsequently 
leads to stress fibre formation and endothelial cells as a result become more rounded 
('blebbing'). Haemorrhagic necrosis follows exacerbating the already hypoxic regions within 
the tumour microenvironment.
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The remodelling of the actin cytoskeleton and formation of actin stress fibres shown in Figure 
1.8 is clearly demonstrated in the Figure 1.9 adapted from Kanthou and Tozer 2002 and has 
also been shown by Siemann (2010).
(b)
(d )
Figure 1. 9 :  Fluorescent staining o f Human umbilical vein endothelial cells, Control and post 
CA4P administration (Kanthou and Tozer 2002). Figure 1.9 shows dual staining for 
filamentous actin (Texas Red Phalloidin (red)) and beta tubulin (green): (a) control actin, (b) 
control tubulin, (c) CA4P (1 uM  for 30 min) actin, (d) CA4P (1 uM for 30 min) tubulin.
In vivo studies using CA-4-P have clearly shown how the effects of the drug can induce vascular 
shutdown resulting in increased hypoxia. (Tozer et al 2008). Studies on mouse models (Figure 
1.10) looking at hypoxic responses in mammary carcinomas after 50mg/kg CA-4-P, indicated 
increased pimonidazole staining compared to non treated. Similarly, dorsal skin flap 
experiments in mice (Figure 1.10) displayed the de-vascularising properties of CA-4-P 
HOmg/kg.
(a)
(c)
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»*«n
Figure 1 .1 0 :  CA-4-P and its effect on hypoxia induction and vascular shutdown (Tozer et al 
2008). Panel A shows pimonidazole staining o f the control untreated tumour at the top with 
the bottom being 1 hour after CA-4-P, panel B is the untreated image of a rat bearing P22 
sarcoma directly below is the tumour 1 hour 40 min post CA-4-P administration in vivo using 
a window chamber method for analysis o f treatments effects.
Abnormal tumor vascular 
network with poor perfusion, 
high interstitial fluid pressure 
and areas of hypoxia
Tumor-VDAs
Blind ends
Abnormal bulges
Direct endothelial cell effects 
Vascular disruption
Remaining rin  of viable 
cells that can be targeted 
with chemotherapeutic 
agents and radiation
Necrotic central core
Decreased nascent 
Vessel number
Anti-VEGF effects
Initial vascular normalization  1
Anti-Angiogenic
Agents
I p  a l i i[ ’.vSi I VS f j Improved blcod flow' 
loading to improved 
delivery of
chemotherapeutic
agents
Figure 1 .1 1 :  Exploitation of tumour vasculature by antiangiogenic treatment and vascular 
disrupting agents (Siemann 2010).
To summarise the different actions of both VDAs and antiangiogenic treatments a diagram 
(Figure 1.11) by Siemann (2010) highlights the preclinical effects of each type.
With all new drugs/ therapies in development there are numerouscomplications to overcome
and consider i.e. the therapeutic window with the balance between safe dosage and the onset
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of adverse effects. The phrase 'tumour evasion' frequents many article titles and appears to be 
a key issue in the advancement of this type of anti-tumour medicine.
Zhi-Chao and Jie (2008) present valid points within their review on tumour evasion in a section 
entitled "Hypoxia: Two sides of the coin". They state that disruption by vascular targeted 
treatment to increase hypoxia severing the lifeline of the tumour, can indeed have undesirable 
consequences. It is suggested that there is a requirement to unravel some 'cause-effect' 
connection. Hypoxia-inducible factors (HIF) have been known to correlate with the up- 
regulation of VEGF, involved in angiogenesis regulation. So could VTTs amplify the angiogenic 
process after the creation of an increased hypoxic tumour environment? Hypothetically 
speaking this could even help the metastatic process ensuing tumour invasion. (Abdollahi and 
Folkman 2010).
Evasion of the hosts' immune system is one feat that the tumour is capable of and there is a 
school of thought that claims there could be a similar evasion mechanism in place against VTTs. 
The heterogeneous nature of the tumour mass could well contain a cell population deemed 
oblivious to vascular targeted strategies. (Zhi-Chao and Jie 2008). The latter is supported by 
the hypothesis of four possible vascular phenotypes in existence; normal pre-existing, tumour 
phenotypic vessels, neo-vasculature which is normal and abnormal neo-vasculature. This 
could explain why some cells remain unaffected including the well documented viable tumour 
rim. (Hinnen and Eskens 2007).
The viable tumour rim being a speculative resistance factor is also thought to achieve evasion 
through its positioning, adjacent to the non-diseased tissue. (Tozer et al 2008). Consequently, 
seizing oxygen and essential nutrients as it resides in this prime location.
The explanations why resistance issues exist against VTTs appears to be complex and multi­
factorial. That said progress is being made through various combination therapies. Xenograft 
experimental models displayed increased quantities of VEGF and basic fibroblast growth factor 
following doses of CA-4-P, with angiogenic circulating progenitor cells in murine studies. (Tozer 
et al 2008) Promising responses have been reported by using VDAs and anti-angiogenic VEGFR 
tyrosine kinase inhibitor treatments in combination therapy.
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1.1.6 Biomarker Discovery
When considering biomarker discovery as it relates to oncology many complexities exist. There 
are countless biochemical pathways with numerous prospective targets, with more layers of 
complexity added by the multifaceted characteristics of the cancer cell. A cell unchallenged by 
host immunogenicity, that has mastered tissue invasion and anti-cancer drug evasion. 
Nevertheless a good place to start is given bythe 'hallmarks' of cancer created by Hanahan and 
Weinberg (2000).
Whilst the 'hallmarks' of cancer reveal the attributes and capabilities of this lethal cell type, a 
further proposal by Lord and Ashworth (2010) relates the possible drug targets to each 
characteristic of the cancer cell to provide inspiration for biomarker exploration. (Lord and 
Ashworth 2010). A diagram in the article by Lord and Ashworth (2010) supplies a wealth of 
information on the latter subject however, one consideration to be made is the possible 
upshot from molecular interactions and when choosing one trait to target such as 'sustained 
angiogenesis' or 'proteotoxic stress'.
This concern is echoed by Lord and Ashworth (2010) as they discuss how in order to decipher 
cancer mechanistics, medicine should bear in mind how drugs disturb whole biochemical 
networks as opposed to solitary pathways. A concept which has been termed, "drugging the 
undruggable".
Over a decade after their original paper, Hanahan and Weinburg (2011) proposed an updated 
version of 'The Hallmarks of Cancer' entitled 'Hallmarks of Cancer: The Next Generation'. The 
idea of two additional hallmarks of cancer were put forward these being the "reprogramming 
of energy metabolism"and "evading immune destruction".
Figure 1.12 displays the original hallmarks with the addition of 'deregulating cellular 
energetics' this referring to reprogramming of cellular metabolism in favour of proliferation 
and 'avoiding immune destruction' which describes the ability to fend off advances from 
macrophages, natural killer cells and T/ B lymphocytes (Hanahan and Weinburg 2011). The 
article proposes two enabling characteristics, genome instability and mutation and tumour- 
promoting inflammation. Both of which are said to be key orchestrators in the original and 
emerging characteristics.
Hanahan and Weinburg also included therapeutic suggestions to hinder a particular cancer 
hallmark as shown in Figure 1.8.
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Avoidingimmune
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Selective anti 
inflammatory drugs
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Figure 1 .1 2 :  Therapeutic targeting o f the hallmarks o f cancer (Hanahan and Weinberg 2011).
Cancer-Associated Fibroblast , 
(CAF)~
Endothelial Cell (EC) 1
Cancer Stem Cell (CSC) 
r -  Cancer Cell (CC)
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' :V  (ICs)
Local & Bone marrow- 
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& Progenitor Cells Invasive Cancer Cell
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Invasive Tumor 
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Figure 1 .13: The cells o f the tumour microenvironment. (Hanahan and Weinberg 2011).
Advances in the knowledge of the individual cancer cells that make up the solid tum our have 
enabled appreciation of their influential drive on the tumour microenvironment. Figure 1.13
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depicts the varied cell types and sub types. Each cell has a specialised role and collectively 
supports the plasticity required for tumourigenesis (Hanahan and Weinberg 2011). 
Interestingly it is known that the inflammatory immune cells present within this cellular 
assemblage, possess both pro-oncogenic and anti-tumour activity. The latter is thought to aid 
future tumour seeding during the metastatic process.
1.1.7 Considering Vascular disrupting agents for anti-cancer therapeutics
It is known that one vessel is primarily responsible for supplying the tumour cell population
with oxygen and nutrients for growth, development and excretion of waste metabolites. 
(Thorpe et al 2003). Disruption of this vital sustenance by vascular disrupting agents causes 
rapid shutdown of blood flow to and from the tumour.
Unlike some conventional cancer therapies which focus on cell killing VDAs create damage via 
morphological changes to produce drastic effects on the tumour microenvironment. Drug 
deliverance is simple due to endothelial positioning near the bloodstream.
In addition to the above, another reason to support the use of vascular targeted therapy is that 
the diploid target cells are thought not to be as drug resistant due to low risk of mutations. The 
drug has good clinical measurability being blood flow, in most cases short-term exposure of a 
VDA creates sufficient hypoxic conditions. To conclude, intermittent dosage with regular 
treatments may be adequate to provide a synergistic effect, not true in the case of 
antiangiogenesis agents. (Thorpe et al 2003).
1.2 The Role of Mass Spectrometry in Biomarker Discovery
1.2.1. Overview of mass spectrometry as an analytical tool
Mass spectrometry can be applied to numerous analytical subject areas from the food industry
to forensic applications to complement various diagnostic and prognostic techniques (Griffiths
2008). Techniques using mass spectrometry have supported the advancement of proteomics, 
metabolomics, lipidomics and atomic physics to forge a place within the clinical setting.
Proteomics is a platform for potential biomarker discovery and mass spectrometry is widely 
used as a discovery tool (Anderson 2005). Advances in mass spectrometry instrumentation 
have resulted in high mass accuracy and vast improvements in sensitivity and specificity (Al- 
Shahib 2012). The forward momentum of mass spectrometry has led to the analysis of 
diseased and non-diseased tissues supported by bioinformatics.
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Recent experimental work by Rower et al (2011) showed development in the early diagnosis 
of invasive ductal breast carcinoma through protein signatures and structural analysis. Such 
progress in the identification of disease biomarkers could not only benefit patients directly but 
support future drug design and development.
1.2.2. Basic principles of mass spectrometry
The mass spectrometer uses an ion source (liquid-phase/ solid-state) to transfer the analyte 
into gas phase ions which then travel to the mass analyser to be sorted according to mass-to- 
charge ratio (m/z), finally a detector accounts for the relative abundance of each ion at a 
particular m/z (Hoffmann and Stroobant 2007). Instrumental calibration and use of analytical 
standards is also vital to produce accurate mass measurements whilst using the many different 
mass spectrometric techniques. External calibration is performed before sample analysis 
where a known selected compound is used for spectral comparison against a reference list 
where assignment of exact masses can then be made. Internal calibration describes a 
calibration method where a reference compound is introduced into the mass spectrometer 
during sample analysis. This technique compensates for any possible changes in conditions in 
the analytical instrumentation (Hoffmann and Stroobant 2007).
Figure 1.14 is a representation of the basic principles of the mass spectrometer.
With regard to proteomics there are a variety of mass spectrometers available some of which 
are described in more detail in later.
The following table (Table 6) adapted from Han et al (2008) details commonly used 
instruments, applications and performance indicated by mass analyser type.
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1.2.3. Ionisation techniques and Mass analysers
In physical chemistry there are four main ways to produce gas phase ions from a molecule 
interest which are; spray ionisation, desorption ionisation, chemical ionisation and electron 
ionisation (Cooks 2010). Figure 1.15 shows these ionisation techniques schematically.
(A) (B)
SampSe 
Capilary
Spraying
Gas
Energy Beam
(C) (D) © v/
o r m —
M — * M H  ++H hv M|
X Q '
Figure 1.15  : Basic ionisation techniques. (Pol et al 2010). (A) spray ionisation, (B) desorption 
ionisation, (C) chemical ionisation and (D) electron ionisation.
Examples of spray ionisation are electrospray and nanospray, these techniques require the 
sample to be in solution and regularly coupled to an LC system (Pol et al 2010). Secondary ion 
mass spectrometry (SIMS), desorption electrospray ionisation (DESI) and matrix assisted laser 
desorption ionisation (MALDI) are all methods using desorption ionisation from a solid surface 
(Pol et al 2010). The desorption methods previously mentioned are used for image acquisition. 
Chemical ionisation and electron ionisation use techniques involving gas-phase ion-molecule 
reactions at atmospheric pressure, atmospheric pressure chemical ionisation (APCI) and 
electron impact are such techniques. APCI can be applied to polar and relatively non-polar 
molecular analysis with electron ionisation is useful for organic compounds.
Figure 1.16 displays current mass analysers at use in the analytical laboratory.
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Figure 1 . 1 6 :  Mass analysers used in mass spectrometers, (a) Quadrupole, (b) Time-of-flight 
(TOF), (c) Magnetic sector, (d) Ion trap, (e) Orbitrap, (f) Ion cyclotron resonance. (Pol et al 
2010,. Trim et al 2012).
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1.2.4. Proteomics using mass spectrom etry
Currently mass spectrometers allow interpretation of complex protein mixtures that contain 
post translational modifications (PTMs) through fragmentation techniques (Hoffmann and 
Stroobant 2007). Tandem mass spectrometry (MS/MS) describes the selection of a precursor 
ion which then undergoes collision induced dissociation (CID) by an inert gas to generate a 
product ion spectrum, b and y ions are generated due to shattering of the peptide C-N 
backbone (Hoffmann and Stroobant 2007). To illustrate the stages of protein identification in 
more detail the flowchart shown in Figure 1.17 adapted from Han et al (2008) segregates the 
various methods into either bottom-up or top-down proteomic methods (Han et al 2008).
Proteins
(Shotgun approach) 
digestion
Protein separation Protein fractionation 
separation
Digestion ^
Online
multidimensional 
separation (nD) LC- 
MS
Online (ID) 
LC-MS
(PMF) Target 
precursor 
ion selection
Peptides
Peptide precursor mass 
measurement Offline static MSPeptide mass measurement
Online LC-MS
Peptide identification
Protein ID from MS
Single protein or 
less complex mixture Peptide mixture
Data dependant MS/MS
Single protein or 
less complex mixture
Bottom
up Topdown
Data dependant MS/MS
Protein ID and 
characterisation from 
peptide MS/MS
Protein ID and characterisation from intact protein MSr
Protein precursor mass measurement
Figure 1 . 1 7 :  Protein identification methods (Han et al 2008).
An article by Djidja et al (2009) regarding the profiling and imaging of glucose-regulated 
protein 78 kDa (Grp78) contains an clear example of peptide identification from the peptide 
mass fingerprint (PMF) of a tryptic digest, a bottom-up method. Here in-situ tryptic digestion 
was performed directly onto tissue sections, the resulting PMF allowed selection of precursor
48
ion for MS/MS. Peptide sequences/ MS/MS spectra are then entered into algorithmic 
bioinformatics programmes i.e. MASCOT that can result in protein identification through 
searches performed against a protein database such as UniProt KB/Swiss-Prot.
Interpretation of comparative proteomics data in itself presents a huge challenge and 
Hodgkinson et al (2011) published an antibody microarray proteomic study based on the 
theory proposed by Petrak et al (2008) that such experiments possibly result in 'repeatedly 
identified differentially expressed proteins' (RIDEPs). Petrak et al (2008) devised a list of 15 
'RIDEPs' that were commonly observable in human and rodent samples. Amongst the RIDEPs 
were heat-shock protein 27, peroxiredoxins, annexins and enolase 1 with proteins such as 
zyxin and smad4 found by Hodgkinson et al (2011). The latter could provide a good place to 
start in any shotgun proteomics experiment, especially assessment of a treatment response 
time course and how these proteins appear to be differentially expressed.
Frequently MS/MS alone is not sufficient enough to provide a good clear fragmentation 
spectrum from the parent ion. Especially when analysing the high abundance of ions 
generated from an on tissue digest. The novel concept of ion mobility-mass spectrometry 
which describes the further separation of isobaric ions indeed facilitates the task of precursor 
ion selection. (McLean et al 2005). Ion mobility separation (IMS) can be applied throughout MS 
acquisition and then again during MS/MS enabling a 'cleaner' peptide mass fingerprint with 
improved subsequent precursor fragmentation. IMS will be discussed further later on.
To conclude this section, the vast amount of data currently now attainable in proteomics 
experiments is remarkable. Dealing with the computational capacity required to process and 
analyse these data will remain a challenge. However this is imperative to contribute to and 
advance proteomic analysis.
1.3 Mass spectrometry instrumentation 
1.3.1 LC-MS
The diagram in Figure 1.18 shows how the analytical technique of high performance liquid
chromatography (HPLC) can be coupled to a mass spectrometer a combination generally
referred to as LC-MS. The nature of this method requires the analyte to be in solution for
injection onto a column packed with coated silica particles (stationary phase) (University of
Bristol 2005). Varying the concentration of the mobile phase passing over the column will then
determine what is eluted in to the mass spectrometer for analysis.
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The sample can either be collected in fractions (Figure 1.18) or sent to the mass spectrometer 
via an interface: Electrospray ionisation (ESI), atmospheric pressure chemical ionisation (APCI), 
thermospray (TSP) and atmospheric pressure photoionisation (APPI) have been or are 
currently used (Hoffmann and Stroobant 2007).
Column selector valve
Autosampler Mass spectrometerColumns□
UV detector
Fraction collector
Flow splitter
HPLC pumps
Figure 1 . 1 8 :  Schematic representation o f a liquid chromatography mass spectrometer. (The 
LC/MS Unit 2009)
LC-MS/MS is regularly used in clinical chemistry for its universal capacity for the detection and 
quantification of small molecules (Jong et al 2011). The technique of LC-MS/MS has proven to 
be invaluable in the diagnosis of pheochromocytoma, a tumour that can develop in the centre 
of the adrenal gland (Lagerstedt et al 2004). Renowned for its specificity and sensitivity LC-MS 
has the ability to measure plasma free metabolites metanephrine and normetanephrine 
occurring in nmol/L, known markers for pheochromocytoma.
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1.3.2. Electrospray ionisation (ESI)
Electrospray ionisation mass spectrometry (ESI-MS) is a highly sensitive soft ionisation 
technique capable of analysing low volume, non-volatile samples (Ho et al 2003).
During flow through the sample (in solution) is nebulised under atmospheric pressure via an 
electrical potential which has been applied to the needle (Gates 2004). Overtime as the 
multiply charged droplet travels towards the sample cone solvent evaporation occurs resulting 
in shrinkage. This is due to the 'Raleigh effect' which describes an event where the surface 
tension can no longer retain the charge (Figure 1.19). The droplet containing the analyte is 
then ripped apart by 'Coulombic explosion'.
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Figure 1 .1 9 :  Schematic o f Electrospray ionisation (Gates P 2004).
The multiply charged droplet is expelled from the needle, overtime solvent evaporation occurs 
resulting in shrinkage of the droplet leading to "Coulombic explosion". There are two models 
of ion generation in ESI, the ion evaporation model (IEM) and the charged residue model 
(CRM) (Wand and Cole 2000). The IEM was first introduced in 1976 by Iribarne and Thomson 
and due to an increasing electrical field present on the surface of the droplet, solvent-ion 
clusters are discharged (Wand and Cole 2000). In the case of the CRM, continuous droplet 
fission through continuous solvent evaporation results in the formation of gas-phase ions.
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1.3.3. Matrix assisited laser desorption ionisation (MALDI)
Matrix assisted laser desorption ionisation (MALDI) is a soft ionisation technique which is
widely used for analysis of non-volatile compounds in many applications including proteomics, 
lipidomics, synthetic polymers and the study of small molecules.
The matrix plays a key role in the successful ionisation of the analyte. After deposition of the 
matrix solution onto the sample, formation of matrix co-crystals occurs after drying/ 
evaporation which form a protective coat from the ablation of the laser (Hoffmann and
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Stroobant 2007). Under vacuum the laser is pulsed onto the matrix embedded sample and 
although not completely understood, it is thought that the energy is transferred from the 
surface of excitation of the matrix crystals to the analyte. The transfer of energy from the laser 
to the matrix then matrix to the analyte is a two step process resulting in the ionisation of both 
enabling the sample molecules to remain structurally intact. It is reported that gas phase ion 
proton transfer is the most accepted explanation for MALDI matrix ionisation (Breuher et 
ol1999). There are also other proposals for this mechanism these being; excited state proton 
transfer, gas phase photoionisation, ion-molecule reactions and desorption of preformed ions 
(Hoffmann and Stroobant 2007). Figure 1.20 aims to depict ionisation principles of MALDI.
Figure 1. 2 0 : Ionisation using MALDI. (Gates 2004). The protonated cloud o f ions is shown 
above the analyte/matrix co-crystallisation.
The formation of Cations with the analyte takes place in the following way;
[M+X]+ (X= H, Na, K etc.) (Gates 2004).
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Selection of a MALDI matrix requires tailoring to the specific analyte chosen and wave length 
of the laser (Hoffmann and Stroobant 2007).
The matrix needs to exhibit stability under vacuum, be soluble in selected solvent, form 
adequate co-crystals with the analyte and absorb the laser wavelength (Sigma Aldrich 2001). 
Examples of common matrices used and the associated applications are listed in Table 7.
The MALDI source consists of a pulsed laser (varying pulse widths) to produce packets of ions 
to be introduced into the time of flight (ToF) analyser (Hoffmann and Stroobant 2007).
Nitrogen lasers were the initial choice for MALDI and are relatively inexpensive compared to 
otheralternatives, although reports claim that irregularity of the beam can lead to 'hot spots' 
typically due to the heterogeneous nature of the N2 laser. (Trim et ol 2010). However the short 
lifespan of the N2 laser is an issue when selecting this laser type for MALDI imaging. Therefore 
these have been largely superseded by the use of ND:YAG solid state lasers. These solid state 
lasers are a common choice for MALDI-MSI due to their high repetition rate and extended 
lifespan (Trim et ol 2012). It is stated that up to 1 kHz having been employed using ND:YAG 
compared to 20 Hz on a standard N2 laser and ~ lx l0 9  shots compared to 2x107-6x107 shots 
respectively.
Trim et al (2010) proposed 2 other alternatives these being; Nd:YLF (yttrium lithium fluoride) 
and Nd:YV04 (yttrium ortho-vanadate). The latter paper continues to investigate the Nd:YV04 
laser and details experiments to progress the appearance of the beam using mechanical 
oscillation to reduce laser 'speckle'. Results with employment of beam enhancement displayed 
improved spectra with increased intensity.
Proteins/ peptides a -  C yano-4-hydroxycinnam ic acid (CHCA), 2,5- 
D ihydroxybenzo ic acid (DHB), 3 ,5 -D im e thoxy-4 - 
hyd roxycinnam ic acid (sinapic) (SA_
Lipids D ith rano l (DIT)
Inorganic molecules T rans-2 -(3 -(4 -te rt-B u ty lphe ny l)-2 m ethy l-2 - 
p ro pe ny lied ene )m a lo no n itr ile  (DCTB)
Organic molecules 2,5 -D ihydroxybenzoic acid (DHB)
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Carbohydrates 2,5 -D ihydroxybenzoic acid (DHB), a  -  Cyano-4- 
hydroxycinnam ic acid (CHCA), 
T rihyd roxyace tophenone (THAP)
Oligonucleotides T rihyd roxyace tophenone (THAP), 3- 
H ydroxyp ico lin ic  acid (HPA)
Synthetic polymers 2,5-D ihydroxybenzoic acid (DHB), D ith rano l (DIT), 
T rans-3-indoleacrylic acid (IAA)
Table 7 : Common matrices used in UV- MALDI.(Hoffmann and Stroobant 2007).
1.3.4. Quadrupole Time of flight mass spectrometry (QqToF)
The term QqToF refers to a hybrid mass spectrometer which the employs a quadrupole, (an
arrangement of four metal rods with applied potentials; +(U+Vcos(wt)) and -(U+Vcos(cot)) 
where fixed U and alternating Vcos(cot) potentials can be applied to selected ions for MS/MS.
The quadrupole arrangement used in a typical QqTOF arrangement is shown in Figure 1.21, 
where Q refers to the mass resolving quad and q describes a hexapole collision cell which can 
further dissociate precursor ions which are then separated again by another quadrupole or 
time of flight mass analyser. (Chernushevich et ol 2001). The diagram (Figure 1.21) shows Q0 
which functions as a "collisional dampening" r.f. quad to focus ions prior entry into the Q1 
mass filter and Q2 collision cell. In some cases instruments can feature Q0 (Figure 1.21) and Q2 
both as hexapoles. The schematic diagram above also illustrates the location of the ToF mass 
analyser and other components within the Q-ToF instrumentation.
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Figure 1. 2 1 : Diagrammatical representation o f a tandem QqTOF mass 
spectrometer. (Chernushevich et a12001).
If only mass spectra in ToF MS mode is required the Q1 quad operates in r.f. mode to simply 
provide a means of transmission for the ions generated which then continue to the ToF mass 
analyser. (Chernushevich et al 2001). Q2 parameters are maintained (<10 electron volts (eV)) 
as such to not induce fragmentation.
In MS/MS mode the precursor ion of interest is selected via the mass filtering Q1 which then 
reaches the Q2 and undergoes collision induced dissociation (CID) with an inert gas i.e. 
nitrogen/ argon. Subsequent acceleration then occurs of ion fragments and corresponding 
parent ions to the ion modulator (see Figure 1.21) in the formation of a continuous beam 
focused by ion optics. The pulsation of ions via an electric field at discreet bursts admits ions 
into the ToF mass analyser (Figure 1.22) in a way governed by the ion’s characteristic trajectory.
55
60
C i alinfi —I r—
I *  u  M n
II
II
l“ l In f r a c t io n  
- *  pulse
Detector
Collision cell Q2
c = a 11!!5. .5
t T i  B H
i)
T roF
Figure 1. 22 : Schematic representation of a ToF modulator (Chernushevich et al 2001).
1.3.5. Synapt HDMS -  travelling wave ion mobility separation.
Briefly mentioned earlier in section 1.2.4. (Proteomics using mass spectrometry), is the
revolutionary concept of ion mobility separation (IMS) coupled with mass spectrometry. This 
novel concept allows visualisation into another dimension of spectral data.IMS has structural 
elucidation capabilities and the capacity to provide a further separation method of isobaric 
ions. (Pringle et al 2007).
The theory of ion mobility describes the separation of bundles of ions under a static electric 
field with the use of a 'background' gas (Pringle et al 2007,. Clemmer and Jarrold 1997,. 
Valentine et al 1997). A novel idea which uses molecular separation by mass, shape (cross 
sectional area) and chiral spin. Work reported in this thesiswas performed usingSYNAPT™ 
G1/G2HDMS systems (Waters Corp., Milford, MA) (Figure 1.23). A series of 3 travelling wave 
stacked ring ion guides (Figure 1.24) constitute the ion mobility segment of the Synapt series 
instruments where packets of ions are allowed to accumulate from previous IMS then released 
to the ion guide for further mobility separation.
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Figure 1. 23 : SYNAPT™ G2 HDMS system (Waters Corp., Milford, MA). (Waters 2012).The Tri 
Wave ion mobility cell is shown where selected ions of interest are separated dependant on 
size, cross sectional area and chiral spin. The mass analyser is set to dual reflectron mode to 
aid the focusing of high energy ions to achieve high mass resolution.
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Figure 1. 24 : Stacked ring ion guide (Pringle et al 2007).
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Travelling wave ion guides (TWIGs) which carry the ions through are the result of a temporary 
dc voltage applied to the RF of opposite electrodes in constant succession throughout the 
instrument. (Pringle et al 2007). The motion of the ions is likened to the "surfing o f ions on the 
wove” . (Giles et al 2004). Figure 1.25 illustrates the travelling wave ion guide, the driving 
force for the movement of ions.
K nit* Hectrode Pan
l l l l l l l l l l l l l l l l l l  
l l l l l l l l l l l l l l l l l l
Time
■ f f f f
r e
1
n *
1 's
■
D C  Pulsc ,ons
Figure 1. 2 5 : Travelling wave ion guide- schematic representation. (Pringle et al 2007).
The principle of ion mobility separation is based on the collision cross-section (Q) as the ions 
traverse through a field of inert gas, this can be expressed in the following equation. The 
values relate to gas-phase collision cross-section (Clemmer and Jarrold 1997):
Q  = -------16 N
Where N is the background gas number density, ze is the ionic charge, p the reduced mass of 
the ion and the drift gas molecules, kb Boltzmann's constant, T gas temperature, A^is the 
mobility to 273.2 K and 760 Torr.
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1.3.6. MALDI-mass spectrometry imaging
Matrix assisted laser desorption ionisation -  mass spectrometry imaging (MALDI-MSI) is an 
advanced analytical tool that allows molecular profiling and imaging of many classes of 
compounds including; proteins, peptides, lipids, drugs and many other molecules directly from 
tissue sections. The use of this technique for the study of biological tissue was first described 
by Caprioli et al. in 1997 and it has been improved and adapted for use in many other studies 
(Caprioli et al 1997., Chaurand et al 2006., Chaurand et al 2003., Stoeckli et al 2007,. Burrell et 
al 2007,. Djidja et al 2008,. Trim et al 2008,. Fournier et al 2008).
MALDI-MSI allows the acquisition of multiple single mass spectra across the tissue section at a 
spatial resolution predefined by the operator (typically 20-200 pm) (Figure 1.27). These mass 
spectra are then combined together in order to generate molecular maps or images which 
represent the distribution and the relative abundance and/or intensity of a specific ion signal 
detected within the tissue section. MALDI-MSI has been shown to be a powerful technique for 
direct protein analysis within tissue sections and in tumour tissue samples, it has been used for 
discrimination between tumour and non tumour regions with no requirement for predefined 
targets (Schwartz et al 2004,. Chaurand et al 2001,. Lemaire et al 2007,. Schwamborn et al
2007,. Lemaire et al 2007). A recent and exciting development in the technique is the use of 
"on-tissue" tryptic digestion in order to achieve direct identification of proteins within a tissue 
section (Lemaire et al 2007,. Shimma et al 2006,. Groseclose et al 2007).
Such molecular profiling and imaging could be described as a bottom-up shotgun approach to 
protein identification, performed directly on cryo-sectioned tissue samples, rather than 
through protein extraction methods. The chance to visualise the position of peptides within an 
image generated by MALDI-MSI could indeed advance our knowledge in cancer research 
studies. Also being able to observe co-localisation of peptides and possibly relate them to 
disease states can provide complementary information regarding cancerous tissues.
A 2009 article by Djidja e ta l mentioned earlier, described the profiling and imaging of glucose- 
regulated protein 78 kDa (BiP/Grp78) in pancreatic tumour sections. As described within the 
article, the MALDI images were the first of their kind, with the discussion emphasising the low 
abundance of this particular heat shock protein. However its importance is not to be 
underestimated in the aggressiveness, progression and drug resistant nature of tumours. The 
paper then goes on to describe how the combination of ion mobility and MALDI helped to 
selectively target specific proteins for imaging. This technique has been called Matrix-Assisted 
Laser Desorption-lonisation-lon Mobility Separation-Mass Spectrometry Imaging (MALDI IMS-
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MSI) and its advantages for imaging of specific proteins has also been described by others 
(McDonnell et al 2010).
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Figure 1. 2 6 : MALDI-MSI workflow diagram (McDonnell et al 2010).
In addition to the matrix deposition shown above in Figure 1.26 displaying a discreet 
arrangement of matrix/ reagent droplets, other methods include manual or automated 
spraying to achieve a finer more homogenous coating for co-crystallisation.
Examples of commercially available sample preparation for enzyme and/or matrix deposition 
are; Chemical Inkjet Printer by Shimadzu a sprayer using vibration vaporisation, Suncollect by 
SunChrom an automated spraying system, Portrait™ 630 Multispotter by Labcyte which works 
using high precision acoustic ejection from a reservoir source. (McDonnell et al 2010).
1.3.7. Quantitiative Proteomics
A number of methods have been proposed for quantitative protoemics.which include both 
label and label free quantitation.
1.3.7.1 Label free quantitation
Immunoassays and immunoblots are methods which are widely used, however development 
and optimisation of protein specific antibodies can be considered both time expensive and 
time consuming (Tate et al 2012). Cross reactivity can also be one of the main pitfalls of 
immune targeted approaches. It can be said that the latter includes some of the reasoning 
behind a shift towards mass spectrometry.
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One of the most basic label free methods of quantitation in proteomics is spectral counting. 
Shotgun proteomics (as shown in Figure 1.17) describes an experiment where MS/MS results 
are summed for each peptide and comparison of summed events for each peptide can then be 
analysed throughout a time course of results (Tate et ol 2012). More detailed analysis of 
spectral counting can involve i.e. counting of unique peptides before and after normalisation.
Measurement of the area generated from peptide signal intensity in the MSI scan is another 
quantitative label free approach (Tate et ol 2012). Quantitative information is acquired via an 
extracted ion chromatogram. This value from the ion of interest is taken at a specific region in 
time. This information is then used to associate the LC elution peak with the selected mass of 
interest. Processing of these data involves the alignment of MSI chromatographic peaks 
throughout the samples/ time course samples analysed, the areas are then profiled.
Figure 1.27 shows an example using Progenesis, one of the proteomic software packages that 
can be used to analyse area measurements as previously described.
Control Treated
Figure 1. 27 :The concept of area peptide measurement coupled with a specific time 
domain,visualisedthrough Progenesis LC~MS software. 
(http://www.nonlinear.com/products/progenesis/lc-ms/overview/)
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1.3.7.2 Labelling fo r proteomic quantitation
Isobaric Tags for Relative and Absolute Quantitation (iTRAQ) have been applied to numerous 
mass spectrometry studies (Song et a/2008,. Ross et ol 2004,. Gygi et ol 1999). iTRAQ enables 
samples to be labelled and then combined to perform 4 plex /  8 plex experiments to analyse 
tryptic digests from cells/ tissue (Shilov et al 2007). Each isobaric tag is comprised of a reporter 
group, balance group and a peptide reactive group. This proteomic bottom up approach 
requires tandem MS to give relative absolute quantitation information using reporter groups 
from 113 -  121. A control is included as a reference in the combined labelled samples and 
quantitation ratios are then relative to the control. MS/MS spectra can then be submitted to 
protein search software which can result in identification of the labelled peptides.
An example of an iTRAQ workflow is shown in Figure 1.28.
Tw\*trr**r* K TfM$r*fw8 TwMfrwtC Tf*»cnwit D
Protein extraction followed by 
enzymatic digestion
Combine labeled digests
Analysis by LC-MS/MS
iTRAQ label rr R A 0114 (TRAQ11S I ITRAQ 116 HRA0117
QUANTIFICATION 
FROM ITRAQ 
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Figure 1. 28 : Simple workflow using Isobaric Tags fo r Relative and Absolute Quantitation 
(iTRAQ). ( Broad Institute 2013 ).Relative quantitation can be measured by observation o f 
the isobaric MS/MS fragments in the region o f the spectra that correspond to a particular 
labelled specimen.
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1.3.8. Aims of the study
The aims of the study reported in this thesis are to develop and utilise mass spectrometry 
imaging techniques (MALDI-MSI), in combination with conventional proteomic methodologies, 
to investigate protein induction in vascular-targeted strategies.
Here MALDI-MSI intended to compliment conventional proteomics to provide information 
relating the spatial distribution of protein/ peptides throughout time course experiments. Both 
CA-4-P susceptible (fibrosarcoma 120) and resistant (fibrosarcoma 188) tumour models were 
used to perform profiling and imaging experiments.
The tumour models used within this study originate from a mouse embryonic fibrosarcoma cell 
line and had been genetically engineered to either express solely the vascular endothelial 
growth factor (VEGF) 120 or 188 isoforms. Vasculature derived from the VEGF 120 growth 
factor characteristically favours cell proliferation but produces an erratic disorganised network 
of blood vessels with 'blind ends' lending itself to haemorrhagic disruption by CA-4-P. Tumour 
blood capillaries in the fibrosarcoma 188 model are less substandard and as a consequence 
mimic a more normal vascular arrangement (Tozer et al 2008). Tozer et al (2008) found that 
VEGF 188 tumour vasculature had increased pericyte support hence adding to CA-4-P 
resistance.
Nine different VEGF isoforms have currently been discovered in humans, with VEGF189, 
VEGF165 and VEGF121 isoforms being the most documented and VEGF120, VEGF164 and 
VEGF188 in mice ( Tozer et al 2008,. Harris et al 2012). VEGF mRNA is transcribed from eight 
exons and splice variants result in the various isoforms mentioned previously. Each isoform is 
known to have its own distinctive vascular modelling and angiogenic configuring capability.
Each VEGF isoform is thought to govern angiogenesis in relation to whether it is matrix bound 
or not and yet little is known with regards to VEGF biological /  mechanistic function (Harris et 
al 2012). VEGF120 does not possess a heparin-binding site and is described as being 'readily 
diffusible'. VEGF188 on the other hand is bound to proteoglycans, components of the 
extracellular matrix or at the cell surface (Figure 1.29) (Tozer et al 2008).
In tumours VEGF is associated with tumour growth and metastasis, increased levels of VEGF is 
said to correlate with poor patient survival.
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Figure 1.29: (A) The exon structure of the mouse VEGF isoforms showing the differences 
/ similarities between exons and nature of each isoform whether diffusible or matrix bound. 
(B) The reverse transcription-PCR of cDNA showing the bands representative of each VEGF 
isoform. Traces of bands relating to other isoforms are present in the control but still align 
with the specific isoform bands (Tozer et al 2008).
PMFs were acquired from in-situ tissue tryptic digestion and proteins thought to be involved in 
tumourigenesis and drug treatment resistance were observed and targets which could be 
linked with hypoxic conditions of the tumour microenvironment.
Multivariate Statistical analysis aimed to observe grouping and classification within data time 
courses post CA-4-P administration.
The techniques used; MALDI-MSI, ESI-LC-MS/MS, LC-MALDI-MS/MS with iTRAQ labelling 
intended to provide cross validation of the effects post administration of vascular disrupting 
agent CA-4-P.
MALDI imaging of proteins related to tumour biology and the stress response could forge a 
place in the clinical setting providing alternative tool in the field of cancer research.
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Chapter 2
Protein induction in a CA-4-P 
susceptible tumour model using
MALDI-MSI
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2.1 Introduction
The discovery of biomarkers that can be used to determine success of cancer therapy or 
resistance to it, at an early stage, presents a very complex problem. There are countless 
biochemical pathways to be considered and the multifaceted characteristics of the cancer cell 
have also to be taken into account; a cell that can largely evade the host's immune responses, 
has mastered tissue invasion and anti-cancer drug resistance.
One promising class of anti-cancer drug currently under developmentis the vascular disrupting 
agents (VDAs) (Kanthou and Tozer 2007). VDAs cause rapid, selective and sustained shutdown 
of tumour blood flow. This produces drastic effects on the tumour microenvironment. Certain 
aspects of blood flow modification are due to the direct effects of the drug on the endothelial 
cells that line the luminal surface of blood vessels.The article by Kanthou and Tozer describes a 
proposed mechanism of action for CA-4-P (Kanthou and Tozer 2007). It is suggested that 
increased permeability after the administration of CA-4-P is one major factor in the disruption 
of endothelial organisation. Interference in vascular integrity due to abnormality in the 
cytoskeleton, subsequently leads to stress fibre formation and endothelial cells become more 
rounded ('blebbing'). Haemorrhagic necrosis follows exacerbating the already hypoxic regions 
within the tumour microenvironment.
As mentioned in the introductory chapter, the remodelling and formation of actin stress fibres 
is clearly demonstrated using immunofluorescence by Siemann (Siemann 2010). The images 
contained in this article are good examples of the "rounding" of endothelial cells and 
"condensation" of the microtubules post CA-4-P treatment.
Drug delivery of VDAs is relatively simple due to endothelial positioning near the bloodstream. 
The diploid target cells are thought not to be directly drug-resistant due to low risk of 
mutations (Thorpe et al 2003).
VDAs have relatively good clinical measurability, i.e. bloodflow and in most cases short-term 
exposure to a VDA creates sufficient hypoxic conditions to induce necrosis. However, the use 
of VDAs to increase hypoxia can also have undesirable consequences (Zhi-chao and Jie 2008), 
(Tozer et al (2008) . Hypoxia-inducible factors (HIF), which are prevalent under hypoxic 
conditions, cause up-regulation of pro-angiogenic factors such as VEGF. VDA smight amplify 
the angiogenic process after the creation of an increased hypoxic tumour environment. 
Hypothetically speaking this could even help the metastatic process ensuring tumour invasion 
(Zhi-chao and Jie 2008).
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In addition to acquired resistance to treatment, the heterogeneous tumour mass could well 
contain a cell population oblivious to vascular targeted strategies, i.e. innate resistance 
(Thorpe et al 2003). Support for this comes from the hypothesis that there are four possible 
micro-vascular phenotypes in existence i.e. normal pre-existing, tumourphenotypic vessels, 
normal neo-vasculature and abnormal (pathological) neo-vasculature. It may explain why 
some tumour regions remain unaffected by VDA treatment, including the well documented 
viable tumour rim (Abdollahi and Folkman 2010). The viable tumour rim is also thought to 
achieve evasion through its positioning, adjacent to the non-diseased tissue, which is well 
supplied with oxygen andessential nutrients (Kanthou and Tozer 2009). Resistance 
mechanisms to VDAs are clearly complex and multifactorial but increased knowledge in this 
area could provide strategiesfor future combination therapies.
The largest group of VDAs are tubulin binding, microtubule-depolymerising drugs such as 
combretastatin A-4-3-0-phosphate (CA-4-P/Fosbretabulin/ZybrestatTM), which is currently in 
late stage clinical trials. Combination of CA-4-P or a related compound, Oxi4503 (CA-l-P), with 
anti-angiogenic therapysuch as VEGF receptor tyrosine kinase inhibitors has already shown 
promise and novel concepts aimed at targeting circulating angiogenic endothelial progenitor 
cells have also been proposed. This area has been recently reviewed by Siemann (Siemann and 
Horsman 2009).
The experimental work reported here, describes a study, by MALDI MSI and MALDI IMS-MSI, 
of the proteins induced in a mouse transplanted fibrosarcoma model (VEGF120 tumours), at a 
number of time points, following treatment with CA-4-P. Imaging of peptide signals after in 
situ tissue tryptic digestion was carried out using MALDI-MS and MALDI IMS-MSI to observe 
their spatial distribution. MALDI-IMS-MS/MS of the peptide signals was performed to identify 
proteins involved in the pharmacodynamic responses to treatment.
2.2 Materials and Samples
2.2.1 Chemicals and Materials
a-Cyano-4-hydroxycinnamic acid (CHCA), aniline (ANI), ethanol (EtOH), chloroform (CHCI3), 
acetonitrile (ACN), octyl-a/b-glucoside (OcGIc), tri-fluoroacetic acid (TFA), ammonium 
bicarbonate, haematoxylin, eosin, xylene and DPX mountant were from Sigma-Aldrich (Dorset,
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UK). Modified sequence grade trypsin (20 pg lyophilised) was obtained from Promega 
(Southampton, UK).
2.2.2 Tissue samples
Severe combined immunodeficiency (SCID) mice were injected sub-cutaneously in the flank 
with a 50 pi tumour cell suspension containing 1 x 106 cells in serum-free medium.The cells 
employed in this study were from the mouse fibrosarcoma cell line, VEGF120. This has been 
engineered to express only the VEGF 120 isoform. Tumours were allowed to grow to 
approximately 500 mm3, before CA-4-P treatment (a single dose of 100 mg/kg i.p). The dosage 
for CA-4-P are consistent with animal studies performed at clinically relevant doses (Galbraith
2003., Prise 2002). Treatment was either Saline/ Control, Mice were killed and tumours excised 
at various times after treatment. In the case of Oh CA-4-P, the tumour was excised 
immediately (within 2mins) after dispatchment. All animal work carried out documented 
herein was performed by Dr. J. E. Bluff, Tumour Microcirculation Group, University of Sheffield, 
UK. Samples were provided as frozen excised tumours and stored at -80°C.
2.2.3. Experimental groups
Controls (no treatment, saline i.p), n = 6 (labelled tu m o u rl_ l -  tumour 1_6), C-A4-P (0 h after 
treatment), n = 6, (labelled tumour2_l -  tumour 2_6), C-A4-P (0.5 h after treatment), n = 
6,(labelled tumour 3_1 -  tumour 3_6), C-A4-P (6 h after treatment),n = 6, (labelled tumour 4_1 
-  tumour 4_6), C-A4-P (24 h after treatment)n = 6, (labelled tumour 5_1 -  tumour 5_6).
2.2.4 Tissue preparation
Frozen tissue sections were cut to give approximately 10pm sections, using a Leica CM3050 
cryostat (Leica Microsystems, MiltonKeynes, UK) (Djidja et al 2009). The sections were then 
freeze thaw mounted on poly-lysine glass slides. Mounted slides were either used 
immediately or stored in an airtight tube at -80 °C for subsequent use.
2.2.5 In  s itu  tissue digestion and trypsin deposition
The triplicate tissue samples to undergo MALDI-MS/MSI were washed initially with 70% and 
then 90% ethanol for 1 min then left to dry, subsequently slides were immersed in chloroform 
for 10 s. Prior to matrix application,
in situ tissue digestion was performed with trypsin solution prepared (from lyophilised trypsin)
at 20 pg/ml by addition of 50 mM ammonium bicarbonate (NH4HC03) pH 8, containing 0.5%
octyl-a/b-glucoside (OcGIc) based on a protocol by Djidja et al (2009).
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Two automated systems were used for trypsin application. The "Suncollect" (SunChrom, 
Friedrichsdorf, Germany) automatic pneumatic sprayer was used to spray trypsin in a series of 
layers. The Portrait™ 630 Multispotter (Labcyte, Sunnyville CA) was used to apply trypsin in a 
200-300 pm array of spots. The sections for MALDI-MS and MALDIMSI were incubated 
overnight in a humidity chamber containing H20  50%: methanol 50% overnight at 37 °C and 
5% C02.
2.3Methods and instrumentation
2.3.1 Matrix deposition
The matrix, a-cyano-4-hydroxycinnamic acid (CHCA) and aniline in acetonitri!e:water:TFA 
(1:1:0.1 by volume), was applied using either the Suncollect (at 5 mg/ml) or the Portrait™ 630 
Multispotter (at 10 mg/ml), as described above. Identical coordinate settings were used as 
with the trypsin deposition, to ensure sample uniformity. Equimolar amounts of aniline were 
added to the CHCA solution, i.e. 1 mlof 5 mg/ml CHCA solution contained 2.4 pi of aniline. 
These matrix deposition parameters were based on methods from Djidja et ol (2009).
2.3.2 Instrumentation
Peptide mass fingerprints and images were acquired by MALDI-MS/MSI using a Q-Star Pulsar i
hybrid quadrupole time-of-flight mass spectrometer (Applied Biosystems/MDS Sciex, Concorde,
Ontario, Canada) fitted with a variable repetition rate Nd:YV04 laser set at 5 kHz. Image
acquisition was performed using raster imaging mode at 150 Im spatial resolution, Biomap
3.7.5.5 software (http://www.maldi-msi.org/) was used for image generation. Instrument
calibration was performed using standards consisting of a mixture of 217 polyethylene glycol
(Sigma-Aldrich, Gillingham, UK) ranging between m/z 100 to 218 3000 Da prior to MALD1-IMS-
MSI analysis.To enable simple visual comparison between images all data were normalised to
m/z 877 (a peak arising from the aCHCA matrix) and intensity scales in the BioMap software
were all set to the same value. MALDI- IMS/MS, MALDI- IMS/MSI and MALDI- IMS-MS/MS
were performed using a HDMS SYNAPT™ G1/G2 system (Waters Corporation, Manchester, UK)
and Drift scope 2.1 software (Waters Corporation, UK). In order to achieve good quality
MS/MS spectra, they were acquired manually moving the laser position and adjusting the
collision energy to achieve good signal to noise for product ions across the full m/z range of
the spectrum. Collision energies were adjusted from 70 to 100 eV during acquisition and
acquisition times were generally of the order of 5-10 s per spectrum. MS/MS spectra were
uploaded to perform a Mascot (Matrix Science, London, UK) search which used the UniProt
database in order to generate a sequence match (see Table 1 for results).
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2.3.3 Haematoxylin and eosin staining
Slides were immersed in haematoxylin for 1 min, rinsed in tap water until the water ran clear, 
immersed in 1% eosin for 30 s and rinsed in tap water until the water ran clear. They were 
then dehydrated as follows: 50% ethanol for 2 min, 70% ethanol for 2 min, 80% ethanol for 2 
min, 95% ethanol for 2 min and 4 changes of xylene applied to each slide for 1 min at a time. 
Finally, they were mounted with DPX mountant and left to dry in the fumehood overnight.
2.3.4 Data pre-processing using SpecAlign and Marker View software
Data lists were exported from Analyst QS software (Applied Biosystems/MDS Sciex, Concorde,
Ontario, Canada) as text files, then imported into SpecAlign (Oxford, UK) to undergo the 
following data processing; baseline subtraction, smooth, denoise, normalise TIC, remove 
negative, generate average spectrum, processing spectral alignment, PAFFT correlation 
method max shift 20. Files were then exported as text files for import into Marker View 
software 1.2 (Applied Biosystems/MDS Sciex, Concorde, Ontario, Canada).
2.3.5 Statistical analysis
PCA-DA was performed using Marker View software 1.2 (Applied Biosystems/MDS Sciex, 
Concorde, Ontario, Canada). Post SpecAlign text files were imported and data was transposed 
into table format. A minimum intensity of 0.1 was selected, with a maximum number of peaks 
of 20,000. Monoisotopic peaks selected by Marker View were used in the supervised PCA-DA. 
PCA and PLSDA was performed using MATLAB®(Matrix Laboratory) (MathWorks, Inc., Natick, 
MA 486USA).The PCA-DA/ PCA/ PLSDA data that follows is representative of the fibrosarcoma 
120 data where 6 biological replicates per time point with 6 technical replicates for each, 
(control -  24 hours). PLSDA Data for ROI study using HDI software (Waters Corporation, 
Manchester, UK) was analysed using one tumour per time point with 9 technical replicates per 
ROI. Variable Importance in Projection (VIP) scores were used from PLSDA regression 
modelling to determine the importance of variables within the data time course.
2.3.6 Data pre-processing usingWaters MassLynx™ Software and MATLAB®
MS results are imported into MATLAB® in .txt or .csv format either post "SpecAlign" or after
application of "automatic peak detection" if using the instrument data processing software 
(Waters MassLynx™ Software). Normalisation (2-Norm) and mean centre were selected, 
"contiguous blocks" was used for cross validation.
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2.4 Results and Discussion
2.4.1 In itial MALDI profiling and imaging of in situ tissue tryptic digests in 
mouse fibrosarcoma 120 models
Initial profiling and imaging experimental work was performed using an Applied Biosystems Q- 
Star Pulsar i Quadrupole ToF Mass Spectrometer. Preliminary peptide mass fingerprints 
(PMF's) (Figure 2.1) where acquired to provide insights into typical high abundant potential 
peptides in order to observe any gross pharmacological responses post CA-4-P administration.
+TGF MS: 42 MSA scans from Sanple 3 (190210_5_6_centre) of 5_6.wiff 
a=3.57031177631956190e-004, t0=5.60672130395284330e+001, Smoothed, Baseline...
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Figure 2 .1 : Representative peptide mass fingerprint (PMF) arising from an on-tissue digest of 
a VEGF120 tumour 24 h after dosing with 100 mg/kg i.p, CA-4-P. Prior to matrix application 
in situ tissue digestion was performed with trypsin solution prepared (from lyophilised 
trypsin) at 20 pg/m l by addition o f 50 m M  ammonium bicarbonate (NH4HC03) pH 8.12, 
containing 0.5% octyl-a/b-glucoside (OcGIc). The matrix employed was a-cyano-4- 
hydroxycinnamic acid (CHCA, 5 mg/ml) and aniline in acetonitrile:water:TFA (1:1:0.1 by 
volume).
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The spectra shown in Figure 2.2 are from the following samples: (a) control/saline, (b) 0 h post 
CA-4-P, (c) 0.5 h post CA-4-P, (d) 6 h post CA-4-P and (e) 24 h post CA-4-P.The increase in the 
relative intensity of m/z 1819.3 along with other readily identifiable haemoglobin peptides (e.g. 
m/z 1529.7HbAa 18-32 (IGGHGAEYGAEALER), m/z 1274.3 HbAb 52-41(LLVVPWTQR)) can be 
seen. This increase in tissue haemoglobin is as would be expected considering the vascular 
damaging propertiesof CA-4-P. Due to disruption of the 3D capillary architecture, endothelial 
cell necrosis, apoptosis and leakage of blood cells into tumour tissues is inevitable. This is 
clearly illustrated by Figure 2.3, where MALDI-MS images for the distribution of m/z 1274 
(HbAb 52-41) at each time point are shown along with photographs of the corresponding 
haematoxylin and eosin stained sections. It is debateable in the Oh treatment how much of the 
drug reaches the tumour, however there is an apparent signal in Figure 2.3 corrresponding to 
m/z 1274. Further drug distribution studies would clarify presence of CA-4-P and its 
metabolites.
Figure 2. 3: MALDI-MS images fo r the distribution of m /z 1274 throughout a fibrosarcoma 
120 timecourse. (HbAb 52-41) in (a) control (saline), (b) 0 h post CA-4-P (c) 0.5 h post CA-4-P, 
(d) 6 h post CA-4-P and (e) 24 h postCA-4-P, along with photographs of the corresponding 
haematoxylin and eosin stained sections.
24 hourS CA-4-P
/ V '  ,  • r•r. J*
. vyjdespread 
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2.4.2 Haematoxylin and Eosin staining of fibrosarcoma 120 tissue
Haematoxylin and eosin (H&E) staining of each fibrosarcoma 120 serial section was performed
after imaging for identification of viable and necrotic tissue and to make observations of the 
tumour rim.
Examples of viable and necrotic tissue are shown in Figure 2.4: (a) control saline-treated 
tumour which is essentially viable, (b) control tumour with a small necrotic region, (c) 0 h CA-4- 
P showing viable tissue, (d) 0 h CA-4-P showing viable and necrotic regions, (e) 0.5 h after CA- 
4-P showing viable tissue, (f) 0.5 h after CA-4-P showing viable and increasing necrotic regions, 
(g) 6 h after CA-4-P showing partially viable regions, (h) 6 h after CA-4-P with haemorrhage and 
necrosis and (i) 24 h after CA-4-P treatment showing total necrosis.
Higher magnification images of the H&E staining of the tumour rim in the VEGF120 tumour 
sections are shown in Figure 2.5: (a) control/ saline, (b) 0 h CA-4-P, (c) 0.5 h after CA-4-P, (d) 6 
h after CA- 4-P and (e) 24 h after CA-4-P. The H&E tissue sections indeed reflect the 
heterogeneous nature of the tumour especially considering the control with no CA-4-P (Figure
2.5 a), however the effect of the vascular disrupting agent is still apparent and the 0.5 h image 
(Figure 2.5 c) suggests a good example of the viable tumour resistant rim.
In all images, viable tumour cells have densely packed nuclei which appear as regions of 
"organised cells" which stain blue in H&E staining whereas regions of necrosis, due to cell lysis 
tend to show as a disorganised region with less blue staining. In these data, haemorrhaging 
also gives a pink colour to the tissue e.g. Figure 2.4h.
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Figure 2. 5: Higher magnification images of the H&E staining o f the tumour rim in the 
VEGF120 tumour sections. Control (saline), (b) 0 h post CA-4-P, (c) 0.5 h post CA-4-P, (d)6 h 
post CA-4-P and (e) 24 h post CA-4-P. The 0.5 h image displays a good example o f the viable 
tumour resistant rim.
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2.4.3 In itial imaging of proteins according to theoretical digests using M A L D I-  
MS1
Proteins which could be of relevance to tumour biology and the stress response were 
tentatively identified according to theoretical digests (Li et al 2011). The following preliminary 
MALDI images were observed to aid focus on potential future protein targets to consider in 
this dose response relationship study.
CHCA matrix peak m/z 877r
■k
r * \
D jlaLC  101I09_5_1(D911101C .h3fxTO _l_m 3.W B *
(c) TNF-a m/z 954
'  '   2 10
.vt * r '
(a) m/z 1887 Grp78
%*
(d) VEGF 120 m/z 1485
(b) m/z 1749 HIF-1a
0 .9 6
(e) VEGF A m/z 1850
Figure 2. 6: MALDI-MSI o f peptides from tumour 5:1 (24hrs CA-4-P). CHCA matrix peak m /z  
877 used for normalisation ,(a) m /z 1887 Grp78, (b) m /z 1749 HIF-la, (c) TNF-a, (d) m /z  
1485.7 VEGF 120, (e) m /z 1850.8 VEGF A (188), according to theoretical digests and (f) 
tumour 5:1 histological section after H8cE staining with magnified insert showing necrotic 
tissue.
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The ion signals shown in Figure 2.6 were generated according to predicted theoretical tryptic 
digests. Although at this stage protein the identifications were not yet confirmed, it was 
fascinating to notice the differing spatial distribution of the potential peptides thus reflecting 
the heterogeneous nature of tumour tissue.
The possible detection and spatial distribution of proteins like glucose-regulated protein 78/ 
Binding immunoglobulin protein (Grp-78/ BiP) (Figure 2.6a) could reveal vital information of 
how CA-4P can effect tumorigenesis thus inducing other pathological stimuli.
The image tentatively identified as belonging to VEGF A (188 isoform using UniProKB database 
(mouse) with 2 missed cleavages) in Figure 2.6 e is quite contradictory to the mouse model 
employed which had been genetically engineered to solely express the VEGF 120 isoform. The 
latter could be due to immune cell infiltration.
It was found however, that through further interrogation of peptide sequence databases i.e. 
Blast (http://blast.ncbi.nlm.nih.gov/) and reference to the article by Tischer et al (1991) that 
the peptide sequence given regarding the VEGF 120 ion at m/z 1485 is incorrect. The latter 
discovery came about whilst checking whether or not the sequence giving the ion signal 
(Figure 2.6 e) at m/z 1850 really matched part of the VEGF 188 protein sequence to support 
the theory of possible immune cell infiltration. It appeared that none of the VEGF 120 peptide 
'RWQKIADELGNR' (2 missed cleavages) giving m/z 1485 provided by UniProKB theoretical 
digest is detectable in the original VEGF nucleotide sequences (Tisher et al 1991). The 
sequence in question when submitted to Blast database gave a result suggesting that the 
peptide could be a zinc finger protein. The VEGF 188 peptide 'FKSWSVHCEPCSERR' (although 2 
missed cleavages) giving m/z 1850, matched with the nucleotide sequences detailed in 
UniProKB, Blast and original VEGF nucleotide sequences presented in Tischer et al (1991). Part 
of the VEGF 188 peptide sequence coincided with nucleotide sequences present in the VEGF 
exon 6, a region of the VEGF gene known exclusively to VEGF 188 (Figure 1.29), hence 
supporting the presence of VEGF 188 in the MALDI-MSI (Figure 6 e).
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2.4.4 Principle component analysis -  discriminant analysis (PCA-DA)
Multivariate analysis was chosen to statistically analyse the complex data sets which arise from
on tissue PMF's. PCA-DA was performed to try and correlate peptide inductionwith dose 
response and to provide a method of further analysingthe PMF data.
Scenes lot Dl 141.5 veisus D2 (33 3 5S). Pareto (DA)
22-
20-
18-
16-
14-
12-
10-
8-
6
4-
2
o 0o
<M 2O
-4
-6 ■
•8-
-10-
•12
-14
-16
-18
•20.
•22.
-24-
?cmouf3!4 d M  2
(a ) tumoui^5_l txt
fumour3 3clxt 
tumom3_bf t*l i• 'a lwmout3_3d lx*
»ijriour3_3e ixl 
turnout 4_c.jxt - T t  urrour3_3b.lxt
lymolw3_3d txt 
■ turoour2_2_d.btltumoui3_6_b;lxt - * -£  ^
li^mow3_4_e lit - t f  lumoui3_&_c txt 
tumour 2_5_b.lii( — H i 
tumour 3_5_b.(xt 
turnout 3 ftict
tusnour5_3_d tx*
Hirnc«ji5^ T " a i.W  YumourS”5 c fy t " 'fC in o u fT ^ e tk f
(urr»ur5 4 f M
tumoui5 1 b Ixl
i  "" TMrtQu5_2_<S Ixl
lumout5_3_4.lxl
t •-tumourS 3 Mxi ,• •  •lumour5 4 d tx t
lumoui5_5_blxl 
tumoui5 5 a Ixt
i >}umout4_5J txt
tumour4_2..e.bct 
tumori4_4_e Ixt ^  
turnout 4j_4_b Ixl 
tumour4i 4 dtxt
1 1
V-
j turnout 4 4 f txl
i tumout4_3_f 1)4 
lj3_b W 
iumoui4_3_d Ixl
lixnour4_|3 txt
Ujrncxji4_3_a ixl t/tumour4 6 dtxt
-40 -35 -30 -25 -20 -15
Dl Score
-10
; tumour 4_3_c Ixt
-i - A ------------
tumourl 
turi»ur2 
tumour 3 
tumour 4 
tumour5
Figure 2. 7: PCA-DA of fibrosarcoma 120 tumour in situ tryptic digests.(a) The scores plot 
showing groupings and variability between tumour time point spectra, Tumour 1-5 indicates 
Saline/Control - 24h post CA-4-P (b) the loadings plot displaying the separation and spatial 
distribution o f m /z values in relation to score plot positions, (c) illustrates the variability of 
two haemoglobin peptides within each tumour section. The red arrow on (b) indicates m /z  
1274 (indicative o f haemoglobin b chain) which is associated with the tumour 4 set (6 h post 
CA-4-P).
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Figure 2.7 shows the results of PCA-DA of VEGF120 in situ tryptic digests: (a) the scores plot 
showing groupings and variability between tumour time point spectra, (b) the loadings plot 
displays the separation and spatial distribution of m/z values in relation to score plot positions, 
(c) illustrates the variability of two haemoglobin peptides within each tumour section and an 
unknown at m/z 901. The simple response present from the haemoglobin peptides was 
regarded as a standard for future time course results to aid validation of dose response 
relationships. The red arrow on Figure 2.7(b) indicates m/z 1274 (indicative of haemoglobin (3 
chain) which is associated with the tumour 4 set (6 h after CA-4-P). In Figure 2.7(b) the green 
data points are peaks identified as monoisotopic by the Marker View 1.2 software and blue 
data points are peaks which have not been assigned as monoisotopic. These are termed 
"default" by the software.
For the chemometric investigation of the proteomics data reported here, multivariate analysis 
was deemed essential because of the large data sets thousands of signals can arise from just a 
single pixel due to the acquisition of full-range mass spectra (McCombie et al 2005). 
Comparisons of spectral signals are required between both biological and technical replicates 
throughout a time course experiment and multivariate analysis allows a better visualisation of 
the "vast data clouds". PCA-DA was chosen to provide preliminary insights into ion signals 
generated by in situ tryptic digestion using MALDI-MSI with the hypothesis that the samples 
should show separation of unique peptides due to known individual treatment time points.
The scores plot in figure 2.7a provides clear separation of tumour treatment groups 3, 4 and 5 
which refer to 0.5 h, 6 h and 24 h post CA-4-P respectively. The earlier time points being 
tumour 1 (control/ saline) and 2 tumour (0 h) are not visible but can been seen if the region 
indicated is expanded. The peaks that appear on the loadings plot (Figure 2.7b) seem to be 
representative of high abundant peptides i.e. histones (m/z 944, m/z 1032, m/z 1325) and 
haemoglobin (m/z 1274, m/z 1416) which relate to the occurrence of haemorrhagic necrosis, 
DNA damage and hypoxic conditions within the tissue.
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2.4.5. Employment of Ion Mobility MALDI-Mass Spectrometry to stud yin situ 
tryptic digestion in fibrosarcoma 120 models
Ion mobility enabled MALDI profiling and imaging describes a further separation method of 
isobaric species thus opening up another dimension to spectral analysis.
*<3 U i
aB^ I ^  ^ lrlI*
m m-m m
Haem oglob in P01942 2858.4 VADALASAAGHLDDLPGALSALSDLHAHK 24 >20
subun it alpha +21.9819 AT D14 C a tion:M g [II] (DE)
[+21.9694], Ca tion:Na (DE) [+21.9819]
2836.4 VADALASAAGHLDDLPGALSALSDLHAHK 87 >20
1819.8 TYFPHFDVSHGSAQVK 106 >36
1529.7 IGGHGAEYGAEALER 98 >18
1416.7 GGHGAEYGAEALER 87 >43
H is tone H4 P62806 1325.7 DNIQGITKPAIR 76 >14
Haem oglob in P02088 1302.6 VNSDEVGGEALGR 79 >38
beta chain 1161.6 LVVYPWTQR 29 >20
1048.5 VVYPWTQR 32 >20
H is tone H2A Q8CGP5 1300.6 NDEELNKLLGR 33 >21
Type 1-F
Ac tin , aortic P62737 1198.7 AVFPSIVGRPR 30 >13
sm ooth 976.4 AGFAGDDAPR 64 >19
muscle
H is tone H3 P68433 1032.6 YRPGTVALR 11 >10
715.4 DIQLAR 19 >17
H is tone H2A Q8CGP5 944.5 AGLQFPVGR 24 >19
Type 1-F
Rho GTPase- Q91V57 844.5 RLTSLVR 21 >18
ac tiva ting
p ro te in  2 / N-
ch im aerin
Table 8: Identities and Mascot scores from the IMS-MS/MS analyses of peptide signals 
showing Mascot score o f mouse protein identifications and corresponding threshold score at 
95% confidence level.
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A representative peptide mass fingerprint obtained from a tumour from an animal sacrificed 6 
h after administration of CA-4-P (hereafter referred to as 6 h CA-4-P) using the Synapt 
instrument, is shown in Figure 2.8. These data illustrate the vast number of peptides that arise 
from an in situ tissue tryptic digest, as previously reported (Schwamborn et a/2007.,Le maire et 
al 2007., Shimma et al 2006., Groseclose 2007).
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Figure 2. 9: IMS-MS/MS data obtained from the peak observed in Figure 2.8 at m /z 1819.3. 
This was identified by Mascot search as arising from Mouse HbAa 42-57 
(TYFPHFDVSHGSAQVK).
Figure 2.9 shows IMS-MS/MS data obtained from the peak at m/z 1819.8. This was identified 
by Mascot search as arising from Mouse HbAa 42-57 (TYFPHFDVSHGSAQVK) (Table 1). These 
data are also a further indication of the advantages of IMS for the identification of "on-tissue" 
generated tryptic peptides. The complexity of the obtained data sets is shown in Figure 2.10a, 
where ions arising from doubly charged species and singly charged species are clearly 
separated by the use of ion mobility and further those singly charged ions arising from 
peptides, matrix adducts and lipids are also separated. Use of IMS separation prior to MS/MS 
yielded good quality MS/MS spectra for peptides that produced a high and significant Mascot 
score.
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Figure 2.10 c: Drift scope plot shows ion mobility separation of ion of interest haemoglobin subunit alpha m/z 1819.8 and C13 as shown on mass 
directly below.
The additional specificity afforded by ion mobility that allows the selection of individual ion 
species can clearly be seen in Figure 2.10c . The white arrow indicates the ion of interest (m/z 
1819.8) and the ion signal directly above depicts the isotope C13 which can be seen on the 
mass spectum below the plot.
Figure 2.11: The distribution o f two known peptides in tumour 5_6, i.e. a tumour 24 h after 
treatment with CA-4-P (a) m /z 1416 from haemoglobin a chain depicting central necrotic 
haemorrhage and (b) m /z 1198 corresponding to actin.
The MALDI MSI images shown in Figure 2.11 show the distribution of two known peptides in 
tumour 5_6, i.e. a tumour 24 h after treatment with CA-4-P: (a) m/z 1416 from haemoglobin a 
chain depicting central necrotic haemorrhage and (b) m/z 1198 corresponding to actin. The 
inverse nature of the ir distribution is striking.
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Figure 2 .12: Overlaid MALDI MSI images showing differing spatial distribution and co­
registration of peptides, (a) m /z 944 Histone 2A in red and m /z 1274 Hb in solid green, (b) 
m /z 1819 Hb in red and m /z 944 Histone 2A in solid green.
Figure 2.12 shows examples of overlaid images to show differing spatial distribution and co­
registration of peptides using MALDI MSI: (a) m/z 944 histone 2A in red and m/z 1274 Hb in 
solid green, (b) m/z 1819 Hb in red (from rainbow) and m/z 944 histone 2A in solid green. The 
Mascot scores for the IMS-MS/MS analyses of these peptides are given in Table 8.
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2.4.6 Rho GTPases: a target to help understand resistance to CA-4-P?
The Rho GTPasesare proteins known to be involved in cell permeability and actin/cytoskeleton
dynamics. (Modolo et al 2012., Aznar and Lacal 2001., Aznar et al 2004., Schmitz et al 2002). 
Influence on extra cellular matrix (ECM) integrity, apoptosis, cell adhesion and proliferation, 
makes them potential targets in the comprehension of anti-tumour drug resistance.
A review by Vega and Ridley (2008) discusses the role of Rho GTPases in cancer cell biology 
and describes them as "molecular switches" which continuously revert from the active and 
inactive forms which are GTP-bound and GDP-bound respectively. In the activated state they 
can bind to many effectors which subsequently elicit a cascade of events leading to the 
processes mentioned previously.
Interestingly with relevance to the work reported here, some Rho proteins promote 
neovascularisation which could be as a result of association with angiogenic factors and drug 
resistance effectors (Vega and Ridley 2008).
Over a decade ago work by Kozma et al (1996) suggested that N-chimaerin (Rho GTPase 
activating protein 2) is implicated in morphological changes of the cytoskeleton when 
associated with cancer related protein Racl and cytoskeleton signalling protein Cdc42Hs 
(Kozma 1996). It is stated that n-Chimaerin induces the formation of the actin-based structures 
lamellipodia (actin projections) and filopodia in migratory mammalian cells and have pro- 
oncogenic properties. It has been suggested that Rho GTPases have strong influence not only 
on tumourigenesis but the migratory functionality of the cancer cell (Figure 2.13), therefore 
key players in the metastatic process (Karlsson et al 2009).
A potential combination therapy for colorectal cancer patients is administration of 
bevacizumab and cetuximab to target vascular endothelial growth factor (VEGF) and epidermal 
growth factor receptor (EGFR) (Leve and Morgado-Di'az 2012). It is known that in gastric 
cancer VEGF interacts with Racl whereas EGFR acts as a stimulatory factor of Rac to encourage 
the migratory process of colonic cells. Therefore the therapeutic likelihood of inhibiting cancer 
progression is evident. In an article by Leve and Morgado-Di'az (2012) it is suggested that it 
could be highly beneficial for the future of anti-cancer therapy to identify inhibitors of the Rho 
GTPase-associated functions.
99
Tumor cell
Cell cycle
Epithelial 
cell polarity
Rho A, Racl
Cdc4^
Angiogenesis
promoting
factors
Migration
Mesenchymal: Racl 
Amoeboid: Rho A 
D i recti onal ity: Cdc42
Figure 2 .13: Major Functions o f Rho GTPases in vitro ( Karlsson et al 2009).
A putative peptide assigned to the Rho protein N-chimaerin as mentioned earlier (Rho GTPase- 
activating protein 2) was identified in the follow ing MALDI-IMS-MS/MS experimental work 
(Table 8). Mascot search results produced the peptide 183-189 (RLTSLVR) for the ion at m/z 
844.5288.
The peak of interest is indicated in the PMF from fibrosarcoma 120 tissue 30min post CA-4-P 
administration (Figure 2.14). The corresponding MALDI image is featured showing the spatial 
distribution of the selected ion at m/z 844. The peptide appears to be located mostly around 
the periphery of the tumour possibly indicative of its involvement in resistant to CA-4-P. The 
IMS-MS/MS data obtained from the peak observed in Figure 2.14 at m/z 844.5 is shown in 
Figure 2.15, the mascot score histogram for the said results is featured in Figure 2.16.
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Figure 2 .15: IMS-MS/MS data obtained from the peak observed in Figure 2.14 at m /z 844.5. 
This was identified by Mascot search as arising from Mouse N-chimaerin (Rho GTPase 
activating protein 2) 183-189 (RLTSLVR), the insert features the matched MS/MS  
fragmentation pattern.
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Figure 2 .16 : Mascot score histogram detailing the results in the identification of N-chimaerin.
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Figure 2 .17 : Zoomed in Driftscope plot showing ion of interest, arrow indicating the peak 
originally selected.
It could be said that there are many overlapping signals in the tryptic peptide MS/MS spectrum 
shown in Figure 2.15 where both the arginine y l  ion (m/z 175) and evidence of potential 
hydoxy fatty acids (m/z 187) are visible. This is also evident in the Driftscope plot (Figure 2.17) 
where the arrows point to the actual peak that was selected for MS/MS fragmentation. The 
dominant peak to the left of the indicated peak in Figure 2.17 would be part of the MS/MS 
spectrum, despite this the peptide was matched and identified (Figure 2.15) having 1 missed 
cleavage from the fragments present in the data.
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The apparent absence/ low abundance of the ion at m/z 844 ( putative peptide, Rho GTPase 
activating protein 2) in the later time points post CA-4-P administration, could be indicative of 
how the drug effects the Rho protein's usual involvement in tumour progression and neo­
genesis of the tumour vasculature. The latter response is evident in the follow ing MALDI-MSI 
(Figure 2.19) of the ion found at m/z 844.5 corresponding to N-chimaerin.
LC_100720_3_ 1 _M $01 J)02J301 _max j j i v  (MEAN 844 530-84*St1OJ. 100 720_ I _5_MS0 t_3G2_M *. {MEAN £4a -yj-AM W0|
1312T0 ;MEAN $4,3 j
Figure 2 .19: MALDI-MSI throughout a fibrosarcoma 120 time course o f the putative peptide 
Rho GTPase activating protein 2 m /z 844 (183-189, RLTSLVR).(a) control (saline), (b) 0.5 h 
post CA-4-P, (c) 6 h post CA-4-P and (d)24 h postCA-4-P, the intensity scales are all set a t 80 
to aid observation of response.
As mentioned previously in this chapter the spatial distribution of this putative protein appears 
to be localised around the periphery of the tumour sections in the Control/ saline and 30min
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post CA-4-P (Figure 2.19). The images mirror the spectra in Figure 2.18 with the peak of 
interest decreasing in abundance as the time course progresses.
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2.4.7.StatisticaI analysis of mouse fibrosarcoma 120 tumour tissue using 
MATLAB®
Principle component analysis (PCA)is an unsupervised test to produce unbiased clustering of a 
data set, once confident that there were some differences emerging due to none 
discrimination of data then partial least squares discriminant analysis (PLSDA) was then 
chosen to provide a classification model.
MATLAB® (Matrix Laboratory) (MathWorks, Inc., Natick, MA 486USA) is used in many areas as 
a computational statistical tool for mass spectrometry multivariate data analysis, and also via 
the Bioinfomatics Toolbox" provides tools for spectral alignment and pre-processing.
Spectral data from both profiling and imaging experiments can be imported into MATLAB® in 
order to build predictive models. This allows the user a powerful means of understanding 
complex data sets. In addition to script writing using the usual MATLAB® command format, use 
of the Eigenvector PLS_Toolbox (http://www.eigenvector.com) enables access to a number of 
advanced statistical tools for the analysis of mass spectrometry (MS) data (Eigenvector 
Research Inc 2012). Recognition of trends within a data time course experiment can be 
detected via decomposition mathematical modelling i.e. principle component analysis (PCA). 
Classification studies of MS spectra were performed using PLSDA, where regression vector 
plots can illustrate presence of ions unique to a particular sample. MS results are imported 
into MATLAB® in .txt or .csv format either post "SpecAlign" or after application of "automatic 
peak detection" if using the instrument data processingsoftware (Waters MassLynx™ 
Software). There are various pre-processing options available to aid linearization of variables 
within MS data with normalisation (2-Norm) and mean centre being frequently selected. 2- 
Norm refers to the sum of the squared value of all variables of the sample (Eigenvector 
Research Inc. 2012). During building of a PCA/PLSDA model the choice of cross validation is 
crucial to determine complexity of the data i.e. to consider data splits samples and/or latent 
variables/principle components. An example for a time course experiment would be selection 
of "contiguous blocks" which would look for assessing predictability between repeat blocks of 
spectra to circumvent the "replicate sample trap" which could lead to overly optimistic fitting 
of data.
In MATLAB® complex data clouds can be modelled with ease via the Eigenvector PLS_Toolbox 
allowing a deeper perception of variability throughout time course experiments.
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Figure 2. 2 0 : PCA of fibrosarcoma 120 tumour tissue in situ tryptic digests. The score plot (a) 
shows groupings between the tumour time points, the loading plot (b) contains the peak 
information which spatial relate to the groupings seen in (a) with dominant Hb peaks.
Figure 2.20a although not aesthetically pleasing as the PCA-DA model featured earlier in Figure 
2.7 shows similar groupings shared by the earlier time points w ith separate regions assigned
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for the 6h and 24h post CA-4-P. The Hb peaks are clearly visible in the later time points of the 
corresponding loadings plot (Figure 2.20b). This now, seemingly a characteristic of the CA-4-P 
susceptible fibrosarcoma model.
The conclusions that can be drawn from these data are fairly limited as the very intense 
haemoglobin and histone peaks appear to dominate the statistics. It could be argued that 
biomarker discovery requires supervised discriminant analysis i.e. PLSDA, opposed to non 
discriminant analysis. The rationale behind this idea is that non discriminant analysis could 
mask expected trends, an example of this scenario would be a treatment time course study. 
The treatment added throughout a time course experiment is a known factor that is expected 
to influence the data generated. Pre-grouping the data before building the statistical model 
could aid the separation of relevant peaks of interest.
PLSDA aimed to provide classification between tumour time points. The PLSDA data that follow 
are representative of the fibrosarcoma 120 data set as described in 2.3.5 Statistical analysis 
section.
An example of the clarity of the data possible from analysis using MATLAB® is shown in Figure 
2.21. Here, the regression vector plots from PLSDA of "on-tissue" digests of fibrosarcoma 120 
Control/Saline and 30 min post combretastatin-4-phosphate (CA-4-P) (a vascular disrupting 
agent), treatment tumour samples show the increased abundance of peaks at m/z 944 and 
1032. This allows classification between data obtained from the control/saline and 30 min post 
treatment tumour samples based on the induction of Histone 2A and Histone H3. The latter 
could possibly be a reflection of DNA damage necrosis and hypoxia as a result of CA-4-P 
administration as discussed in a previous section.
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The nature of this CA-4-P susceptible model could mean suppression of vital low abundant 
peptide information.
2.4.8 Region of interest (ROI) study for the analysis of tumour rim and 
necrotic regions within fibrosarcoma 120 tissue.
To enable further examination of tryptic digest spectra from MALDI images acquired using the 
fibrosarcoma 120 tumour set a ROI study was performed. ROI's were exported from the 
tumour rim and necrotic regions using the H&E tissue viable and necrotic areas for image co­
registration. Straightforward selection of 'central necrosis' and Viable rim' regions was not 
possible as the complex patterns of necrotic infiltration required a mixture of microscope and 
whole scanned image analysis.
Peptide induction was observed via PLSDA and Variable Importance in Projection (VIP) scores 
were used from PLSDA regression modelling to determine the importance of variables within 
the data time course.
HDI software (Waters Corporation, Manchester, UK) was used to view the MALDI-MSI for the 
following statistics. ROI's were selected according to areas either being necrotic or directly on 
the tumour rim for export to WatersMassLynx™ Software. After using the automatic peak 
detection processing option the text files were then imported intoMATLAB® where predictive 
statistical models were built.
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The zoomed insert in Figure 2.24 shows a clear separation between control and 24h post CA-4- 
P.
To examine this data further the follow ing VIP scores show the variables w ithin the 
fibrosarcoma 120 ROI study that are deemed most important.
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Figure 2.25: VIP scores for the Control fibrosarcoma 120 tumour rim regions. The Rho protein 
N-chimaerin is indicated at m/z 844, Histone 2A at m/z 944 and actin aortic smooth muscle 
at m/z 1198. These data is in good agreement with the increased ion signal for m/z 844.5 
displayed in earlier results for this protein.
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Figure 2.26: VIP scores for the 24h post CA-4-P fibrosarcoma 120 tumour rim regions. The 
Rho protein N-chimaerin is indicated at m/z 844, Histone 2A at m/z 944 and actin aortic 
smooth muscle at m/z 1198 and a Hb peaks at m/z 1529. The above results reflect the 
decrease in m/z 844.5 evident in results shown previously.
The VIP score plots provide an interesting compliment to the data shown in the PLSDA 
regression vector plots. Figure 2.25 illustrates the ion at m/z 844.5 as a key peptide in the rim 
region, a response echoed in the peptide's spatial distribution in Figure 2.19a and 2.19b.
In contrast to this Figure 2.26 displays the contrary showing Hb and markers of necrosis as the 
key players influencing variability, with marked decrease of importance for N-chimaerin.
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2.4.9 Concluding Remarks
The potential for investigations into protein induction following drug treatment strategies is 
phenomenal. Currently one major challenge is the management and analysis of the large 
amounts of data generated. Considering each of the peptide mass fingerprints (Figures 2.2 and 
2.8), on first inspection these seem to be very noisy, however this could be a signature of a 
successful tryptic digestion. Therefore the many low-abundance peptide signals contained in 
the apparent noise could house evidence of significant proteins such as heat shock proteins in 
addition to the expected and readily visible abundant peptide signals (actin, histones etc.). Due 
to the nature of these results one has to question whether or not each peak is worthy of 
further scrutiny, or should the vast amount of peaks be simply treated as noise/interference. 
The use of ion mobility separation and its associated data extraction software certainly 
appears to ease this dilemma making many more signals visible for subsequent examination by 
MS/MS. In this work the suspected pharmacological response of haemorrhaging to treatment 
with CA-4-P was investigated (Figure 2.3). The MALDI-MS images generated from m/z 1274 in 
Figure 2.3 show a clear increase in Hb with time after treatment with CA-4-P. The latter is then 
confirmed in Figure 2.4 in the H&E sections. At 6 h after CA-4-P treatment, the tumour in 
Figure 2.4 was partially necrotic and Hb was evident in both necrotic and viable tumour 
regions. The tumour excised at 24 h was almost completely necrotic. The increase in 
haemoglobin is also clearly visible in Figure 2.7(c), the time course plot extracted from the 
PCA-DA data, where again the increase in m/z 1274 and m/z 1820 can be clearly observed. 
Many other peptides were observed in this work, including some tentatively identified as 
arising from VEGF isoforms other than VEGF120 Figure 2.6e. This mostly likely could be due to 
infiltration of immune cells (McDonnell et al 2012) especially after further investigation into 
the VEGF 188 peptide 'FKSWSVHCEPCSERR' which confirmed that it was present in the exon 6 
region known exclusively to VEGF 188. This influx and subsequent induction of certain 
chemokines is a studied response to tumour vascular targeted therapy. In the case of the VEGF 
120 signal at m/z 1485, it was found to be vital to cross check protein database outputs and 
refer back to the original publication detailing the sequencing of that particular gene to be sure 
analysis of the correct peptide sequence information.
In PCA-DA of complex data sets, the scores plot (in this case Figure 2.7a) represents the 
variance of the original variables, i.e. the obtained sample groups. The loadings plot (in this 
case Figure 2.7b) describes the variable behaviour and differences between the observed 
groups. The PCA-DA of tryptic digest spectra from fibrosarcoma 120 tumour tissue reported 
here shows good grouping of the tumour time points (Figure 2.7a). Confirmation of the
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increase in haemoglobin due to CA-4-P treatment is given by the association of haemoglobin 
ions with the 24 h tumour in the loadings plot (Figure 2.7b) and this is shown further in Figure 
2.7(c). Further analysis of this large data was required. The aim of this was to examine whether 
changes in signals arising from proteins of lower abundance provided an insight into other 
pharmacodynamic responses to the treatment.
After the discovery via Mascot search of protein N-chimaerin (Figure 2.16) (Rho GTPase 
activating protein 2), spectra in Figure 2.18 and MALDI images in Figure 2.19 depicted the 
proteins decreased expression over time and peripheral spatial distribution in the early time 
points. The latter could be due to interference by CA-4-P. Driftscope plots (Figure 2.17) helped 
to build evidence of its response throughout the time course of experiments. Statistical 
analysis using MATLAB® confirmed the earlier findings from this chapter namely reflecting 
haemorrhaging, necrosis and N-chimaerin responses.
MALDI MSI has been used to study the effect of treatment with CA-4-P, a vascular disrupting 
agent in late stage clinical trials, on mouse VEGF120 tumours. A strategy incorporating "on- 
tissue" tryptic digestion, MS/MS identification peptides and ion mobility separation to improve 
specificity was employed. By taking tumour samples at a number of time points after 
treatment, gross effects were clearly visible through changes in the expression of certain 
peptides. These were identified as arising from haemoglobin and indicated the disruption of 
the tumour vasculature. It was hoped that the use of PCA-DA, PCA and PLSDA would reveal 
more subtle changes taking place in the tumour samples however at present these are masked 
by the dominance of the changes in the haemoglobin signals and other proteins of high 
abundance.
The MALDI-IMS-MS/MS reported here was performed manually by direct peptide/ protein 
profiling. The numerous signals from the PMF's generated most likely contain many peaks 
which have been post translationally modified thus hampering peptide identifications. The 
MS/MS spectrum in Figure 2.15 is an example of this, clearly containing overlapping MS/MS 
fragmentation patterns. Therefore the experimental work reported in the following chapters 
which describes similar experiments conducted using a CA-4-P resistant mouse model explores 
not only MALDI-MSI but the use of conventional proteomic techniques to compliment and aid 
interpretation of the MALDI-MSI data.
119
References
Abdollahi A and Folkman J (2010) Evading tumour evasion: Current concepts and perspectives 
of anti-angiogenic cancer therapy. Drug Resistance Updates. 13.16-28
Aznar S, Fernandez-Valeron P, Espina Carolina, Lacal Juan Carlos (2004) Rho GTPases: potential 
candidates for anticancer therapy.C ancer Letters.206.181-191
Aznar S and Lacal JC (2001) Searching new targets for anticancer drug design: the families of 
Ras and Rho GTPases and their effectors.Progress in Nucleic Acid Research and Molecular 
Biology.67.193-234.
Djidja M-C, Claude E, Snel MF, Scriven P, Francese S, Carolan V, Clench MR (2009) Maldi-ion 
mobility separation-mass spectrometry imaging of glucose-regulated protein 78 kDa (Grp78) in 
human formalin fixed paraffin-embedded pancreatic adenocarcinoma tissue sections. Journal 
of Proteome Research.8. (10) 4876-4884
Eigenvector Research Inc (2012) About PLS Toolbox and Solo, available at URL: 
http://wiki.eigenvector.com, Last accessed 18/11/12
Galbraith SM, Maxwell RJ, Lodge MA, Tozer GM, Wilson J, Taylor NJ, et al. (2003) 
Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated 
by dynamic magnetic resonance imaging. Jornal of Clinical Oncology. 21. 2831-2842
Groseclose MR, Andersson M, Hardesty WM,Caprioli RM (2007)ldentification of proteins 
directly from tissue: in situ tryptic digestions coupled with imaging mass spectrometry. Journal 
of Mass Spectrometry.42. (2) 254-262.
Kanthou C and Tozer GM (2007) Selective destruction of the tumour vasculature by targeting 
the endothelial cytoskeleton.Drug discovery today: Therapeutic strategies. 4. (4) 237-243
Kanthou C and Tozer GM[2009)Microtubule depolymerizing vascular disrupting agents: Novel 
therapeutic agents for oncology and other pathologies. International Journal of Experimental 
Pathology 90 (3) 284-294
Karlsson R, Pederson ED, Wang Z, Brakebush C (2009) Rho GTPase function in tumorigenesis. 
Biochimica et Biophysica Acta -  Reviews on cancer. 1796.(2), 91-98
Kozma R,Ahmed S, Best A, Lim L (1996) The GTPase-Activating Protein n-Chimaerin Cooperates 
with Racl and Cdc42Hs To Induce the Formation of Lamellipodia and FilopodiaVol. Molecular 
and Cellular Bio!ogyl6.(9) 5069-5080
Lemaire R, Desmons A, Tabet JC, Day R, Salzet M, Fournier I (2007) Direct analysis and 
MALDI imaging of formalin-fixed, paraffin-embedded tissue sections.Journal ofProteome 
Research6. (4) 1295-1305.
Lemaire R, Menguellet SA, StauberJ, MarchaudonV, Lucot J, Collinet P, Farine M, Vinatier D, 
Day R, Ducoroy P, Salzet M, Fournier I (2007) Specific MALDI Imaging and Profiling for
Biomarker Hunting and Validation: Fragment of the 11S Proteasome Activator Complex, Reg 
Alpha Fragment, Is a New Potential Ovary Cancer Biomarker. Journal of Proteome Research.6. 
(11) 4127-4134.
Leve F and Morgado-Di'az JA(2012) Rho GTPase Signalling in the Development of Colorectal 
Concer.Journal of Cellular Biochemistry Volume.113. (8)
Li X, Zhang K, Li Z (2011) Unfolded protein response in cancer: the Physician's perspective. 
Journal of Hematology & Oncology.4. (8) 1-10.
Lord Q and Ashworth A (2010) Biology-driven cancer drug development: back to the future. 
BMC Biology.8. (38) 1-12
McCombie G, Staab D, Stoeckli M, Knochenmuss R (2005) Spatial and spectral correlations in 
MALDI mass spectrometry images by clustering and multivariate analysis. Analytical 
Chemistry.77. (19) 6118-6124
McDonnell LA, Corthals GL, Willems SM, Remoortere van A, Zeijl van RJM, Deelder AM (2010) 
Peptide and protein imaging mass spectrometry in cancer research. Journal of Proteomics.73. 
(10) 1921-1944.
Modolo MF, Tillmann Biz M, Machado de Sousa S, Fachinelli RL, Crema VO (2012) 
Immunohistochemical expression of Rho GTPases inameloblastomas. Journal of Oral Pathology 
and Medicine.41. (5) 400-407
Prise VE, Honess DJ, Stratford MRL, Wilson J, Tozer GM (2002) The vascular response of tumor 
and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at 
clinically relevant doses. International Journal of Oncology. 21. 717-26.
Schmitz AAP, Govek EE, Bottner B, Aelst LZ (2000) Rho GTPases: Signaling, Migration, and 
Invasion.Experimental Cell Research. 261. (1) 1-12
Schwamborn K, Krieg RC, Reska M, Jakse G, Knuechel R, Wellmann A (2007) Identifying 
prostate carcinoma by MALDI-lmaging.\nterr\at\ona\ Journal of Molecular Medicine.20. (2) 
155-159.
Shimma S, Furuta M, Ichimura K, Yoshida Y, Setou M, (2006) A Novel Approach to in situ 
Proteome Analysis Using Chemical Inkjet Printing Technology and MALDI-QIT-TOF Tandem 
Mass Spectrometer. Journal of Mass Spectrometry Society Japan.54. (4) 133-140.
Siemann DW (2010) The unique characteristics of tumour vasculature and preclinical evidence 
for its selective disruption by tumour-vascular disrupting agents. Cancer Treatment Reviews.37. 
(1) 63-74
Siemann DW and Horsman MR (2009)Vascular targeted therapies in oncology. Cell and Tissue 
Research.335.(l) 241-248
Thorpe PE, Chaplin DJ, Blakely DC (2003) The first international conference on vascular 
targeting: Meeting overview. Cancer Research.63.1144-1147
121
Tozer GM, Kanthou C, Lewis G, Prise VE, Vojnovic B, Hill A (2008) Tumour vascular disrupting 
agents: combating treatment resistance. The British Journal of Radiology.81. S12-S20
Trim PJ, Djidja MC, Muharib T, Cole LM, Flinders B, Carolan VA, Francese S, Clench MR (2012) 
Instrumentation and software for mass spectrometry imaging—Making the most of what 
you've got. Journal of Proteomics.75. (16) 4931-4940
Vega FM and Ridley AJ (2008) Rho GTPases in cancer cell biology.FESS Letters.582. 2093-2101
Zhi-chao SI, Jie L (2008) What 'helps' tumours evade vascular targeting treatment?Chinese 
Medical Journal.121. (9) 844-84
122
Chapter 3
Protein induction post CA-4-P 
administration in a resistant 
fibrosarcoma 188 mouse model
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3.1 Introduction
In this Chapter data from the analysis of a mouse fibrosarcoma model tumour genetically 
engineered to solely express the insoluble matrix bound VEGF 188 isoform is described. In 
contrast to the soluble VEGF 120 isoform type that were the focus of Chapter 2, which have 
been found to be susceptible to VDA , the VEGF188 isoform type have been reported to be 
resistant to treatment with VDA (Tozer et al 2008) . In bone development, VEGF 120 and 
VEGF 188 both have d ifferent roles in vascularisation (Maers et al 2004). VEGF 188 is amongst 
the matrix bound isoforms thought to be involved in vascularisation of the metaphyseal bone 
regions, whereas the soluble VEGF components are concerned w ith the epiphyseal area. It is 
stated that the various isoforms of VEGF all play unique roles in the proliferation and 
chondrocyte survival in a hypoxic environment (Maers et al 2004).
Capitalfemoralepiphysis
Epiphysis
Growth plate 
Metaphysis ' MMG 2mi5
Figure 3.1: Diagrammatical cross section of the region present at the end of growing long 
bones showing the areas involved in epiphysis and metaphysis. (Ortho paediatrics group 
(2012) (http://www.orthopediatrics.com/docs/Guides/slipped_CFE.html)
The term fibrosarcoma describes a malignant fibrous mesenchymal neoplasm which is said to 
be found in the femur, humerus, jaw bone and is sometimes present in organs/ soft tissues 
(Encyclopaedia Britannica Inc 2013),. Angiero et al 2007).
In tumours VEGF is known to be a potent angiogenic stimulator and levels are found to be 
elevated in both the tumour cells and stroma (Harris et al 2012, Saharinen et al 2011). The 
tumour microenvironment is said to promote the recruitment of inflammatory cells due to 
chemoattractants. These actions are said to result in such cells becoming a major component
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of the actual tumour mass (Saharinenet al 2011). Pro- and/or antitumorigenic functions can 
result as a consequence of immune cell infiltration which is largely tissue/ tumour dependant. 
Tumour associated myeloid cells (TAMs) are known to secrete numerous factors which favour 
angiogenesis some of which include; VEGFs, TNF-a, interleukin (IL)-lb, matrix 
metalloproteinases, PDGFB, basic fibroblastgrowth factor.
In the data to follow using fibrosarcoma 188 tumours, a further time point of 72h post CA-4-P 
was added based on the more resistant nature of this matrix bound VEGF isoform model 
(Tozer et al 2008). The rationale for this decision was to try to observe any response which 
could be indicative of drug resistance and a potential switch back to tumour viability.
The use of CA-4-P treatment could enhance knowledge of the proteins induced in tumours 
expressing either fibrosarcoma 188/ 120 isoforms under hypoxic conditions. The following 
data aims to provide proteomic comparisons throughout a treatment time course using 
fibrosarcoma 188 models, and allow observational differences to me made between the 
expression of proteins in the resistant fibrosarcoma 188 and susceptible 120 tumour models.
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3.2 Materials and Samples
3.2.1 Chemicals and Materials
a-Cyano-4-hydroxycinnamic acid (CHCA), aniline (ANI), ethanol (EtOH), chloroform (CHCI3), 
acetonitrile (ACN), octyl-a/b-glucoside (OcGIc), tri-fluoroacetic acid (TFA), ammonium 
bicarbonate, haematoxylin, eosin, xylene and DPX mountant were from Sigma- Aldrich 
(Dorset, UK). Modified sequence grade trypsin (20 pg lyophilised) was obtained from Promega 
(Southampton, UK).
3.2.2 Tissue samples
Mice were injected sub-cutaneously in the flank with a 50 pi tumour cell suspension containing 
1 x 106 cells in serum-free medium. The cells employed in this study were from the mouse 
fibrosarcoma cell line, VEGF188. This has been engineered to express only the VEGF188 
isoform. Tumours were allowed to grow to approximately 500 mm3, before CA-4-P treatment 
(a single dose of 100 mg/kg i.p). The dosage for CA-4-P are consistent with animal studies 
performed at clinically relevant doses (Galbraith 2003., Prise 2002). Mice were sacrificedand 
tumours excised at various times after treatment. All animal work carried out documented 
herein was performed by Dr. J. E. Bluff, Tumour Microcirculation Group, University of Sheffield, 
UK. Samples were provided as frozen excised tumours and stored at -80°C.
3.2.3. Experimental groups
Controls (no treatment, saline i.p), n = 4 (labelled tumour 6_1 -  tumour 6_4), C-A4-P (0.5 h 
after treatment), n = 5, (labelled tumour 7_1 -  tumour 7_5), C-A4-P (6 h after treatment), n = 
5, (labelled tumour 8_1 -  tumour 8_5), C-A4-P (24 h after treatment), n = 5, (labelled tumour 
9_1 -  tumour 9_5), C-A4-P (72 h after treatment) n = 4, (labelled tumour 10_1 -  tumour 10_4).
3.2.4 Tissue preparation
Frozen tissue sections were cut to give approximately 10pm sections, using a Leica CM3050 
cryostat (Leica Microsystems, Milton Keynes, UK) (Djidja et al 2009). The sections were then 
freeze thaw mounted on poly-lysine glass slides. Mounted slides were either used 
immediatelyor stored in an airtight tube at -80 °C for subsequent use.
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3.2.5 In situ tissue digestion and trypsin deposition
The tissue samples in triplicate to undergo MALDI-MS/MSI were washed initially with 70% and 
then 90% ethanol for 1 min then left to dry, subsequently slides were immersed in chloroform 
for 10 s. Prior to matrix application, in situ tissue digestion was performed with trypsin solution 
prepared (from lyophilised trypsin) at 20 pg/ml by addition of 50 mM ammonium bicarbonate 
(NH4HCO3) pH 8, containing 0.5%octyl-a/b-glucoside (OcGIc) based on a protocol by Djidja et al 
(2009).
The "Suncollect" (SunChrom, Friedrichsdorf, Germany) automatic pneumatic sprayer was used 
to spray trypsin in a series of layers. The sections for MALDI-MS and MALDI- MSI were 
incubated overnight in a humidity chamber containing H20 50%: methanol 50% overnight at 
37°C and 5% C02.
3.3 Methods and instrumentation
3.3.1 Matrix deposition
The matrix, a-cyano-4-hydroxycinnamic acid (CHCA) and aniline in acetonitrile:water:TFA 
(r.l:0.1 by volume), was applied using either the Suncollect (at 5 mg/ml) or the Portrait™ 630 
Multispotter (at 10 mg/ml), as described above. Identical coordinate settings were used as 
with the trypsin deposition, to ensure sample uniformity. Equimolar amounts of aniline were 
added to the CHCA solution, i.e. 1 mlof 5 mg/ml CHCA solution contained 2.4 pi of aniline. 
These matrix deposition parameters were based on methods from Djidja et al (2009).
3.3.2 Instrumentation
MALDI- IMS/MS, MALDI- IMS/MSI and MALDI- IMS-MS/MS were performed using a HDMS 
SYNAPT™ G2 system (Waters Corporation, Manchester, UK) and Drift scope 2.1 software 
(Waters Corporation, UK). Instrument calibration was performed using standards consisting of 
a mixture of 217 polyethylene glycol (Sigma-Aldrich, Gillingham, UK) ranging between m/z 100 
to 218 3000 Da prior to MALDI-IMS-MSI analysis. In order to achieve good quality MS/MS 
spectra, they were acquired manually moving the laser position andadjusting the collision 
energy to achieve good signal to noise for product ions across the full m/z range of the 
spectrum.Collision energies were adjusted from 70 to 100 eV during acquisition and 
acquisition times were generally of the order of 5-10 s per spectrum. MS/MS spectra were 
uploaded to perform a Mascot (Matrix Science, London, UK) search which used the UniProt 
database in order to generate a sequence match.Image acquisition was performed using raster 
imaging mode at 30-100 pm spatial resolution, Biomap 3.7.5.5 software (http://www.maldi-
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msi.org/) was used for image generation. To enable simple visual comparison between images 
all data were normalised to m/z 877/ m/z 1066 (peaks arising from the aCHCA matrix).
The LC-ESI-MS/MS analysis of prepared tissue digests was performed by Adam Dowle at the 
Proteomics Technology Facility, Department of Biology (Area 15), University of York. LC-ESI- 
MS/MS analyses were performedwith a Bruker nanoESI source fitted with a steel needle using 
Ion spray voltage of 1500V. MS/MS was acquired using the following Auto MSMS settings: MS: 
0.5 s (acquisition of survey spectrum), MS/MS (CID with N2 as collision gas): ion acquisition 
range: m/z 300-1,500,0.1 s acquisition for precursor intensities above 100,000 counts, for 
signals of lower intensities down to 1,000 counts acquisition time increased linear to Is, the 
collision energy and isolation width settings were automatically calculated using the 
AutoMSMS fragmentation table:, 5 precursor ions, absolute threshold 1,000 counts, preferred 
charge states: 2 - 4 ,  singly charged ions excluded. 1 MS/MS spectrum was acquired for each 
precursor and former target ions were excluded for 30 s. The data obtained from the 
University of York was in the MASCOT .data file format. The .dat files selected used the 
following modification searches and parameters using the MASCOT Mus (Musculus) protein 
database:
Fixed modifiation: Carbamidomethyl (C) and variable modifications: Acetyl (Protein N-term), 
Gln->pyro-Glu (N-term Q),Glu->pyro-Glu (N-term E),Oxidation (M).
Massvalues: Monoisotopic, protein Mass : Unrestricted, peptide Mass Tolerance : ± 10 ppm, 
fragment Mass Tolerance: ± 0.1 Da and max Missed Cleavages : 1
These data were then processed using Scaffold 3 proteomic software tool for visualisation and 
analysis of the LC-ESI-MS/MS data (http://www.proteomesoftware.com/). The data files (.dat) 
produced from MASCOT which corresponded to each digested analysed, were uploaded 
individually. Analysis with X! Tandem was selected in order to improve protein identifications 
with searching through an additional database.
3.3.3 Haematoxylin and eosin staining
Slides were immersed in haematoxylin for 1 min, rinsed in tap water until the water ran clear, 
immersed in 1% eosin for 30 s and rinsed in tap water until the water ran clear. They were 
then dehydrated as follows: 50% ethanol for 2 min, 70% ethanol for 2 min, 80% ethanol for 2 
min, 95% ethanol for 2 min and 4 changes of xylene applied to each slide for 1 min at a time. 
Finally, they were mounted with DPX mountant and left to dry in the fumehood overnight.
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3.3.4 Statistical analysis
PCA and PLSDA was performed using MATLAB® (Matrix Laboratory) (MathWorks, Inc., Natick, 
MA 486 USA). The PCA/ PLSDA data that follows is representative of the fibrosarcoma 188 data 
where either n= 4/5 biological replicates per time point with up to 6 technical replicates for 
each, (control -  72 hours). PLSDA Data for ROI study using HDI software (Waters Corporation, 
Manchester, UK) was analysed using one tumour per time point with 9 technical replicates per 
ROI. Variable Importance in Projection (VIP) scores were used from PLSDA regression 
modelling to determine the importance of variables within the data time course.
3.3.5 Data pre-processing using Waters MassLynx™ Software and MATLAB®
MS results wereimported into MATLAB® in .txt or .csv format after application of "automatic
peak detection" using the instrument data processing software (Waters MassLynx™ Software). 
Normalisation (2-Norm) and mean centre were selected, "contiguous blocks" was used for 
cross validation.
3.3.6Protein network analysis
Accession lists generated by results from the LC-ESI-MS/MS Mascot searches were imported 
into the STRING 9.0 database (from Mus (Musculus) MASCOT protein database). Observations 
of the relationships were made between the proteins indentified throughout a fibrosarcoma 
188 time course. The sample data was used to build predictive proteomic pathways and study 
the predicted functional partners of known protein-protein interactions (http://string-db.org/).
3.3.7 Immunohistochemical staining
3.3.7.1 Chemicals a nd  M a te ria ls
Methanol, Acetone, Hydrogen peroxide solution 30% wt., Xylene, Ethanol, Gill's Haematoxylin 
and DPX mountant were all purchased from Sigma Aldrich UK. Phosphate buffer saline tablets 
(Dulbecco 'A' Tablets) were from Oxoid Ltd. Normal goat serum, ImmEdge hydrophobic barrier 
pen, 10X Casein solution, Avidin/Biotin horseradish peroxidise complex blocking kit, ABC 
solution kit, Diaminobenzidine (DAB) substrate kit were from Vector Laboratories Ltd UK. HSP- 
90 (abl3494,16F1) and Plectin (ab32528, E398P) antibodies were from Abeam, Cambridge UK. 
Macrophage cell surface marker F4/80 (MCA497GA, CI:A3-1) antibody was from AbD Serotec.
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3.3.7.2 Im m unoh is tochem ica l m ethods
Mounted frozen tissue sections were allowed to equilibrate to R.T for 5 min. Slides were then 
fixed in ice cold acetone for 20 min then rinsed in PBS. Endogenous peroxidases were blocked 
using 30% H202 and Methanol. After rinsing in PBS, tissues were blocked for lhr using Goat 
sera containing 10% Casein. After PBS washes, Primary Ab was added and left O.N at 4°C. To 
aid optimisation of immunohistochemistry, Ab's were first diluted using dilutions ranging from 
1:50 -  1:1600 depending on Ab and manufacturer's guidelines. Primary antibody dilutions 
were; 1:400 for both Plectin and F4/80 and 1:2000 for HSP-90. Isotype IgG controls were used 
for F4/80 and for Plectin and HSP-90 primary antibody was just omitted a negative control. 
After overnight incubation and subsequent PBS washes, Secondary Ab was added diluted 
(1:200) in 2% Goat sera and left for an incubation time of lh  at R.T. After this period, ABC 
solution was added after rinsing in PBS and left to incubate for 45min at R.T. After PBS 
washing, DAB solution was applied and left to allow development of the staining. Slides were 
rinsed in tap water prior to immersion in Gill's Haematoxylin for 2min. After slide dehydration 
using 70% -100% EtOH tissue was immersed in 2 changes of Xylene for 5 min each. Slides were 
mounted using DPX mountant.
3.3.8 Protein precipitation and digestion
3.3.8.1 Chemicals and  m a te ria ls
Chloroform (CHCI3), methanol (MeOH), acetonitrile (ACN), hydrochloric acid (HCI), tri- 
fluoroacetic acid (TFA), ammonium bicarbonate, ,DL-Dithiothreitol solution, lodoacetamide, 
urea, potassium di-hydrogen phosphate (KH2P04), TRIzol were from Sigma-Aldrich (Dorset, 
UK). Modified sequence grade trypsin (20 pglyophilised) was obtained from Promega 
(Southampton, UK,).
3.3.8.2Tissue hom ogen isa tion  and  p re c ip ita t io n  o f  p ro te in
The fibrosarcoma 188 tumour tissue was homogenised in 800pl of TRIzol solution using a 
micro-homogeniser (Kline and Wu 2009). Homogenised solution was centrifuged (1,500 rpm) 
for 5 min to pellet out nuclei/ unbroken cells. Post-nuclear supernatant was then centrifuged 
(14,000 rpm) for 30 min. Resulting supernatant was discarded and cellular membrane pellet 
was retained for protein precipitation. 200pl of MeOH and 50pl of CHCI3 were then added to 
each protein pellet sample. After vortexing, 150pl HPLC H20 was added with further vortexing. 
After centrifugation (14,000 rpm) for 2 min, the bottom CHCI3 layer was removed. A further 
50pl CHCI3 was added, removal of the bottom CHCI3 layer was repeated following
130
centrifugation (14,000 rpm) for 2 min. Subsequent removal of the H20 layer resulted in the 
remaining protein precipitate layer. CHCI3 (50pl) and MeOH (150pl) were added directly to the 
protein precipitate, after vortexing solution was centrifuged (14,000 rpm) for 2 min. 
Supernatant was removed and protein pellet was then allowed to air dry for 2 min.
3.3.8.3 P ro te in  D igestion
lOOpI of 0.1% RapiGest in 50mM NH4HC03 buffer (pH 7.8) was added to the air dried protein 
pellet. Each sample pellet/ solution was consecutively vortexed, incubated at -80°C (~ lhr) and 
heated to 70°C (1 min) until solubilised. Once fully solubilised the sample was heated to 100°C 
(2 min) and then left to reach room temperature. Each sample was reduced with DTT (final 
concentration 5mM) for 30 min at 60°C the left to reach room temperature. Solutions were 
then alkylated with iodoacetamide (final concentration 15mM) in the dark for 30 min at room 
temperature. Sequence grade modified trypsin was added (20pg/ml) to 80pg of protein 
following the BCA Protein Assay (see 3.3.9) used for protein determination. In-solution digests 
were incubated over night at 37°C with shaking.
3.3 .8A  P repa ra tion  o f  sam ples f o r  co lum n lo ad ing
Fibrosarcoma 188; HCL (final concentration lOOmM) was added to the overnight digest, 
solution was then incubated for a further 45 min at 37°C. After this step the sample was then 
centrifuged (14,000 rpm, 4°C) for 10 min, the supernatant removed for analysis. This 
remaining solution was lyophilised and stored at -80°C until further use.
3.3.9 Protein estimation -  BCA assay
3.3.9.1 Chemicals and  m a te ria ls
BCA protein assay reagent (bicinchoninic acid), copper (II) sulfate pentahydrate 4% solution, 
protein standard solution, 1.0 mg/mL bovine serum albumin (BSA) were from Sigma Aldrich 
UK. RapiGest detergent solution was purchased from Waters (UK).
3.3.9.2BCA m ethod
Solubilised protein pellets were thawed, vortexed and centrifuged ready for the BCA assay. 
BSA standards were prepared within an analytical range of 0-4 mg/ml. BCA reagent was added 
to BCA standards and tumour tissue solution samples and left to incubate at R/T for 30min. 
BCA standards were measured in triplicate and Samples were measured in duplicate in a 96 
well plate using a Wallac plate reader (spectrophotometer) at 570nm.
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3.4 Results and Discussion
3.4.1 MALDI-MSI of fibrosarcoma 188 CA-4-P treated tumour tissue
The MALDI spectra from both fibrosarcoma 188 and 120 on tissue digests contain numerous
peaks, the challenge so far has been exploration and identification of the low abundant species 
present.
One of the main aims at this point of the project was to develop a system of techniques that 
could be used in collaboration with each other in order to co-validate proteomic responses 
observed within a treatment time course.
Proteins of interest possibly induced as a result of CA-4-P treatment were firstly visualised by 
MALDI-MSI as putative protein targets. These responses therefore could then be supported by 
immunohistochemical staining. Similarly protein responses observed employing conventional 
proteomic techniques i.e. Liquid Chromatographic methods coupled with ESI or MALDI, were 
then used to relate back to MALDI-MSI.
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3.4.1.1 Trypsin application fo r the avoidance of protein delocalisation
One of the main potential pitfalls of in situ tissue tryptic digestion is protein delocalisation. A
factor which when occurs eliminates the analysis of spatial protein distribution. To ensure 
good tryptic digest MALDI-MSI, a homogeneous coating is essential during trypsin application.
Other issues to consider would be the tissue type, section size and to ensure a suitable flow 
rate is employed when using a pneumatic sprayer for trypsin deposition. Too much trypsin 
sprayed per cycle could lead to 'over wetting' of the tissue and subsequent protein 
delocalisation. The follow ing images were as a result of initial trypsin application optimisation 
involving flow rates, cycles and gas pressure in order to avoid any issues previously mentioned.
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Figure 3. 2: Screen shot of protein delocalisation in MALDI-MSI, visualised using BioMap 
imaging software. Figure 3.2 displays a screen shot of MALDI-MSI of an on tissue tryptic
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digest where trypsin applied using a pneumatic sprayer has caused delocalisation of proteins 
as a result of an incorrect spraying speed. The trypsin therefore; has not had sufficient drying 
time and over wetting of the tissue has occurred. The cross hairs which map the ion signals in 
the top MALDI-MSI in Figure 3.2, show lots of tryptic peptide signals outside of the tissue, 
indicative that the spatial distribution of the proteins have changed. The signals given from 
the cross hairs in the bottom image in Figure 2 show a substandard tryptic spectrum as a 
result.
The MALD-MSI featured in Figure 3.3 can be regarded as an exemplar of on tissue tryptic 
digestion. The characteristic contrast of discreet CHCA matrix clusters seen in the left hand 
MALDI-MSI, compared to the tryptic PMF evident from the cross hair mapping on the tissue 
image shown to the right.
The most suitable parameters for spraying trypsin were found to be the employment of a 
series of 5 layers at a flow rate of 2.5pl/ minute. To avoid protein delocalisation and ensure 
sample spray uniformity the regions set for trypsin application allowed enough drying time 
between each spray pass. A fine spray was found to be essential with a view to maintain 
protein positioning within the tissue and the nitrogen gas pressure used was ~15 psi for 
spraying trypsin.
For matrix application, the same principles were applied but the gas pressure was decreased to 
~10 psi. The flow rate was adjusted to 4pl/ minute to take into account of solvent evaporation 
and aid sample coverage and co-crystallisation.
134
m p m
t w m m
13
5
The spectra in Figure 3.4 are typical representations of fibrosarcoma 188 peptide mass 
fingerprints (PMF) throughout the CA-4-P treatment time course studied.
The spectra within the time course of Figure 3.4 all appear to be quite similar upon first 
inspection. The zoomed in regions of the fibrosarcoma 188 time course now shown in Figure
3.5 shows subtle differences of the appearance of Hb at m/z 1416 and appearance of an 
unknown at m/z 1577. The high abundant Hb peaks (m/z 1274, m/z 1302, m/z 1529 and m/z 
1819) which are evident in the spectra from Figures 2.1 and 2.2 in Chapter 2, do not dominate 
the fibrosarcoma 188 spectra. This could be due to the CA-4-P resistant nature of this tumour 
mouse model.
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Figure 3.6 displays the spectra from examples of control tumour tissue from each tumour 
model, fibrosarcoma 120 and 188. The peak tentatively relating to the Rho GTPase protein 
discussed in Chapter 2 can be seen in the fibrosarcoma 120 spectra (indicated by an arrow), 
but not at the same intensity in the spectra corresponding to fibrosarcoma 188. Similarly, the 
same can be deduced for the ion at m/z 1325 relating to Histone H4 seen in the 188.
Although further work is required to determine the relevance of increased Histone H4 
intensity seen here, there have been many studies on the analysis of Histone H4 acetylation/ 
deacetylationwith the premise of histone deacetylase inhibitors as potential anti-cancer 
treatment (Advani et al 2010). It is stated that expression of Histone acelylation in cancers can 
influence patient prognosis. Reports claim that increased levels of acetylated Histone H4 in 
patients with esophageal squamous cell cancer can correlate with an encouraging clinical 
outcome (Toh et al 2007).
Ultimately, histones are said to be key in gene regulation (Grunstein 1997). In the 188 Control 
spectra seen here (Figure 3.6), the prominent Histone H4 could be a characteristic of this more 
drug resistant fibrosarcoma 188 tissue.
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3.4.1.3 MALDI-MSI and immunohistochemistry to analyse a fibrosarcom a 188  
treatm ent course
Initial MALDI-MSI using the fibrosarcoma 188 tissue was carried out at a resolution of 100pm 
employing a spot to spot laser pattern with the SYPNAT G2 HDMS system (Waters, UK). The 
gross haemorrhagic pharmacological response that already has been shown in Chapter 2 using 
the fibrosarcoma 120 tumours was considered a good place to start when validating responses 
seen by other ions. Figure 3.7 shows a multi time point MALDI image of a fibrosarcoma 188 
time course ranging from Control -  72 hours post CA-4-P. The MALDI images were taken from 
a slide containing multiple samples.
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Figure 3. 7: MALDI-MSI multi image of a fibrosarcoma 188 time course. The images show the 
spatial distribution of a peptide of haemoglobin subunit alpha at m/z 1819 throughout a 
treatment time course from Control-7 2  hours post CA-4-P administration.
The MALDI-MSI shown in Figure 3.7 of the matrix bound VEGF 188 model shows a different 
response to that seen of a Fib peptide in Figure 2.3 (Chapter 2). The haemorrhagic response is 
observed much later in the 24h tissue opposed to the 6h sample in the fibrosarcoma 120 
MALDI-MSI. In contrast to to the evidence of complete necrosis and vascular disruption in the 
last time point of the fibrosarcoma 120 (Figure 2.3 -  24h), here the 72h time point exhibits a 
very different response. There appears to be evidence of a switch back to viable tissue in this 
more resistant tumour model.
141
Heat shock protein 90 (HSP-90) is ubiquitous in all normally functioning cells and serves to 
prevent the misfolding of proteins by helping to retain the correct structural format of the 
protein (Neckers 2007). The characteristic tumour microenvironment renders cancer cells to 
anoxia, alterations in pH and attack via pharmacological anticancer agents. HSP-90 has been 
suggested as a potential target protein for anticancer therapy due to the dependence on 
structural conformity by the cancer cell (Den and Lu 2012).
It is known that inhibition of HSP-90 results in the degradation of the HSP-90 stabilised protein 
(client protein) via the proteasome.
Elevated levels of HSP-90 in breast cancer patients have been found to correlate with poor 
patient survival due to the conserving effect of HSP-90 on human epidermal growth factor 
receptor 2 (Jameel et al 1992). It is also stated that HSP-90 is highly expressed in solid tumours 
and it is suggested that HSP-90 plays a key role in the evasion of apoptosis thus promoting 
tumour cell survival (Den and Lu 2012).
There are over 20 known clinical trials taking place which currently involve the use of HSP-90 
inhibitors (Den and Lu 2012). A review article by Den and Lu (2012) poses the question of 
which tumour type is the most suitable for HSP-90 inhibition study and whether or not the 
anticancer target should be the HSP-90 'client protein' i.e. epidermal growth factor receptor in 
non-small cell lung cancer/ human epidermal growth factor receptor 2 in breast cancer.
The MALDI images in Figure 3.8 display the spatial distribution and relative abundance of an 
ion at m/z 1168 corresponding to HSP-90. The optical scans shown in Figure 3.6 show the 
immunohistochemical staining of HSP-90.
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Figure 3. 8: Fibrosarcoma 188 MALDI-MSI multi image showing spatial distribution of HSP-90. 
MALDI images showing spatial distribution of HSP-90 alpha at m/z 1168.
The presence of HSP-90 is shown throughout the fibrosarcoma 188 time course. The MALDI 
image corresponding to 24hr post CA-4-P is indicative of complete HSP-90 saturation. This 
response is matched by HSP-90 immunohistochemical staining seen in Figure 3.8.
The possible 'switch bock to viable tissue' is also exhibited by the 72h time point in Figure 3.8. 
This potential evidence of tumourigenesis can also be seen in the immunohistochemical 
equivalent in Figure 3.9.
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Figure 3. 9: Immunohistochemical staining of a fibrosarcoma 188 time course. Evidence of 
complete HSP-90 saturation can be observed in the 24h optical scan with the indication of 
tumour tissue rejuvenation in the 72h tumour time point.
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The microscopic images in Figure 3.10 were captured in brightfield 10X to enable closer 
inspection of the immunohistochemical staining seen here in Figure 3.9.
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Figure 3.10; (a) displays the negative Control for HSP-90the time point used was 24h post 
CA-4-P, (b) HSP-90 staining using fibrosarcoma 188 Control tissue/ (c) HSP-90 staining ofO.Sh 
post CA-4-P, (d) 6h post CA-4-P,(e) HSP-90 staining of24h post CA-4-P showing HSP-90 tissue 
saturation status and (f) HSP-90 of the saturated necrotic central region and viable tissue 
regional indicated by the bracket.
The HSP-90 immunohistochemical staining in Figure 3.10 was captured at 10X magnification to 
allow closer inspection of the HSP-90 optical scans previously shown. The apparent saturation 
of HSP-90 in the 24h time point visible in the MALDI-MSI and in Figure 3.9 can be seen in 
Figure 3.10(e). The lOx image of HSP-90 showing the regional switch back to viability can be 
clearly observed in Figure 3.10(f), the viable tumour cells are highlighted by the bracket.
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3.4.1.4 High resolution MALDI-MSI using fibrosarcom a 188 tum our tissue
The MALDI-MSI featured here employed high resolution imaging with a view to focus down on
the tumour rim regions.
Tissue was imaged using vertical sliced regions which encompassed both the tumour rim and 
central area.
Figure 3.11: SYNAPT G2 MALDI imaging plate indicating tissue image regions. The regions 
selected for MALDI-MSI analysis have been superimposed over the histological tissue 
sections.
The 40pm resolution image show in Figure 3.12 shows the spatial distribution of m/z 844.5 
which corresponded to the putative Rho GTPase activating 2 protein mentioned earlier in 
Chapter 2. Although not a dominant peak within the fibrosarcoma 188 spectra, the spatial 
distribution of this ion is shown to be localised around the periphery of the tumour tissue in 
the follow ing MALDI-MSI of a 72hr treatment time point.
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Figure 3 .1 2 :40pm MALDI-MSI of24h post CA-4-P fibrosarcoma 188 tumour tissue. 
Peripheral localisation of n-Chimaerin at m/z 844.5.
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Figure 3 .1 3 :40pm MALDI-MSI of m/z 944.5 in fibrosarcoma 188 tumour tissue. The differing 
spatial distribution of an ion is shown here corresponding to Histone 2A.
An image from the same acquisition shown in Figure 3.12 is displayed in Figure 3.13. The ion at 
m/z 944.5 (Histone 2A) is located in the necrotic region of the tissue, emphasising the 
distinction in spatial distribution between m/z 844.5 and 944.5. The necrotic region is 
indicated by the H and E in Figure 3.14.
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Figure 3.14: 40pm MALDI-MSI of a on tissue try tic digest and corresponding H and E 
histological section. A necrotic region is seen here to correlate with the spatial distribution of 
Histone 2A.
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Figure 3.15: 30 pm MALDI-MSI of a Control fibrosarcoma 188 tumour on tissue tryptic digest. 
The spatial distribution of Actin (a) and Rho GTpase activating protein 2 (b) is shown in the 
30pm MALDI-MSI.
30pm images (Figure 3.15) were performed to investigate the tumour rim and although images 
appear slightly 'grainy', distribution of known peptides could still be visualised. This 'grainy' 
appearance of the MALDI-MSI here could be an artefact of 'over sampling' due to the laser 
spot size measuring ~60-70pm teamed w ith the 30pm high resolution laser spot to spot 
pattern.
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3.4.2 Statistical analysis of mouse fibrosarcoma 188 tumour tissue using 
MATLAB®
Initial statistical analysis on the fibrosarcoma 188 tryptic digest spectra was performed using 
Principle component analysis (PCA) via MATLAB® through the Eigen Vector tool box, to 
produce an unbiased clustering of spectra acquired from MALDI-MSI of the fibrosarcomal88 
data. As discussed in Chapter 2, there is a requirement for an element of discrimination in a 
statistics model for known time course data. This considered, a preliminary PCA test was done 
to predict potential groupings between time points. This PCA consisted of 9 technical 
replicates from MALDI images acquired in triplicate to include an example of each CA-4-P 
treatment time point. The results are shown in Figures 3.16 and 3.17.
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Figure 3.16: PCA score plot of fibrosarcoma 188 tumour tissue in situ tryptic digests. The 
score plot in Figure 3.16 shows the potential groupings between the tumour time points in 
this fibrosarcoma 188 study. From this preliminary PCA test there does appear to be a 
separation between tumour treatment groups with an apparent overlap observed here in the 
Control (6:4) and 0.5h post CA-4-P (7:2)
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Figure 3.17: PCA loadings plot fibrosarcoma 188 tumour tissue in situ tryptic digests, (a) 
corresponds to a peak relating to N-Chimaerin mentioned earlier, (b) Histone H4 and (c) 
Histone 2A.
The loadings plot contains the peak information which spatial relate to the groupings seen in 
Figure 3.17. The loadings plot seen here does not appear to exhibit the Hb dominance that was 
visible in the PCA loadings plot featured in Figure 2.20, Chapter 2.
The region in Figure 3.17 that spatially relates to the 72h post CA-4-P tissue contains many 
unknown peaks between the mass range of 700-800 Da. Further confirmation is required to 
elucidate peak identifications here as to whether the peaks are indicative of the viable tissue 
switch discussed previously, or due to matrix/ lipid peak signals.
PLSDA was then carried out on a larger data set then the VIP scores for each time point were 
then analysed. For the PLSDA analysis, 3 biological repeats per tumour time point were used 
via MALDI-MSI acquisitions and 6 technical spectral repeats were taken from each biological 
replicate.
PLSDA models were built to compare the treatment time points against the Control tumour 
tissue.
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Figure 3. 18: Partial least squares discriminant analysis (PLSDA) regression vector plot 
comparing MALDI "on-tissue" digest data from samples of fibrosarcoma 188 Control and 
0.5h post combretastatin-4-phosphate (CA-4-P), treatment tumour samples.The increased 
abundance of Actin at m/z 1198.7 in the 0.5h post treatment sample can be clearly seen.
As previously mentioned, there are numerous peaks in the low mass range seen here in the 
regression vector plot especially in the Control tissue. The peptide corresponding to Actin is 
seen to be increased in the 0.5h treatment. A similar treatment response was reported by 
Kanthou and Tozer (2002) (discussed in the Introduction) with fluorescent staining of Human 
umbilical vein endothelial cells, Control and post CA4P administration. The results from this 
study showed an increase of filamentous Actin overtime after treatment.
The follow ing regression vector plot generated using PLSDA is between Control and 6h post 
CA-4-P treatment.
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Figure 3.19: Partial least squares discriminant analysis (PLSDA) regression vector plot for the 
comparison of Control and 6h post CA-4-P fibrosarcoma 188 on tissue digests. The bracket 
designates areas which illustrate an abundance of shared peaks.
The results from Figure 3.19 display copious amounts of shared peaks, especially in the region 
indicated by the bracket andit is quite d ifficult to distinguish trends between the two time 
points.
The main response considered could be the increase in Histone H3 at m/z 1032, also present in 
Figure 3.18.
Due to the substandard tumour vascular and high proliferative state, increased hypoxia is 
typical of the tumour microenvironment. It is thought that the latter triggers hypoxia-inducible 
factor 1 (HIF-1) which is considered a key transcription factor along with, nuclear factor kappa- 
light-chain-enhancer of activated B cells (NF-kB), activator protein 1, tumour protein 53 (p53), 
and c-Myc (Kenneth and Rocha 2008). The outcome via certain genes from the transcriptional 
activation of these factors would be anti-apoptotic, pro-angiogenic, an increase in glycolysis 
and support in the formation of metastasis (Zhou et al 2010).
The methylation of genes; Histone H3 lysine 4 (H3K4), H3K36, and H3K79 are said to be 
transcriptionally active and a study by Zhou et al (2010) concluded that under hypoxic 
conditions, H3K4me3 was found to be increased in human lung carcinoma A549 cells.
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This link between the increase in Hypoxia and Histone H3 could be an explanation for the m/z 
1032 peak observed in the regression vector plots of the fibrosarcoma 188 tumour tissue. The 
increase in Histone H3 could therefore be linked to drug resistance.
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Figure 3. 20: Partial least squares discriminant analysis (PLSDA) regression vector plot for the 
comparison of Control and 24h post CA-4-P fibrosarcoma 188 on tissue digests.The blue 
arrows are indicative of Histone 2A (m/z 944), Histone H3 (m/z 1032), Actin (m/z 1198) and 
the red arrows correspond to Hb peaks; m/z 1274, m/z 1416 and m/z 1529.
Overtime in the 24h treatment (Figure 3.20) PLSDA the appearance of the Hb peaks can be 
seen in this CA-4-P resistant tumour model. The Actin peak is still increased in relation to the 
Control vector plot with the same true for Histone H3. Histone 2A is now also observed, 
possibly reflecting the occurrence of cellular necrosis and DNA damage as a result of 
Combretastatin administration.
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Figure 3. 21: Partial least squares discriminant analysis (PLSDA) regression vector plot for the 
comparison of Control and 72h post CA-4-P fibrosarcoma 188 on tissue digests.Histone H3 
(m/z 1032) and Haemoglobin subunit alpha (m/z 1416) are highlighted by arrows.
The Hb peaks are still observable in Figure 3.18 from the 72h treatment sample. The Histone 
H3 ion could be regarded as a dominant factor again resulting in suppression of the other 
peaks. One explanation for this could be the requirement for tumour rejuvenation/ 
proliferation as signified by the viable tissue regions seen in earlier MALDI-MSI and HSP-90 
immunohistochemistry.
155
VIP scores were then observed which considered 0.5h, 6h, 24h and 72h time points based on 
the PLSDA predictive models in Figures 3.18-3.21. Inspection of these data aimed to observe 
the variables w ithin the fibrosarcoma 188 study that are considered most important to that 
time point.
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Figure 3. 22: VIP scores for the 0.5h post CA-4-P fibrosarcoma 188 on tissue digest.
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Figure 3. 23: VIP scores for the 6h post CA-4-P fibrosarcoma 188 on tissue digest.
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Figure 3. 24: VIP scores for the 24h post CA-4-P fibrosarcoma 188 on tissue digest.
Variables/Loadings Plot for Table from Markerview fro MATLAB V188.txt
120
VIP scores for 72h 
post CA-4-P
100
80
60
40
20
0!
2000
Variable
Figure 3. 25: VIP scores for the 72h post CA-4-P fibrosarcoma 188 on tissue digest.
The VIP scores featured in Figures 3.22-3.25 highlight Actin, Histone 2A, Histone H3 ,Histone 
H4 and Hb as some of the important targets, albeit with differing intensities. The main trend 
gained from these VIP score data gives the impression of transcriptionally active tumour 
tissues. Throughout the treatment time course structural modifications are apparent via the 
Actin and Hb peaks present teamed w ith increases in hypoxia related Histone H3 (m/z 1032).
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Histone H4 (m/z 1325) is deemed to have a key position in the time points apart from in the 
24h samples which could be indicative of CA-4-P interference before the regenerative tumour 
action commences, seen in the 72h treatment.
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3.4.3 Label free LC-ESI -MS/MS for the identification of proteins in a CA-4-P 
treated fibrosarcoma 188 mouse model
Recognition of proteins via label free MS/MS peptide identification describes the widely used 
technique of Bottom Up shotgun proteomics. As mentioned earlier (see Introduction), this 
methods uses enzymatic digestion of proteins prior to data-dependent mass spectrometric 
analysis (Old et al 2005). MS/MS fragmentation spectra are matched against a proteomic 
database in order to achieve a unique, rank 1 peptide identification.
The method reported here is based on multidimensional protein identification technology 
(MudPIT) involving reversed-phase (RP) HPLC (Kline and Wu 2009,. McCormack et al 1997,. 
Link et al 1999,. Wolters et al 2001).
Label free LC-ESI-MS/MS was employed to study protein response throughout the 
fibrosarcoma 188 treatment time course. Control, 0.5h, 6h, 24h and 72h post CA-4-P 
treatments were used for analysis.
Scaffold 3 proteomics software tool was used for the analysis of the following Label free LC- 
ESI-MS/MS. Time course protein responses were plotted using normalised spectral counting 
calculated and presented via Scaffold 3. Gene ontology pie charts were included in the 
experimental output from Scaffold to aid understanding of biological function of the protein 
indentified.
Figure 3.26 displays a screenshot from the fibrosarcoma 188 Label free LC-ESI-MS/MS data list. 
After importing of data, 201 proteins were listed which included those which have a minimum 
of 2 peptides assigned per protein, 99% minimum protein and 90% minimum peptides.
The data options for exportation to excel are; protein identification probability, percentage of 
total spectra, number of assigned spectra, number of unique peptides, number of unique 
spectra, percentage coverage, un-weighted spectrum count and quantitative value.
The Control/ CA-4-P protein response bar graphs to follow use the quantitative value based on 
normalised spectrum counts.
Figures 3.27 -  3.33 show the entire Scaffold 3 protein list and corresponding normalised 
spectrum counts that were generated. Figure 3.34 features a response bar graph of selected 
proteins of interest.
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The rationale for selection of the proteins included in Figure 3.34 was from proteins that either 
had a high percentage of co-variance throughout the time course (as seen in Scaffold 3), 
provided a known validating response or may be of relevance to the stress response and could 
be characteristic of tumour biology.
The increases in Figure 3.34 from both Haemoglobin subunit alpha and Haemoglobin subunit 
beta-2 exhibit the distinctive gross pharmacological response from administration of a vascular 
disrupting agent.
Disruption in the architectural integrity of the vasculature is indicated by decreases in 
structural Tubulin beta-5 chain and Tubulin alpha-lB chain compared to the Control tumour 
tissue.
Actin, cytoplasmic l(Beta-actin) and Actin, alpha skeletal muscle precursor (Alpha-actin-1) 
appear to show different trends throughout the LC- ESI-MS/MS data here in Figure 3.34.
It is known that the reorganisation and/or disruption of the cytoskeleton results in stress fibre 
formation (Kanthou and Tozer 2007). Administration of CA-4-P elicits such a response on the 
tumour cells thought to be induced by stress activated apoptosis.
Overtime the tumour appears to 'retaliate' favouring actin polymerisation after a brief 
decrease of Beta-actin in the 6h time point with increased levels evident in the 24h and 72h 
time points.
An overall decrease of alpha skeletal muscle precursor (Alpha-actin-1) towards 72h post CA-4- 
P is visible from Figure 3.34. This decline could be due to disruption by CA-4-P, further shotgun 
proteomics and immunohistochemical studies could ascertain the trend in the decreased seen 
here ofAlpha-actin-1. An article by Hemingway et al (2012) reports of a study looking at the 
expression of Alpha isoform of smooth muscle actin (SMA) in primary, benign and malignant 
bone tumours. It was found that SMA was differentially expressed in the primary tumours and 
although findings were inconclusive, interestingly SMA expressing pericytes (peri-vascular 
cells) present in bone marrow/ were also mentioned as a source of SMA levels.
The concept of progenitor cells, infiltrating immune cells or indeed a full stromal cell 
population could be regarded as a key factor to consider when analysing protein dose 
response relationships.
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Figure 3. 35: MS/MS spectrum and normalised intensity graph of Alpha-2-macroglobulin in 
fibrosarcoma 188 LC-ESI-MS/MS results.lnsert displays the normalised spectral counts for 
Alpha-2-macroglobulin throughout the time course post CA-4-P.
Alpha-2-macroglobulin is a carrier protein and is known to have strong associations w ith 
growth factors and cytokines i.e. basic fibroblast growth factor, Interleukin 1- (3 (IL-1(3) and 
transforming growth factor beta (as seen in Figure 3.34) (Feige et al 1996,. Wellcome trust 
Sanger Institute 2012). Alpha-2-macroglobulin is also known to be synthesised locally in tissues 
by infiltrating macrophages.
The dose response relationship of this protein from the LC-ESI-MS/MS results can be observed 
in Figure 3.35 via the Scaffold 3 viewer proteomics tool. Levels here appear to be undetected 
by this technique in the early fibrosarcoma 188 treated time points but a sudden increase is 
evident from the 6h treated sample, a surge in the 24h time point with the 72h representing a 
drop in expression.
With aim to study this response further, immunohistochemical staining was performed on 
F4/80, a macrophage cell surface marker to see whether or not this response could be studied 
indirectly as a reflection of infiltrating immune cells in response to CA-4-P treatment.
170
m E B S m
400 \im
4Q0 pm
.^,-::v
T^Vr- • i, ■ •. . w ■• : r ■>'■"
1x1) .
W $ 0 .
400 ym
171
Figure 3. 36: Immunohistochemical staining o f macrophage cell surface marker FA/80 using 
fibrosarcoma 188 tissue lOx. (a) negative FA/80 isotype control using 72h post CA-A-P 
fibrosarcoma tissue -  central region, (b)negative FA/80 isotype control using 72h post CA-A-P 
fibrosarcoma tissue -  rim region, (c) FA/80 staining of Control -  central region, (d) FA/80 
staining o f Control -  rim region, (e) FA/80 staining o f 0.5h post CA-A-P -  central region, (f) 
FA/80 staining of0.5h post CA-A-P -  rim region, (g) FA/80 staining of6h post CA-A-P -  central 
region, (h) FA/80 staining o f 6h post CA-A-P -  rim region, (i) FA/80 staining o f 2Ah post CA-A-P 
-  central region with bracketed region showing macrophage population within the necrotic 
tissue, (j) FA/80 staining of 2Ah post CA-A-P -  rim region, (k) FA/80 staining o f 72h post CA-A- 
P -  central region, the arrows indicate evidence o f macrophages still present and an example 
of a necrotic region is labelled with N (I) FA/80 staining of 72h post CA-A-P -  rim region, the 
bracket indicates a macrophage population with the V labelling an example o f viable tissue.
There appears to be few macrophages present mainly around the periphery of the tumour in 
the Control tissue (Figure 3.36 c and d) as indicated by the arrow with a meagre presence 
visible w ithin the central region shown. Similar staining is evident in the 0.5h treatment (Figure 
3.36 e and f) central and rim areas. The latter could explain the undetected presence of Alpha- 
2-macroglobulin in the equivalent Scaffold 3 LC-ESI-MS/MS results.
An army of macrophages are now seen to be infiltrating the 6h post CA-4-P rim and central 
tissue regions in Figure 3.36 (g) and (h) with populations still present in the 24h treatment 
fibrosarcoma tissue.
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The isotype controls for the immunohistochemical staining of F4/80 are shown in Figure 
3.36(a)-(b) using the same tissue from 72h images in 3.36 (k) and (I). There appears to be 
macrophages still present in the necrotic and viable tissue as indicated.
The engulfing of cellular debris due to the phagocytic nature of the macrophage could explain 
the decrease at 72h following the surge at 24h. The steep increase could be as a result of the 
widespread necrosis observed at 24h post CA-4-P and influx of debris clearing immune cells 
overtime between 6h/24h time points henceAlpha-2-macroglobulin accumulation in the 
tissue. The decreased levels of Alpha-2-macroglobulin at 72h could be indicative of an efflux in 
macrophage cell populations.
The tumour associated macrophages (TAM's), known to stimulate angiogenesis undoubtedly 
play a major role in drug resistance (Welford et al 2011,. Ey et al 2006,. Bingle et al 2002). The 
complex tumour microenvironment can result in the promotion of anti-tumour T cells yet 
conversely studies have shown that biological events within the tumour can 're-programme' 
TAM's to possess pro-oncogenic, assisting tumour growth and progression. The F4/80 staining 
in the 72h could suggest a possible pro-tumourigenic action via the macrophage population 
considering their presence in the viable tissue region.
The HSP-90 beta levels in the label free quantitation graph (Figure 3.34) show a steady 
increase in response to CA-4-P administration. The HSP-90 alpha however is in close 
agreement with the earlier MALDI-MSI in Figure 3.8 and HSP-90 immunohistochemical staining 
in Figure 3.9 mirroring the 24h HSP-90 saturation prior to a slight decrease in the 72h due to 
the switch back to viable tissue concept.
Plectin (Figure 3.34) was found to have a high value of percentage co-variance (170%) 
throughout the sample time course so this effect was investigated inorder to relate the 
response to the biological action oftumour tissue. The graph of Fibrosarcoma 188 time course 
results post CA-4-P treatment using LC-ESI-MS/MS (Figure 3.34), indicates a marked 
abundance of Plectin in the Control then levels dramatically decrease overtime.
Figure 3.37 displays an example of a Plectin MS/MS spectra visualised through Scaffold 3 
software.
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Figure 3. 37: MS/MS spectrum and normalised intensity graph o f Plectin in fibrosarcoma 188 
LC-ESI-MS/MS results. Insert displays the normalised spectral counts fo r Plectin throughout 
the time course post CA-4-P.
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Figure 3. 38: Fibrosarcoma 188 MALDI-MSI multi image showing spatial distribution of 
Plectin. MALDI images showing spatial distribution of Plectin at m /z 977.
The MALDI-MSI shown here in Figure 3.38 are in good agreement with the LC-ESI-MS/MS label 
free quantitative results w ith an apparent abundance of Plectin in the Control with the 
reduction in levels overtime post CA-4-P.
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Immunohistochemical studies using anti-Plectin were performed to visualise this response in 
histological tumour sections.
400 fjm
Figure 3. 39: Immunohistochemical staining of Plectin in Fibrosarcoma 188 tissue post CA-4-P 
treatment.Figure 3.39- (a) anti-Plectin staining of fibrosarcoma 188 Control tissue, (b) anti- 
Plectin staining o f fibrosarcoma 188 tissue 0.5h post CA-4-P, (c) anti-Plectin staining of 
fibrosarcoma 188 tissue 6h post CA-4-P, (d) anti-Plectin staining of fibrosarcoma 188 tissue 
24h post CA-4-P, (e) anti-Plectin staining o f fibrosarcoma 188 tissue 72h post CA-4-P, the 'V' 
is indicative of the viable tissue stained here using anti-Plectin and the 'N' relates to the 
necrotic area which remained unstained and (f) the negative control using fibrosarcoma 188 
tissue 72h post CA-4-P.
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The anti-Plectin staining in Figure 3.39 (a) suggests that Plectin is highly expressed in the 
Control tissue which correlates with both MALDI-MSI and LC-ESI-MS/MS data seen earlier 
(Figure 3.38 and 3.37 respectively). In addition to this, there is also evidence of a reduction in 
Plectin expression as the time course progresses as seen in Figures 3.39 (b)-(e).
From the anti-Plectin immunohistochemistry it is also apparent that Plectin is distributed in 
the viable tissue regions.
Plectin is decribed as a 'cytolinker' and has a key role in the stabilisation of the cytoskeleton via 
the formation of a mesh-like scaffold (Liu et al 2011,. Wiche 1998). An article by Katada et al 
(2012) suggested that Plectin could be a 'novel prognostic marker' for head and neck 
squamous cell carcinoma. The article concluded that Plectin had a strong influence on tumour 
survival and metastatic processes and further work would elucidate how Plectin mediates 
cancer migration and invasion. Plectin is amongst the proteins said to be increased in tumour 
tissue and studies have found elevated levels of in colorectal cancer, prostate cancer and 
pancreatic ductal adenocarcinoma (Winter and Wiche 2013,. Nagel et al 1995,. Lee et al 2004,. 
Katada e ta l 2012).
The response reported here using CA-4-P treated fibrosarcoma 188 tissue suggested that 
Combretastatin greatly interferes with Plectin expression. In addition to this, the decrease in 
Plectin expression overtime could be an indication of apoptosis and/or necrosis within the 
tumour tissue. It is known that initiator caspase 8 translocates to Plectin after apoptotic 
induction leading to remodelling of actin/ microfilaments (Stegh et al 2000).
Remodelling and degradation of proteins occurs via the intrinsic and extrinsic apoptotic 
pathways (Elmore 2007). Executioner caspases (i.e. caspases 3, 6, 7) supersede initiator 
caspases (caspases 2, 8, 9 ,10) to then play a role in protein degradation.
Gelsolin, a known substrate for executioner caspase 3 will then go on (after itself being cleaved 
by caspase 3) to cleave Actin to essentially destroy the architectural integrity of the 
cytoskeleton (Elmore 2007).
Interestingly, from the immunohistochemistry reported here there is strong evidence of an 
inverse correlation between the HSP-90 and Plectin. This enabled visualisation of regions 
associated with tumour stress response versus those exhibiting tumour survival, growth and 
progression. This inverse correlation is displayed in Figure 3.40.
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Figure 3. 40: Optical scans o f anti-Plectin and HSP-90 Immunohistochemical staining in 
fibrosarcoma 188 serial sections, 72h post CA-4-P treatment.The necrotic (N) and viable (V) 
tissue regions are indicated.
A clear inverse correlation is displayed between the viable Plectin stained tissue and the 
necrotic HSP-90 stained regions in Figure 3.40.
In Chapter 2 a Rho GTPase activating protein 2 was identifiable from the MALDI-MSI-MS/MS of 
fibrosarcoma 120 tissue, here in the fibrosarcoma 188 samples Ras GTPase-activating-like 
protein (IQGAP1) has been matched.
IQGAP1 is said to be a multimodal scaffolding protein and is implemented in actin dynamics, 
tubulin multimerisation, cell motility and migration via numerous signalling pathways 
(Malarkannanet ol 2012). There are that studies report that increased expression of IQGAP1 
resulted in disruption of cell-cell junctions thus promoting a migratory, invasive phenotype 
(Mataraza et al 2003). In Figure 3.34 IQGAP1 is undetected in the Control but visible from the 
graph in the 0.5h from which point levels decrease in an 'L' trend through to the 72h 
treatment, suggesting possible CA-4-P pharmacological action.
An example of an MS/MS spectrum corresponding to IQGAP1 and normalised spectrum time 
course graph is featured in Figure 3.41.
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Figure 3. 41: Example MS/MS spectrum and normalised intensity graph o f IQGAP1 in 
fibrosarcoma 188 LC-ESI-MS/MS results. Insert displays the normalised spectral counts for 
IQGAP1 throughout the time course post CA-4-P.
It can be said that the glycoprotein Tenascin (C), has similar functions to those of IQGAP1 
having involvement in tumour survival and the outgrowth of circulating cancer cells (Oskarsson 
et al 2011).
The levels seen in Figure 3.34 show a marked increase in the 0.5h compared to the Control 
with decreases evident in the later time points to follow, a similar response to that observed 
from IQGAP1.
An example MS/MS spectra with intensity graph is shown in Figure 3.42.
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Figure 3. 42: Example MS/MS spectrum and normalised intensity graph o f Tenascin C in 
fibrosarcoma 188 LC-ESI-MS/MS results. Insert displays the normalised spectral counts fo r 
Tenascin C throughout the time course post CA-4-P.
The action of CA-4-P does appear to have an inhibitory effect on Tenascin C however there is 
literature to suggest that its fellow glycoprotein, Tenascin W could prove to be a more suitable 
marker in solid tumours (Brellier et al 2012). This article reports that the expression of 
Tenascin W is more specific in tumours compared to healthy tissues therefore facilitating the 
grading/ scoring of diseased tissue. Future studies involving Mass spectrometric techniques 
could help to ascertain this claim.
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Figure 3. 43: Example MS/MS spectrum and normalised intensity graph o f Alpha-enolase in 
fibrosarcoma 188 LC-ESI-MS/MS results. Insert displays the normalised spectral counts for 
Alpha-enolase throughout the time course post CA-4-P.
Alpha-enolase is thought to be implemented in many processes. In addition to its role as a 
glycolytic enzyme it is known to have transcriptional capacity and molecular chaperone 
capabilities (Pancholi 2001,. Kang et al 2008). The overall reaction to CA-4-P treatment by 
Alpha-enolase is a steady increase from Control -  72h. Alpha-enolase is regarded as a tumour 
associated antigen (TAA) and when elevated levels are present in tumour tissue activation of 
immune responses occur in patients w ith cancer (Capello et al 2011). Increased expression of 
Alpha-enolase is also indicative of aggressive tumour progression.
The response seen here by Alpha-enolase in Figures 3.34 and 3.43 could be a reflection of this 
CA-4-P resistant tumour type which is now shown to have regenerative capability.
Transforming growth factor-beta-induced protein ig-h3 (Tgfbi) is featured in the follow ing 
Figure (3.41).
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Figure 3. 44: Example MS/MS spectrum and normalised intensity graph o f Transforming 
growth factor-beta-induced protein ig-h3 (Tgfbi) in fibrosarcoma 188 LC-ESI-MS/MS results. 
Insert displays the normalised spectral counts fo r Tgfbi throughout the time course post CA- 
4-P.
From the LC-ESI-MS/MS time course results in Figure 3.34/ 3.44, Tgfbi is shown to demonstrate 
a 'L' shape trendline similar to that seen from Plectin (Figure 3.34) w ith high levels in the 
Control compared to the samples post treatment.
The latter response is a trend similar to the results documented in an article by Li et al (2012) 
entitled ‘The role o f TGFBI in mesothelioma and breast cancer: association with tumor 
suppression'. It is stated that Tgfbi is a known tumour suppressor and expression of TGFBI is 
reported to be greatly reduced in many tumour cell lines (Kim et al 2000,. Zhao et al 2004,. 
Shao et al 2006). However a dual role is suggested for Tgfbi which proposes an anti- 
tumourigenic function in early tumour growth and as a pro-oncogenic supporter in late stage 
tumours.
It is hard to ascertain whether the response seen here is solely by Tgfbi in this resistant tumour 
type or as a result of a synergistic effect from Tgfbi-CA-4-P interaction.
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3.4.4 Protein relationship mapping of fibrosarcoma 188 LC-ESI-MS/MS data 
using String 9.0
Visualisation of the complex protein pathways and networks that govern tumour biological 
function could help the understanding of protein dose response relationships.
The follow ing protein-protein interactions visualised by String 9.0, are depicted by spatial 
positioning and linear connections w ith thicker lines representing stronger associations 
between proteins.
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Figure 3. 45: LC-ESI-MS/MS proteins o f interest from fibrosarcoma 188, visualised through 
proteomic pathway software STRING 9.0.
The String 9.0 association network in Figure 3.45 consisted of the proteins chosen in the LC- 
ESI-MS/MS proteins of interest graph (Figure 3.34).
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The focal pathway association seen here (Figure 3.45) within this group of proteins is the 
linkage between the heat shock proteins; HSP-90a, HSP-90P, GRP-78 (Hspa5) and Actin, 
cytoplasmic 1 and Ras GTPase-activating-like protein (IQGAP1).
The stronger association within this pathway runs directly from HSP-90a through to IQGAP1 
encompassing Actin, cytoplasmic 1. The latter is characteristic of an active tumour micro­
environment incorporating the morphological changes exhibited by architectural remodelling 
of Actin due to CA-4-Padministration.
Although not directly linked Plectin and Tenascin display close positioning to IQGAP1 all of 
which as previously mentioned, are known to be involved with promoting tumour survival, 
cellular migration and metastatic invasion.
A strong link is visible between fellow tubulin proteins and interestingly AL022784 (Alpha- 
enolase) is in close proximity to carrier protein Alpha-2-macroglobulin (A2m). Close positioning 
of AL022784 to macrophage related protein A2m is indicative of allergic stress response which 
remains true to the pharmacological intervention here. Haemoglobin subunit beta positioned 
above (A2m and AL022784) supports the haemorrhagic theory.
Tumour suppressing adhesion protein Transforming growth factor-beta-induced protein ig-h3 
(Tgfbi), is joined in this structural reorganisational milieu, as mentioned earlier the protein has 
involvement in cell-collagen interactions.
The full pathway from the LC-ESI-MS/MS results recognised by String 9.0 is featured in Figure 
3.46.
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The proteomic network association tool String 9.0 is featured in more detail in Chapter 4 in the 
iTRAQ proteomic analysis section.
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3.4.5 Concluding remarks
The data reported here in this Chapter appears to be suggestive of an active tumour 
microenvironment possibly relating to this resistant nature of this fibrosarcoma 188 model.
The VIP scores (Figures 3.22-3.25) based on the PLSDA results gave the impression of 
transcriptionally active tumour tissues. Structural modifications were apparent via the Actin 
and Hb peaks present teamed with increases in hypoxia related Histone H3. As mentioned 
earlier, Histone H4 (m/z 1325) is believed to have a chief position in all time points apart from 
in the 24h samples. Further work would be required to confirm if this is due to CA-4-P 
interference before the regenerative tumour action commences, seen in the 72h treatment.
Collectively the results from the LC-ESI-MS/MS comprise of proteins connected with necrosis, 
cell structural reorganisation, polymerisation, tumour survival and stress induced molecular 
chaperones. The inverse correlation of molecular chaperone HSP-90 and survival promoting 
Plectin is evidence of this showing the distinct regional differences in the MALDI-MSI, 
immunohistochemistry and LC-ESI-MS/MS results.
Overall the levels of the proteins involved in heat shock response i.e. GRP-78, HSP-90(3, HSP-70 
are increased overtime, but interestingly HSP-90a displays the reduction in the 72h treatment, 
possibly highlighted the switch back to tumour viability. Mentioned previously in the 
introductory chapter regarding the concept of 'repeatedly identified differentially expressed 
proteins' (RIDEPs). A few were also seen in the full list of proteins identified which included 
HSP-70, enolase protein and peroxiredoxin.
Future studies could also consider the potential pharmacological interactions with the tumour 
suppressor Tgfbi, to clarify whether a dual role is undertaken, dependant on dose response 
relationships.
Combination anticancer therapy is a known route of choice in the treatment of patients. The 
future of disease diagnostics could include MALDI imaging as a diagnostic tool in combination 
with conventional imaging and proteomics. A novel and exciting approach was reported by 
Balog et al (2010) which described how mass spectrometry could be incorporated directly into 
the surgical theatres to identify tumour tissue boundaries and proximal metastases via Rapid 
Evaporative Ionization Mass Spectrometry. The latter subsequently substituting the wait for 
histological confirmation.
Label free LC-ESI-MS/MS shotgun proteomicsis a powerful technique with the potential to 
identify thousands of proteins. Like all methodologies in science it can be said that 
optimisation is key when performing shotgun proteomics. Further optimisation not only during
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sample preparation but throughout data-dependent acquisition mode could prove invaluable 
to advance proteome analysis and coverage (Kalli and Hess 2012).
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Chapter 4
LC-MALDI-MS/MS using iTRAQ 
labelling to investigate protein 
induction in CA-4-P treated 
fibrosarcoma 120 and 188 mouse
models
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4.1 Introduction
It is known that potential disease biomarkers are of relative low abundance thus making data 
validation a challenge (Ye et al 2010). The 'matrix suppression effect' is considered to 
exacerbate analysis of low abundant species (Knochenmuss and Zenobi 2003). An article by 
Knochenmuss and Zenobi (2003) states that in MALDI, matrix ions can be suppressed if 
sufficient analyte is present. In on tissue tryptic digestion, this is seldom the scenario for ions 
of interest. Suppression from high abundant Hb/ histones within MALDI-MS spectra is another 
example of ion suppression. Such ion suppression by high abundant Hb and histone species 
was evident in Figure2.1 in Chapter 2.
iTRAQ labelling coupled with LC-MALDI is a technique which aims to provide relative absolute 
quantitation of fractionated samples to give protein response information using the reporter 
ions generated (Chen et al 2012). Up to 8 samples can be combined for analysis and the 
method is described as a robust labelling technique implemented by N-hydroxysuccinimide 
(NHS) ester chemistry (Evans et al 2012, Noirel et al 2011). Sensitivity is improved as the mass 
spectra displays summed peptide ion signals from the isobaric labelled sample combination. 
The principles of iTRAQ multiplex chemistry are shown in Figure 4.1 (Ross et al 2004).
A  Isobaric Tag Total mass = 145 A .
Reporter Group mass 
114-117 (Retains Charge)
Amine specific peptide 
* reactive group (NHS)
PEPTIDE
Balance Group 
Mass 31-28 (Neutral loss)
c
11141—| 31 [—NHS
m/z114 (+1) 13C
m/z 115 (+2) 13C2
m/z 116 (+3) 13C2 «N
m/z 117 (+4) 13C3 15N
ISq  18Q  
18Q
13C
(+3)
(+2)
(+1)
(+0)
+ P E P T ID E
115 - 30 —WHS + P E P T ID E MS/MS
116 -  29 -NHS + P E P T ID E
NHS + P E P T ID E
30 l-NH-P E P T ID  E
29 l-NH-PEPTIDE
-NH-PEPT DE
114
115
116
117
Reporter-Balance-Peptide INTACT 
- 4 samples Identical m/z
-Peptide fragments EQUAL 
-Reporter ions DIFFERENT
Figure 4 .1 : The principles of multiplex tagging chemistry. (Ross et al 2004). A, illustrates the 
3 main components of the isobaric tag molecule; reporter, balancer and reactive group. B, 
shows the formation of an amide linkage created with a peptide amine, CID induces 
fragmentation here similarly to that of the peptide backbone. C, depicts the individually 
labelled peptides which when combined cannot be resolved by MS intact analysis, upon CID
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the reporter ions emerge as separate masses retaining the b-/y- ion information. The 
intensity of the corresponding reporter ions determines the concentration of the peptides.
The technique of iTRAQ is a recognised method widely used throughout Oncology (Sutton et al 
2010). Ruppen et al (2010) studyingKiSS-1 (a metastasis suppressor gene) in bladder cancer 
reported the use of iTRAQ to help predict the involvement of proteins in biological 
disease.iTRAQ analysis was performed on protein extracts from transfected (vector containing 
KiSS-1 gene) bladder cancer cells (EJ138). iTRAQ comparisons were done of the transfected, 
mock, and empty vector-exposed cells. A recent paper by McMahon et al (2012) employed 
iTRAQ to studyglobal changes in protein expression in a regional analysis experiment using 
multicell tumour spheroids. The article also used immunohistochemistry, Western blotting and 
enzyme assays to complement the iTRAQ findings. The aim of the work reported in this 
Chapter was to support/validate the results found using MALDI-MSI, LC-ESI-MS/MS and 
immunohistochemistry described in Chapter 3.
4.2 Materials and Samples
4.2.1 Chemicals and Materials
a-Cyano-4-hydroxycinnamic acid (CHCA), aniline (ANI), ethanol(EtOH), chloroform (CHCI3), 
methanol (MeOH), acetonitrile (ACN), hydrochloric acid (HCI), tri-fluoroacetic acid (TFA), 
ammonium bicarbonate, BCA protein assay reagent (bicinchoninic acid), copper (II) sulfate 
pentahydrate 4% solution, protein standard solution, 1.0 mg/mL bovine serum albumin 
(BSA),DL-Dithiothreitol solution, lodoacetamide, urea, potassium di-hydrogen phosphate 
(KH2P04), TRIzol were from Sigma-Aldrich (Dorset, UK). Modified sequence grade trypsin (20 
pglyophilised) was obtained from Promega (Southampton, UK,).Modified sequence grade 
trypsin (lmglyophilised) was obtained from Roche (Roche Products Limited Pharmaceuticals, 
UK). iTRAQ reagents (AB Sciex, Warrington, UK). Isolute C18 RP LC column (Kinesis Ltd., St. 
Neots, UK)./?op/Gest SF Surfactant was from Waters (UK). Peptide Calibration Standard II 
(Bruker Daltonics, Bremen, Germany).
4.2.2 Tissue samples
Mice were injected sub-cutaneously in the flank with a 50 pi tumour cell suspension containing 
1 x 106 cells in serum-free medium.The cells employed in this study were from the mouse
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fibrosarcoma cell lines, VEGF120 and VEGF188. Thesehave been engineered toexpress either 
the VEGF120 or VEGF188 isoforms only. Tumours were allowed to growto approximately 500 
mm3, before CA-4-P treatment (a single doseof 100 mg/kg i.p). The dosage for CA-4-P are 
consistent with animal studies performed at clinically relevant doses (Galbraith 2003., Prise 
2002). Mice were killed and tumours excised at varioustimes after treatment. All animal work 
carried out documented herein was performed by Dr. J. E. Bluff, Tumour Microcirculation 
Group, University of Sheffield, UK. Samples were provided as frozen excised tumours and 
stored at -80°C.
4.2.3. Experimental groups
Fibrosarcoma 120 tumour samples: Controls (no treatment, saline i.p), n = 6 (labelled 
tumourlJL -  tumour 1_6), C-A4-P (0 h after treatment), n = 6, (labelled tumour2_l -  tumour 
2_6), C-A4-P (0.5 h after treatment), n = 6,(labelled tumour 3_1 -  tumour 3_6), C-A4-P (6 h 
after treatment),n = 6, (labelled tumour 4_1 -  tumour 4_6), C-A4-P (24 h after treatment)n = 6, 
(labelled tumour 5_1 -  tumour 5_6).
Fibrosarcoma 188 tumour samples: Controls (no treatment, saline i.p), n = 4 (labelled tumour 
6_1 -  tumour 6_4), C-A4-P (0.5 h after treatment), n = 5, (labelled tumour 7_1 -  tumour 7_5), 
C-A4-P (6 h after treatment), n = 5, (labelled tumour 8_1 -  tumour 8_5), C-A4-P (24 h after 
treatment), n = 5, (labelled tumour 9_1 -  tumour 9_5), C-A4-P (72 h after treatment) n = 4, 
(labelled tumour 10_1 -  tumour 10_4).
4.2.4 Tissue preparation
The following preparation was performed on sections from fibrosarcoma 120 and 188 tissue 
with one example used from each tumour treatment time point. Frozen tissue sectionswere 
cut to give approximately 10 x lOpmsections per sample for digestion, using a Leica CM3050 
cryostat (Leica Microsystems, MiltonKeynes, UK) (Djidja et al 2009). Sample sections were 
stored in airtight tubes at -80°C until further use.
4.2.5 Tissue homogenisation and precipitation of protein
The tissue as described in 4.2.4 was homogenised in 800pl of TRIzol solution using a micro- 
homogeniser (Kline and Wu 2009). Homogenised solution was centrifuged (1,500 rpm) for 5 
min to pellet out nuclei/ unbroken cells. Post-nuclear supernatant was then centrifuged 
(14,000 rpm) for 30 min. Resulting supernatant was discarded and cellular membrane pellet 
was retained for protein precipitation. 200pl of MeOH and 50pl of CHCI3were then added to 
each protein pellet sample. After vortexing, 150pl HPLC H20  was added with further vortexing.
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After centrifugation (14,000 rpm) for 2 min, the bottom CHCI3 layer was removed. A further 
50|il CHCI3 was added, removal of the bottom CHCI3 layer was repeated following 
centrifugation (14,000 rpm) for 2 min. Subsequent removal of the H20  layer resulted in the 
remaining protein precipitate layer. CHCI3 (50pl) and MeOH (150pl) were added directly to the 
protein precipitate, after vortexing solution was centrifuged (14,000 rpm) for 2 min. 
Supernatant was removed and protein pellet was then allowed to air dry for 2 min.
4.2.6 Protein Digestion
lOOpI of 0.1% RapiGest in 50mM NH4HCO3 buffer (pH 7.8) was added to the air dried protein 
pellet. Each sample pellet/ solution was consecutively vortexed, incubated at -80°C (~ lhr) and 
heated to 70°C (1 min) until solubilised. Once fully solubilised the sample was heated to 100°C 
(2 min) and then left to reach room temperature. Each sample was reduced with DTT (final 
concentration 5mM) for 30 min at 60°C the left to reach room temperature. Solutions were 
then alkylated with iodoacetamide (final concentration 15mM) in the dark for 30 min at room 
temperature. The fibrosarcoma 120 samples were then lyophilised and re-suspended in 5pl of 
8M urea in 400mM NH4HCO3 buffer prior to tryptic digestion. Sequence grade modified trypsin 
was added (20pg/ml or lmg/ml) to80pg (fibrosarcoma 188) /  lOOpg of protein (fibrosarcoma 
120), a BCA Protein Assay Reagent (bicinchoninic acid) was used for protein determination. In­
solution digests were incubated over night at 37°C with shaking.
4.2.7 Preparation of samples for column loading
Fibrosarcoma 120; after overnight digestion the solution was centrifuged (1,500 rpm) for 1 min 
and reaction stopped by placing samples on ice where 10pl of 10% TFA was added. Each 
sample for analysis was de-salted using C18 Bond-elute columns and subsequently lyophilised 
until required.
Fibrosarcoma 188; HCL (final concentration lOOmM) was added to the overnight digest, 
solution was then incubated for a further 45 min at 37°C. After this step the sample was then 
centrifuged (14,000 rpm, 4°C) for 10 min, the supernatant removed for analysis. This 
remaining solution was lyophilised and stored at -80°C until further use.
4.2.8 C18 bond-elute preparation
The C18 columns were wetted with 1ml MeOH, equilibrated with (x2) 1ml solvent A (2% ACN, 
0.05% TFA), after the addition of the sample two wash steps were performed with (x2) 1ml 
solvent A (2% ACN, 0.05% TFA) and peptides were collected in a fresh tube after 1ml solvent B 
(80% ACN, 0.05% TFA).
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4.2.9 Sample re-suspension
Each lyophilised sample was re-suspended in 10pl of TEAB, 0.1% SDS, vortexed and centrifuged 
(14,500 rpm) for 1 min at room temperature.
4.2.10 iTRAQ labelling
The iTRAQ reagents (AB Sciex, Warrington, UK) were removed from -20°C storage and allowed 
to equilibrate to room temperature. After brief centrifugation(bench top), 40pl of isopropanol 
was added to each iTRAQ vial, vortexing and brief centrifugation followed. Transfer of each 
individual iTRAQ vial to each corresponding sample tube was as follows:
8-plex Fibrosarcoma 120; (a)Control - sample 1 -  iTRAQ 113, (b)Control- sample 2 -  iTRAQ 
114, (c)0h post CA-4-P - sample 3 -  iTRAQ 115, (d)0.5h post CA-4-P - sample 4 -  iTRAQ 116, 
(e) 0.5h post CA-4-P - sample 5 -  iTRAQ 117, (f)6h post CA-4-P - sample 6 -  iTRAQ 118, (g)6h 
post CA-4-P - sample 7 -  iTRAQ 119, (h)24h post CA-4-P - sample 8 -  iTRAQ 121.
All iTRAQ ratios were calculated relative to the control labelled 113.
(a)Control - sample 1 -  iTRAQ 113, (c)0h post CA-4-P - sample 3 -  iTRAQ 115, (d)0.5h post CA-
4-P - sample 4 -  iTRAQ 116,(f)6h post CA-4-P - sample 6 -  iTRAQ 118,(h)24h post CA-4-P - 
sample 8 -  iTRAQ 121 combinations are shown here for comparison to fibrosarcoma 188.
5-plex Fibrosarcoma 188;(a)Control - sample 1 -  iTRAQ 113, (b)0.5h post CA-4-P - sample 2 -  
iTRAQ 114, (c)6h post CA-4-P - sample 3 -  iTRAQ 115, (d) sample 4 -  iTRAQ 116, (e)24h post 
CA-4-P - sample 5 -iTRAQ 117.
All iTRAQ ratios were calculated relative to the control labelled 113.
To ensure maximum iTRAQ reagent transfer a further lOpI of isopropanol was added to each 
iTRAQ reagent tube to then vortex and centrifuge. The contents were transferred to the 
corresponding iTRAQ/ sample contents. Each sample with iTRAQ reagent was then thoroughly 
vortexed and centrifuged (1 min) (NB -  no turbidity observed). The pH was tested for each 
sample and adjusted to pH 7.0 -  10.0 with 1M TEAB (maintain organic concentration of 60%). 
50pl of HPLC H20  was added to each reaction, vortex followed by bench top centrifugation. 
The corresponding samples were all combined into 1 reaction tube. A further 25pl of HPLC H20  
was added to the combined reaction tube before lyophilisation (50°C aqueous and then stored 
overnight at 4°C).
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4.2.11 SCX
The SCX column was washed/wetted using 1ml HPLC grade H20  (assisted by a syringe) 
followed by 1ml (x2) of loading buffer. The combined sample was re-suspended in 1ml loading 
buffer (25% ACN: 75% HPLC H20) and pH checked to adjust to approximately pH 2.5-3 with 
10% TFA. The sample was added to the SCX column by passive hydrostatic pressure and the 
flow through collected (FT1). A further 1ml of was added directly to the SCX column and flow 
through collected (FT2). For the elution of peptides varying concentrations of 500pl 60mM -  
lOOOmM KCL were added to the column resulting in fractions El -  E6. Fractions were de-salted 
with C18 Isolute columns. Prior to de-salting 1.5ml HPLC solvent A was added (2% ACN, 0.05% 
TFA) to the fractions. After de-salting the samples were lyophilised and stored at -20°C until 
further use. As required, each eluate was re-suspended in 13pl of 10% ACN.
4.3Methods and instrumentation
4.3.1 Sample fractionation and matrix deposition
The Bruker PROTEINEER fc LC-MALDI Fraction Collector (Bruker Daltoniks, GmbH Bremen, 
Germany) was used to deposit the LC separated peptide fractions in a combination of CHCA 
matrix and peptide solution. Fractions were automatically spotted onto MALDI AnchorChip 
targets. The matrix, a-cyano-4-hydroxycinnamic acid (CHCA) was used, in EtOH: Acetone (2:1), 
lOOmM ammonium phosphate, 10% TFA.
4.3.2 Instrumentation
Liquid chromatography was performed with LC Packings/Dionex Ultimate 3000 capillary HPLC 
system (Dionex, Camberley, Surrey, UK). Samples were injected onto a C18, 300pm x 5mm, 
5pm diameter, 100A PepMap pre-column (LC Packings, Sunnyvale, CA) on an LC Packings 
UltiMate 3000 (McMahon et al 2012,. Montgomery et al 2012). The sample was washed with 
mobile phase A for 3.5 minutes at a flow rate of 300 nl/min on the pre-column before being 
switched onto a C18, 75pm x 15cm, 3pm diameter, 100A PepMap column (LC Packings) 
equilibrated with mobile phase A at a flow rate of 300 nl/min. Mobile phase B (80% 
acetonitrile, 0.05% TFA) was increased to 10% and then increased with a linear gradient to 
either 30% - 40% over 105 minutes. The fractions after HPLC were coeluted with 1.2 pL of 
saturated a-cyano-4-hydroxy cinnamic acid (CHCA) matrix solution. Peptide Calibration 
Standard II (Bruker Daltonics, Bremen, Germany) was as listed; Angiotensin I, Angiotensin II, 
Substrate P, Bombesin, ACTH clip 1-17, ACTH clip 18-39, Somatostatin 28, Bradykinin 
fragment 1-7 and Renin Substrate Tetradecapeptide porcine. The calibrant covered a mass of
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range 700-3200 Da. Peptide mass fingerprints and MALDI-MS/MS were acquired by using a 
MALDITOF/ TOF UltraFlex II instrument (Bruker Daltonics, Bremen, Germany) with a 200 Hz 
smartbeam laser (>250 pJ/pulse) in reflectron positive ion mode. WarpLC software (vl.2) was 
used in automated mode which comprised of data acquisition (FlexControl version 3.0) and 
peak detection (FlexAnalysis version 3.0, using the Snap peak detection algorithm), initially in 
MS mode screening LC fractions between 700 and 3000 Da to generate a list of peptides. 
External calibration was carried out for each during MS analysis. For Each peptide MS/MS 
analysis was performed using LIFT mode (FlexControl 3.0). Mass lists (FlexAnalysis 3.0, using 
TopHat baseline subtraction, Savitzky- Golay smoothing and Snap peak detection algorithms) 
from each MS/MS spectrum were compiled into a batch file for exportation to perform protein 
database searching.
4.3.3 Data pre-processing
Mascot software version 2.2 (Matrix Science, U.K.) was used for protein identification 
searching, comparisons of the MS fragmentation data were made against the Swiss-Prot 2010 
Mus (Musculus) protein database. The Mascot search parameters included used Mudpit 
scoring with the following post translational modification parameters for both tumour types;
Fixed modifications : Carbamidomethyl (C) (fixed)
Fixed modifications : Carbamidomethyl (C) with a filter of protein score> 28 (fixed filtered)
Variable modifications : Carbamidomethyl (C), Acetyl (Protein N-term),Gln->pyro-Glu (N-term 
Q),Glu->pyro-Glu (N-term E),Oxidation (M) (variable - fixed)
Variable modifications : Carbamidomethyl (C), Acetyl (Protein N-term),Gln->pyro-Glu (N-term 
Q),Glu->pyro-Glu (N-term E),Oxidation (M) with a filter of protein score> 28 (variable filtered - 
fixed)
The confidence threshold selected was 95% (p < 0.05) for MS/MS data mining. Proteinscape 
software v2.1 (Bruker Daltonics, Bremen, Germany) was used to collate the total 7 LC-MALDI 
runs in eacg case (fibrosarcoma 120/fibrosarcoma 188) into a single nonredundant protein list 
(comprising at least one unique peptide and in the filtered search cases with a Mascot score of 
>28) (McMahon et al 2012,. Montgomery et al 2012). The protein lists generated by 
ProteinScape was manually filtered to flag proteins iTRAQ labelled/ un-labelled, peptides that 
were not ranked first were discarded.
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4.3.4 Statistical analysis
Excel spreadsheets were generated via exportation of data lists generated by ProteinScape for 
both fibrosarcoma 120 and fibrosarcoma 188 tumours analysed. The ratios were all quantified 
relative to the control at time zero and normalised to the average of 1. Thus allowing the study 
of quantitative information from the iTRAQ reporter ions throughout the time course of 
samples, post CA-4-P administration. Scaffold 3Q+ was used for additional visualisation and 
analysis of the iTRAQ data (http://www.proteomesoftware.com/). The data files (.dat) 
produced from ProteinScape which corresponded to each fraction analysed, were uploaded 
individually selecting 'iTRAQ 8-plex' and 'MudPit Experiment (combine samples)'. The .dat files 
selected were using a fixed modification search. Analysis with X! Tandem was selected in order 
to improve protein identifications with searching through an additional database.
4.3.5 Protein network analysis
Accession lists generated by ProteinScape were imported into the STRING 9.0 database to 
observe the relationships between the proteins indentified and study the predicted functional 
partners of known protein interactions (http://string-db.org/).
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4.4 Results and discussion - Fibrosarcoma 120
4.4.1. HPLC UV profiles of fibrosarcoma 120 tumour fractions
VEGF 12 D E I V E G F 123r :
VEG F12D E3 VEGF 12D,
VEGF 120 UV[ 280 . 0nm>
U V | 2 1 5 . 0 n mt
I ii toy iliw^ |M««»
,'EGF 12D F-
Figure 4.2: UV profiles from the fibrosarcoma 120 fractions after SCX. (a) shows the UV 
profile from the first eluant (E l) after 60mM KCI following the flow through (FT) fraction 
from strong cation exchange, (b) 120mM KCI (E2), (c) 180mM KCI (E3), (d) 300m M  KCI (E4), 
(e) 500mM KCI (E5), (f) lOOOmM KCI (E6) and (g) (FT) after addition o f the combined iTRAQ 
labelled sample. The FT UV profile (Figure 4.2 (g)) does not show many peptide peaks which 
could be a sign o f good binding of the sample to the CSX column. It appears from the UV 
profiles that the most o f the peptides are present in fractions E3-E6. For these HPLC runs the 
gradient was reduced to 30% to maximise peptide elution from the column.
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4.4.2 Frequency of unique peptides identified
Number of unique peptides identified andcorrespondingfrequency
120
1 00  —
Q.aao<u-Q
E3Z
60 —
40
20
-W -
52 6 81 3 4 7 9 10 11 12
Frequency
Figure 4. 3: Frequency of detection of unique peptides by LC-MALDI-MS/MS. The graph shows 
the range o f unique peptides detected, for example 112 unique peptides were only seen once 
with only 1 peptide having 12 unique peptides assigned to it.
4.4.3. Analysis using excel
Spreadsheets were prepared which featured exported lists generated from ProteinScape. 
Figure 4.4 displays a screen shot of an excel spreadsheet used for protein analysis and ratio 
comparison. This relevance of this data output was to observe the full protein list supplied by 
MASCOT (using the 'mus' search database) prior to importing into Scaffold proteomic tool 
software using a simple colour coded thresholds shown in Figure 4.4. The thresholds were 
determined for each column by using the standard deviation (SD) value. To depict down 
regulation values lower that the SD were coloured red, up regulation was determined by 
values of 1 + SD and values that fell between the thresholds were coloured yellow.
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The results featured in Figure 4.5 are from the complete excel spreadsheet in Figure 4.4.
The iTRAQ ratio response relative to the control (113) shown in Figure 4.5, displays various 
outcomes throughout the tumour time course post CA-4-P. Due to the CA-4-P susceptible 
nature of the fibrosarcoma 120 model the dominant factors apparent from the bar graph 
(Figure 4.5) appear to be from the Hb peptides Haemoglobin subunit alpha, Haemoglobin 
subunit beta-1 and Haemoglobin subunit beta-2.
Keratin-1 (KRT1) also produced an increased response compared to the control tumour tissue 
and it is difficult to explain the increase seen here in the Oh time point. Further work is 
therefore required to validate such a response so soon after treatment. Interestingly, an 
article by Tang et al (2012) proposes Keratin 1 as acis-diamminedichloroplatinum-resistant 
(cDDP) protein innasopharyngeal carcinoma cell lines. The data from this Nasopharyngeal 
carcinoma study concluded that the expression of KRT1 was related to the issue of drug 
resistant in this particular cancer and suggested KRT1 as a potential biomarker and key player 
in the mechanism of multidrug resistance in Nasopharyngeal carcinoma (Tang et al 2012).
It is known that the type I and II keratins (polypeptides of the non-hair category) are co­
expressed during the differentiation of tumours, consist of either acidic or basic proteins and 
are found mostly in epithelial cells (Karantza 2011). KTR1 is present in normal endothelia, 
benign and malignant tumour tissue (Remotti et al 2001). It is also suggested that KRT1 has a 
key role in the architectural integrity of the cytoskeleton in tumour cells (Reichelt et al 2004). 
The increased response found in Figure 4.5 (0h-24h post CA-4-P) relative to the control 
tumour tissue could be a evidence of the need to maintain epithelial cellular architecture as 
KRT1 levels are still elevated in the later time points (Karantza 2011).
In contrast to the latter, type 3 mesenchymal intermediate filament Vimentin, is shown to be 
greatly decreased in response to CA-4-P administration (Figure 4.5). Vimentin is expressed in 
normal mesenchymal tissue and considered to have involvement in migratory, adhesive and 
cell survival mechanisms (Lahat et al 2010).
Vimentin is said to play a role in mesenchymal transition in cancerous tissues with a study by 
Handra-luca et al (2011) reporting a three-fold higher expression of vimentin in pancreatic 
neoplasms. Increased expression of Vimentin is not seen in the time points following the 
control, possibly suggesting an inhibitory action due to CA-4-P. However due to the results 
here (Figure 4.5) being n=l then further repeats would clarify the response from Vimentin. 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is commonly used as a housekeeping 
gene in quantitative experimental studies (protein/ RNA analysis) where expression levels are 
used for normalisation purposes (Barber et al 2005). GAPDH levels therefore are renowned for 
consistency throughout various tissues strengthening its use as an internal standard. Reports 
by Said et al (2009) revealed that under hypoxic conditions GAPDH in hepatocellular
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carcinoma, human lung adenocarcinoma epithelia and colon cancer cell lines (in vitro) remains 
unregulated by hypoxia. The article concludes that a GAPDH-hypoxia study is not a suitable 
strategy for future anti-cancer therapeutics in hepatocellular carcinoma, human lung or human 
colon cancer. The GAPDH results in Figure 4.5 are in opposition to this hypothesis. A 
considerable increase in the 0.5h post CA-4-P time point is evident whilst the Oh post CA-4-P 
remains consistent with the control tissue. Unfortunately the protein remained undetected in 
the later time points therefore making it impossible to deduce the complete response 
throughout the time course. The other assumption could be that the absence of GAPDH in the 
6h and 24h (post CA-4-P) samples is due to the effects of CA-4-P induced hypoxia.
With a view to validate the uncharacteristic alteration in GAPDH response in the later time 
fibrosarcoma time points, the responses exhibited by Hb could be considered. GAPDH showed 
a marked increase relative to the control as a result of treatment with the vascular disrupting 
agent CA-4-P. Peptides relating to GAPDH were absent from the 6hand 24h samples. The 
internal standard in the case of this iTRAQ experiment validating the GAPDH reaction post CA- 
4-P could be the characteristic haemorrhagic response evident from Haemoglobin subunit 
alpha, Haemoglobin subunit beta-1 and Haemoglobin subunit beta-2.
The protein lists reported here were generated using ProteinScape applying fixed modification 
Carbamidomethyl (C), and filteredusing a Mascot score >28 which yielded 29 protein 
identifications.
The protein lists generated using the alternative modification parameters; fixed, variable 
filtered and variable gave the following proteomics outcomes:
fixed -  99 protein identifications, variable filtered - 31 protein identifications, variable -  352 
protein identifications.
4.4.4. Analysis w ith Scaffold Q+
A screen shot of a protein list generated in Scaffold proteomic software from the LC-MALDI- 
MS/MS results is shown in Figure 4.6. The corresponding list generated after applying iTRAQ 
quantitative 3Q+ using the parameters above in displayed in Figure 4.7.
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The fold change ratios which can be seen in Figure 4.7 are displayed in Figure 4.8.
The search parameters applied by Scaffold proteomic software using the .dat file from 
fibrosarcoma fixed search gave information for 17 proteins (Figure 4.8). The subsequent data 
shows examples of protein sequences found and spectra used for protein identification and 
relative quantitation by Scaffold 3 Q+ using LC-MALDI-MS/MS. The following proteins detailed 
are; Vimentin, Hb subunit beta, Peroxiredoxin-1 (Macrophage 23kDa stress protein), Tubulin 
beta-5 chain, Annexin A5 and Keratin -1 (type II skeletal-1).
Vimentin (Figure 4.9), Hb subunit beta (Figure 4.10), Tubulin beta-5 chain (Figure 4.12) and 
Keratin -1 (type II skeletal-1) (Figure 4.14) are portrayed similarly to the excel analysis in Figure
4.5 as previously discussed. The employment of an unfiltered fixed modification search 
(proteins > 10 Mascot score) yielded Annexin A5 and the missing peptides for 6h and 24h post 
CA-4-P corresponding to Peroxiredoxin-1 (Macrophage 23kDa stress protein). The Log2 of 
normalised intensity in Figure 4.11 shows an initial decrease of Peroxiredoxin-1 with levels 
recovering during the 6h and 24h time points. The latter matches the iTRAQ ratio initial 
response of Peroxiredoxin-1 shown in Figure 4.5 evident in the Control and Oh time points. 
Peroxiredoxin-1 is thought to be involved in hypoxia/ reoxygenation process and levels appear 
elevated in a number of cancers (Park et al 2007). A recent study by Kalinina et al (2012) 
looking at cisplatin resistance formation in cancer cells using peroxiredoxin genes included 
PRDX1.It was found that elevated levels of PRDX1 was found in 3 cisplatin resistant cell lines. 
Over expression of the PRDXlgene is said to act as a protective mechanism against H20 2 
induced apoptosis (Kalinina et al 2012). Could this be an explanation for the regenerative 
response seen here by Peroxiredoxin-1?
The biological role of Annexin A5 has yet to be fully determined however it is commonly used 
as a marker of apoptosis (Rand et al 2012). This is due to the favourable binding affinity of 
Annexin A5 to phosphatidylserine which is expressed on the cell surface of cells undergoing 
programmed cell death. Expression levels of Annexin A5 are known to be increased in vascular 
endothelium cells. Interestingly the results in Figure 4.13 show an increase in Annexin A5 as 
the time course progresses fitting in with the increase in necrotic tissue postulated by CA-4-P 
administration.
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4.4.5 Protein relationship mapping of fibrosarcoma 120 data using STRING 
9.0
Observation of protein relationship maps facilitates the analysis of complex proteomic data 
sets. Understanding known protein-protein interactions could provide an insight into potential 
biomarkers. The proteomic pathway software STRING 9.0 proposed known protein pathways 
and networks with an additional predicted functional partners feature (http://string-db.org/).
The following proteomic networks generated by STRING 9.0 will feature zoomed in sections of 
the original networks shown in Figures 4.15 and 4.16 to ease interpretation. Evidence and 
confidence views are included which depict evidence of association and strength of association 
respectively. To relate to the fixed unfiltered search list imported into Scaffold 3 Q+ the same 
list will be used for compilation of the following protein relationship maps.
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Figure 4 .17: Zoomed in region o f a fixed modification search, iTRAQ fibrosarcoma 120 
samples.
There is a link suggested in Figure 4.17 between Peroxiredoxin-1 (Prdxl) and prolyl 4- 
hydroxylase beta (P4hb). Considering Prdxl potential involvement in reoxygenantion and anti- 
apoptosis, a link with P4hb fits. P4hb function includes the inhibition of aggregated malfolded 
proteins (http://string-db.org/). P4hb protein then has strong associations w ith Hspa5 (78 kDa 
glucose-regulated protein) and Hsp90bl. Hsp90bl was mentioned earlier in Chapter 3 along 
with its relevance to tumour biology and the stress response. Calreticulin (Calr) is also included 
to have strong associations w ith P4hb. Trace levels of Calr are found on normal lung cells but 
highly expressed in lung cancer cells (Liu et al 2012). Alpha Enolase 1 (Enol, 8 peptides found, 
collective Mascot score of 241) can be seen in the zoomed region in Figure 4.17, it also 
features in iTRAQ ratio response graph (Figure 4.5) and the iTRAQ fold change graph (Figure 
4.8). Both graphs display an early increase in the Oh and 0.5h post CA-4-P with levels 
decreasing towards Control levels in the 6h and 24h samples. Enol is known to be involved in 
tumourigenesis, proliferation and cancer cell metastasis due to its role as a plasminogen 
receptor (Capello et al 2011). It could be suggested that its sudden decrease in the later time 
points maybe as a result of increased necrosis by CA-4-P affecting the role of hypoxia tolerance 
by Enol (http://string-db.org/).
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Figure 4.18: Zoomed in region of a fixed modification search, iTRAQ fibrosarcoma 120 
samples.
Annexin A5 (Anxa5) where functional properties are mentioned earlier in this chapter, has 
several associations. Galectin-1 (Lgalsl -  2 peptides identified w ith a collective Mascot score 
of 54) is one such protein and is thought to have functional influence on cell proliferation, 
apoptosis and differentiation, therefore enhancing tumour progression (Banh 2011). Figure 4.5 
displays a contradictory trend to this where all the other time points relative to the control are 
notably decreased, again suggesting an inhibitory effect by CA-4-P.
The same response exhibited by Galectin-1 is true for S100 calcium binding protein A6 (see 
Figure 4.5) (Calcyclin -2 peptides identified w ith a collective Mascot score of 56). Functions of 
Calcyclin include an indirect role in cell motility and cytoskeleton restructuring (Ning et ol 
2012).
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The Tubulin proteins (Tubalc, Tubb5, Tuba 8) are shown with associations feeding into 
Vimentin with branching from Tubb5 to Cofilin 1, a protein which too intervenes in the 
regulation of morphological cell changes and cytoskeletal architecture.
Actin cytoplasmic 1 (Actb) is positioned prominently linking the proteins relevant in structural 
integrity, necrosis and heat shock molecular chaperones expressed due to malfolded un­
glycosylated proteins.
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4.5 Results and discussion - Fibrosarcoma 188
4.5.1. HPLC UV profiles of fibrosarcoma 188 tumour fractions
UV| 280 . 0nmJ
UV) 215 . 0nm|
V E G F 1 S S E l VEGF1SS E2
VE G F1SS E3 VEG F1SE E4
VEGF1ES E5 VE G F1E S E 6
VEGF1ES r
Figure 4. 19: UV profiles from the fibrosarcoma 188 fractions after SCX. (a) shows the UV 
profile from the first eluant (El) after 60mM KCI following the flow  through (FT) fraction 
from strong cation exchange, (b) 120mM KCI (E2), (c) 180mM KCI (E3), (d) 300m M  KCI (E4), 
(e) 500mM KCI (E5), (f) lOOOmM KCI (E6) and (g) (FT) after addition o f the combined iTRAQ 
labelled sample.
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The UV profiles in Figure 4.19 appear to indicate a greater protein elution compared to those 
in Figure 4.2 w ith a more even spread of UV signal, possibly indicating improved separation of 
peptides.
4.5.2 Frequency of unique peptides identified
Num ber o f unique peptides identified and corresponding frequency
B  no o f peptides
y  _  t._
1 2 3 4 5 6 7 8 9  10
F re q u e n c y
Figure 4. 20: Frequency of detection of unique peptides by LC-MALDI-MS/MS. The graph 
shows the range o f unique peptides detected. Here 49 unique peptides were only seen once 
whereonly 2 proteins had 10 unique peptides assigned to them.
4.5.3. Analysis using excel
Spreadsheets were prepared employing the methods describedin section 4.43. Figure 4.21 
displays a screen shot of an excel spreadsheet containing the fibrosarcoma 188 iTRAQ samples 
used for protein analysis and ratio comparison.
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The proteins seen in Figures 4.22a and*4.22b are from the same excel spreadsheet separated 
into two bar graphs to aid interpretation. These data has been generated via ProteinScape and 
exported to excel for analysis employing the same parameters prior to examination as detailed 
in the previous section entitled '4.3.4 Statistical analysis'.
The fixed filtered search performed on the fibrosarcoma 188 samples resulted in a greater 
peptide yield in comparison to the fibrosarcoma 120 results. 45 proteins were identified, 
opposed to 29 proteins in the fibrosarcoma 120 data set. The latter could be due to differing 
factors during the tissue digestion, SCX or LC fractionation. Another factor to consider could be 
the more CA-4-P resistant nature of the fibrosarcoma 188 tumour where different peptides 
identified could be as a result of decreased suppression from high abundant proteins i.e. 
Haemoglobin/ Histones.
The discussion that follows aims to highlight key responses from Figures 4.22a and 4.22b.
The haemoglobin peptides (Haemoglobin subunit alpha, Haemoglobin subunit beta-1, 
Haemoglobin subunit beta-2 and Haemoglobin subunit epsilon-Y2) are consistently present in 
Figure 4.22a to aid validation of the other protein responses however even with the fixed 
filtered search parameters many different proteins are observable.
Heat shock protein HSP 90-beta is increased in the 6h-72h time points with what appears to be 
a saturation point achieved in the 24h. This response by Heat shock protein HSP 90-beta was 
discussed in Chapter 3 where evidence of the switch back to viable tissue was observed both in 
the MALDI-MSI and immunohistochemistry.
A similar surge pattern of GAPDH levels (Figure 4.22a) seen previously in Figure 4.5 can be 
observed. The sudden increase appears in the 0.5h fibrosarcoma 120 time point (Figure 4.5) 
whereas in the fibrosarcoma 188 samples the surge is seen 6h post CA-4-P with decreased 
levels apparent in the 24h and 72h samples. An explanation of the delayed response in the 
Fibrosarcoma 188 data could be indicative of more resistant tumour model.
Tumour enhancing protein Galectin-1 (Figure 4.22a) is shown to be decreased relative to the 
control but later on in the 72h sample a small increase is observable possibly indicative of 
tumour regeneration.
Elongation factor 1-alpha 1 is a protein giving very different responses in the two tumour 
models. In the fibrosarcoma 188 samples levels are elevated throughout the time points in 
Figure 4.22b relative to the control. In contrast to this, levels in the fibrosarcoma 120 iTRAQ. 
results are all decreased relative to the control. Elongation factor 1-alpha 1 is a known
229
regulator of the cytoskeleton (Shiina et al 1994,.Veremievaet al 2010). One explanation could 
be that the elevated levels seen in the fibrosarcoma 188 samples maybe due to some form of 
pharmacological conflict elicited by this CA-4-P resistant tumour model.
The Complement system exhibits regulatory influences on host immune, inflammatory 
processes. Activation of this complex cascade of biological events is triggered via 3 main 
activation routes; the alternative, classic, and lectin pathways. (Nunez-Cruz et al 2012) 
Complement C3 is the key activator of the 3 main routes previously mentioned. Studies have 
shown that increased Complement anaphylatoxin levels have been detected in the peritoneal 
cavity fluid of ovarian cancer patients (Bjorge et al 2005). In vivo studies by Nunez-Cruz et al 
(2012) used complement deficient mouse models crossed with epithelial ovarian cancer 
susceptible mice. One of the key findings in this article was that tumour growth was either 
absent or greatly retarded in the offspring, compared to the wild- type. Thus indicating the 
importance of Complement C3 in tumour progression. Figure 4.22a shows that the iTRAQ ratio 
responses from 0.5h, 6h and 24h are reduced after CA-4-P treatment with a slight increase 
emerging from the 72h time point.
Plectin, not identified in the fibrosarcoma 120 data set is shown to have a greatly reduced 
response relative to the control in Figure 4.22b. Plectin is has been shown to be present in high 
levels in cancers such as head and neck squamous carcinoma and correlates with poor patient 
survival (Katada et al 2012). The ITRAQ data presented here show good agreement with the 
findings presented in Chapter 3 where MALDI-MSI and LC-ESI-MS/MS label free results 
displayed increased Plectin levels in the Control fibrosarcoma 188 samples with a dramatic 
decrease evident over the 0.5h-72h time course. Hence a decrease in Plectin expressions 
protein associated with tumour aggressiveness, does therefore appear to be a response to CA- 
4-P dosage.
The protein lists reported here were generated using ProteinScape applying fixed modification 
Carbamidomethyl (C), and filteredusing a Mascot score >28 which yielded 45 protein 
identifications. The protein lists generated using the alternative modification parameters; fixed, 
variable filtered and variable gave the following proteomics outcomes: 
fixed -  318 protein identifications, variable filtered - 51 protein identifications, variable -1 0 88  
protein identifications.
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4.5.4. Analysis with Scaffold Q+
A screen shot of a protein list generated in Scaffold proteomic software from the LC-MALDI- 
MS/MS results is shown in Figure 4.23. The corresponding list generated after applying iTRAQ 
quantitative 3Q+ using the parameters detailed in section 4.4.4.
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The fold change ratios which can be seen in Figure 4.24 are displayed in Figure 4.25.
To analyse the data from fibrosarcoma 188 models the search parameters applied by Scaffold 
proteomic software using the .dat file from fibrosarcoma fixed search gave information for 16 
proteins (Figure 4.25). The subsequent data shows examples of protein sequences found and 
spectra used for protein identification and relative quantitation by Scaffold 3 Q+ using LC- 
MALDI-MS/MS. The following proteins detailed are; Vimentin, Hb subunit beta, Pyruvate 
kinase isozymes M1/M2, Tenascin and Fibronectin precursor. The rationale for selection of 
these proteins was to assess differences and similarities in the Scaffold 3 Q+ results in the 
fibrosarcoma 120 model and observe proteins which did not appear in the VEGF 120 samples.
The Vimentin response observed by the resistant 188 model in Figure (4.26) bears some 
similarity to the study mentioned by Handra-luca et al (2011) reporting elevated Vimentin in 
pancreatic neoplasms. Although levels are still low in the 72h post CA-4-P sample a 
considerable increase is evident from the 6h and 24h time points, not observed in the earlier 
Vimentin VEGF 120 Log2 normalised intensity graph (Figure 4.9).
Hb subunit beta in Figure 4.26 does not exhibit a steady haemorrhagic response but levels still 
remain increased toward the final 72h time point.
Results displayed in Figure 4.25 of Pyruvate kinase isozymes M1/M2 show greatly increased 
fold change ratios when compared to the equivalent fibrosarcoma 120 graph in Figure 4.8. The 
fibrosarcoma 188 6h value shows over a 3 fold increase along with a 2.5 fold increase in the 
72h for Pyruvate kinase isozymes M1/M2, opposed to the 120 model which only shows a 1.8 
fold in the 24h. Pyruvate Kinase isozyme M2 is found in tumour cell and proliferating tissues 
alike and hypoxia-inducible factor 1 is said to play a role in its induction (Ye et al 2012).
Glycoprotein Tenascin, is seen in the fold change ratio graph (Figure 4.25). Tenascin appears to 
exhibit a 'peak-trough-peak' response throughout the timecourse. Due to the non 
identification of this protein in the fibrosarcoma 120 data set, it is difficult to validate or 
comment on this reaction. Tenascin is reported to promote metastasis (Minn et al 2005,. 
Oskarsson et al 2011). Studies by Oskarsson et al{2011) link Tenascin expression to the 
aggressiveness of breast cancer cells and their ability to further produce lung metastases. 
Considering the latter could the last 'peak' previously mentioned be a feature supportive of 
the 'switch back to viability concept' overtime after treatment.
Fibronectin precursor is known to bind to Tenascin, interestingly when comparing the fold 
change responses (Figure 4.25), both proteins appear to have an inverse fold change
235
relationship; Tenascin 'peak-trough-peak', Fibronectin 'trough-peak-trough'. Further study is 
needed to confirm and comprehend this trend of protein-protein interaction.
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4.5.5 Protein relationship mapping of Fibrosarcoma 188 data using STRING 
9.0
The proteomic networks to follow will feature the same format as the protein relationship 
analysis in section 4.4.5.
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Figure 4. 31: iTRAQ Fixed modification search using Fibrosarcoma 188 tumours, visualised by STRING 9.0 (Confidence view).
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Col4a2
A c tn l '
Anxal
Angp?S3Pled
Apoal
S100a6
Abca?
"TV-Anxa2
Tubb5
Dnaja3
Hspa4
Faml35a
Prdx4
H istlh lc
Figure 4. 33: Zoomed in region of a fixed modification search, iTRAQ fibrosarcoma 188 
samples, visualised through STRING 9.0.
Vimentin, Tenascin and Plectin are all grouped together in this zoomed region from Figure 4.33. 
The roles of this trio all involve tumour progression through individual unique mechanisms as 
discussed earlier in this chapter. A clear link can be seen with Tenascin and Fibronectin (fn l) to 
support findings in the literature reported back in section 4.5.4.
Actin has associations either directly or indirectly with Vimentin, Tenascin and Plectin to 
ascertain the ir roles in actin dynamics and general integrity and structural reorganisation. 
Another strong association with Actin is the Zyxin Gene anadhesion plaque protein further 
linking the latter to a Heat shock 90 containing group (not shown) via the Cingulin gene 
(http://string-db.org/). Cingulin is thought to be involved w ith cell junction permeability.
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Figure 4. 34: iTRAQ fibrosarcoma 188 zoomed in region of a fixed modification search, 
visualised through STRING 9.0.
This section of the STRING fixed fibrosarcoma 188 search displays most of the proteins seen in 
the 120 STRING results; Galectin, Annexin A5, Peroxiredoxin, Enolase 1. A protein in Figure 
4.34 however does not feature in the fixed fibrosarcoma 120 STRING results, this being 
Glucose-6-phosphate isomerase (Gpil). It has strong associations w ith hypoxia tolerance 
regulator Enolase 1, interestingly Gpil is known to function as a 'tumour-secreted cytokine' 
and features in angiogenesis encouraging endothelial cell motility (Ahmad et al 2011).
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Csnkld H2afzLmna
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Figure 4. 35: iTRAQ fibrosarcoma 188 zoomed in region of a fixed modification search, 
visualised through STRING 9.0.
Many proteins that feature in Figure 4.35 are already familiar i.e. Heat shock proteins, 
Calriticulin, Elongation factor 1 alpha. Perhaps disregarded is the important connection 
between Histone 2A and Actin. Although widely acknowledged and easily detected in both 
MALDI profiling and imaging, this connection could be regarded as a marker of the re- 
organisational transition towards tissue necrosis during anti-cancer treatment. Numerous 
associations can be clearly seen branching from these links downstream from Hsp 90 and 
Elongation factor 1 alpha.
4.5.6 Protein dose response relationship analysis using String 9.0
The follow ing data presented here analyses the protein dose response relationships and
associated pathways using the iTRAQ results from fixed medication searches, employing a filter 
score of > 28. Fibrosarcoma 120 and 188 lists were prepared for import into proteomic 
pathway software String 9.0 to observe proteins that were flagged either to exhibit a marked 
increased expression or decreased expression. This proteomic information was taken from the 
original iTRAQ spreadsheets featured in Figures 4.4 and 4.21. The normalised values were 
highlighted in either green, yellow or red indicating response relative to the control e ither 
increased, no change or decreased respectively.
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4.5.6.1 iTRAQ F ib rosarcom a 120 dose re la tio n sh ip  resu lts  us ing S tr in g  9.0
The protein pathways featured in Figure 4.36 show the proteins that were found to
demonstrate either increased or decreased responses in the particular treatment sample.
Aldaartl
Up - 24h post CA-4-P
Aldoartl
Gapdh
Up -  0.5h post CA-4-P
TubbS
Tuba8
Down - 24h post CA-4-P
U spell
H2afz@ ~~ ^
Down-0.5h post CA-4-P
0Pdia3
S100a6
H2afz
Figure 4. 36: iTRAQ proteomic response results using a Fibrosarcoma 120 treatment 
timecourse. Proteins are shown to either increase or decrease relative to the Control 
fibrosarcoma tissue, relationship links are shown between the proteins that have strong 
biological associations with each other.
In Figure 4.36 the increased proteins (Up -  24h post CA-4-P, Up -  0.5h post CA-4-P) displayed 
do not show any associations w ith each other. However both 0.5h and 24h share increased 
Keratin, type II cytoskeletal 1 (Krtl) and Fructose-bisphosphate aldolase A (Aldoartl). 
Mentioned earlier in this Chapter, K rtl is thought key player in the mechanism of multidrug 
resistance in some cancers (Tang et ol 2012). The unusual increase in GAPDH as previously 
discussed is seen here in the 0.5h.
A ldoartl is a component of the glycolytic pathway and increased expression of this enzyme is 
found in many cancers including cancer of the lung, kidney and cervix (Mhawech-Faucegliaet ol 
2011,. Takashi et ol 1990,. Oijika et al 1991). Perhaps increased response of A ldoartl here is an
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indicator of a tumour survival strategy against CA-4-P treatment. Elevated levels of this 
enzyme could be indicative of a high glycolytic rate, a key factor in tumour survival and 
metabolism (Saw 2006,. Beckner et al 1990).
The proteins that are decreased as a result in the 0.5h time point in Figure 4.36 include Tubulin 
alpha (Tuba8) and Tubulin beta-5 chain (Tubb5), linked by a strong association. This decrease 
could be as a result of disturbance due to the vascular disrupting agent. Although no direct link 
is seen between Tubb5 and adjacent proteins Galectin-1 (Lgalsl) and Heat shock protein 60 
(Hspdl), a close positioning is observed. The latter could echo the morphological transitions 
underway by Tubulin hence induction of Hspdl and decrease in Lgalsl which mentioned 
previously to be involved in cell proliferation, apoptosis and differentiation (Banh 2011).
The 24h decreased proteins in Figure 4.36 show a greater degree of protein-protein interaction 
with triplet links between Lgalsl, Calcyclin (S100a6) and Vimentin (Vim) and a further linkage 
between Elongation factor 1-alpha 1 (Eeflal) and Histone H2A.V (H2Afz).
S100a6, involved in restructuring of the cytoskeleton along with Vimentin and Lgalsl are 
decreased in the 24h and appear to be retarded by the effects of CA-4-P. Low levels of Eeflal 
in this CA-4-P susceptible tumour model reflect that at 24h the tumour tissue is almost totally 
necrotic.
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SlQ0a6
HspaS
U p -  Oh postCA-4-P Down -  Oh post CA-4-P
Figure 4. 37: Fibrosarcoma 120 proteomic response using String 9.0.iTRAQ increased and 
decrease protein response for tumour time point Oh post CA-4-P administration.
In the case of the fibrosarcoma 120 Oh time point there was only one marked early increase, 
this being Keratin, type II cytoskeletal 1 (Krtl) (Figure 4.37). This remained elevated 
throughout the later time point as shown in Figure 4.36. No associations were seen in the 
corresponding decreased set of proteins in the Oh post CA-4-P. 78 kDa glucose-regulated 
protein (Hspa5, Grp78) remains low in this early time point and would be expected to be 
elevated here in the later time points. However the threshold levels determined in the 
spreadsheet featured in Figure 4.4 did not highlight the values to be included in the increased 
group of proteins. Upon close observation of the spreadsheet the values w ithin the 'no 
change' (yellow) bracket for this protein did show a gradual increase throughout the time 
points.
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Aldoartl
Up com binationGapdh
H2afz
Pdia3
S100a6
Eeflal
Down com b ination
Figure 4. 38: iTRAQ combinations of fibrosarcoma 120 increased and decreased proteins. The 
protein relationships in Figure 4.38 are a representation of combined responses throughout 
the time points previously discussed.
In summary of the combined responses seen in Figure 4.38, the increased protein combination 
depicts the haemorrhagic pharmacological response, the potential multidrug strategy of Krtl, 
an uncharacteristic influence on GAPDH and evidence of a need for tumour cell survival due to 
the elevated levels of glycolytic enzyme Aldoartl. Amongst the proteins shown to decrease in 
Figure 4.38 is a triangular triplicate linkage between Actin, Histone 2A and E efla l. This appears 
to reflect the disrupting effects post CA-4-P treatment. The combination seen here 
encompassing the transitional changes in cellular integrity and attempts by the drug to retard 
growth and induce necrosis. The same effect is true for the other linear trio of proteins w ith 
the decrease of Lgalsl, S100a6 and Vimentin. Links between Protein disulfide-isomerase A3 
and Hspa5 imply evidence of the stress response and apoptotic processes respectively. Down
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regulation of Protein disulfide-isomerase A3 was only seen in the 24h time point indicating 
that extensive tissue necrosis was already present.
4.5.6.2 iTRAQ F ibrosarcom a 188 dose re la tio n sh ip  resu lts  using S trin g  9.0
Pfdn2
Rnfl60
Cct6a
Up - 72h post CA-4-P Down -  72h post CA-4-P
Figure 4. 39: iTRAQ proteomic response results using a Fibrosarcoma 188 treatment time 
course. Predicted functional partners are shown for increased Cct2 (indicated by the arrow) 
in the 72h time point and proteins that were decreased in the 72h post CA-4-P sample.
In Figure 4.39, the T-complex protein 1 subunit beta (Cct2) is shown with predicted functional 
partners which include fellow chaperone proteins. Cct2 is known to have actin/ tubulin re- 
organisational properties (http://string-db.org/). This increase could reflect a 'switch back to 
viable tissue' strategy with an army of chaperones which favour cell proliferation and tumour 
survival. RING finger protein 160 (Zinc finger protein 294, Rnfl60) and Triosephosphate 
isomerase (Tp il) are shown to decrease in the 72h time point. No known links are shown 
between the two proteins, Rnfl60 can be implicated in cell death and T p il involved in 
glycolysis (Orosz et al 2006,.http://www.uniprot.org/).
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Hist2h4
Hnmphl
HspyQabl
I I r f r l l r l c
Cct2
' ■
Colla2
Alb
Flna
Mem 5
Up - 24h post CA-4-P Down - 24h post CA-4-P
Figure 4. 40: iTRAQ proteomic response results using a 24h post CA-4-P Fibrosarcoma 188 
treatment. The proteins shown here depict the responses seen that were either increased or 
decreased as a result of CA-4-P administration.
In Figure 4.40 there is a strong link evident connecting Actin and Hsp90 flanked by Hbb-y and 
Heterogeneous nuclear ribonucleoprotein H (Hnrnphl).
The notable increase in 24h Hsp90 is seen in the immunohistochemical/ MALSI-MSI in Chapter 
3, where abundant appears to reach saturation point. Elevated levels of Hsp90 could be 
explained by the direct link here to Actin. The changes in Actin dynamics due to the drug could 
indeed have a positive effect on Hsp90 expression, due to the need for protection against the 
misfolding of Actin. Cct2 is also seen here to be increased as shown in the 72h (Figure 4.39) 
response, again involved in Actin re-organisation. The Histone HI increased response could be 
another indication of architectural remodelling of the tumour cells. The Haemoglobin subunit 
epsilon-Y2 (Hbb-y) is again indicative of vascular disruption with Hnrnphl having mRNA 
transcriptional influence on Hsp90.
P le d
Pdcd6ip
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Rnfl60
Histlhl
Vcp Tpil
Cct2
Prdxl
_  McmSMem 10
Tnc Hist2M
Up - 0.5h post CA-4-P Down - 0.5h post CA-4-P
Figure 4. 41: iTRAQ proteomic response results using a 0.5h post CA-4-P Fibrosarcoma 188 
treatment. The proteins in the 'Up' 0.5h time point do not have any associations here, in the 
'Down' group a strong associative link is present between McmlO and Mcm5 with a weaker 
relationship clear between Prdxl and Tpil.
The protein corresponding to Tenascin (Tnc) in Figure 4.41 is shown to be increased in the 0.5h 
time point. This protein was discussed earlier in this Chapter, said to be involved in the 
aggressiveness of breast cancer cells and the ir ability to further produce lung metastases 
(Oskarsson et al2011). The other proteins in this group have no association here, but all seem 
to be a sign of an active proliferating tissue, characteristic of this CA-4-P resistant tumour 
model.
There are 2 linkages seen in Figure 4.41, a strong associative link is present between McmlO 
and Mcm5 and a weaker relationship clear between Prdxl and Tpil.
The precise function of Protein MCM10 homolog (McmlO) is said to be unclear, it is thought to 
play a role in DNA replication and the prevention of DNA damage, but is reported to perform 
in different ways dependent on the particular organism (Ricke and Bielinsky 2004,. 
http://string-db.org/). DNA replication licensing factor MCM5 (Mcm5) is known to have similar 
functions to McmlO (Schultz et al 2009).
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There is a link between Peroxiredoxin-1 (Prdxl) and glycolytic enzyme Triosephosphate 
isomerase (Tpil). As mentioned previously in this Chapter, elevated expression of the 
PRDXlgene is said to act as a protective mechanism against H20 2 induced apoptosis (Kalinina 
et ol 2012). The level here is shown to be markedly decreased which could relate to the nature 
of the resistant tumour type, where at this early treatment time point there is no requirement 
as yet for protective mechanism against H20 2 induced apoptosis.
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McmlO Mem 5
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Figure 4. 42: iTRAQ combinations of fibrosarcoma 188 increased and decreased proteins. The 
protein response relationships in Figure 4.42 are a representation of combined responses 
throughout the time points previously discussed in the iTRAQ fibrosarcoma 188 treatment 
time points.
255
To summarise the combination of groups seen in Figure 4.42, the 'Up' combination of proteins 
similarly to those in the Fibrosarcoma 120 proteins includes increased Hb, however this is 
where the similarities cease. Tnc is now seen, a protein observed in aggressive cancers and 
along with Hsp90, Cct2 gives the notion of a more active, drug resistant class of tumour tissue.
4.5.7 Relation of MALDI-MSI to iTRAQ proteomic response
The relation of MALDI-MSI to other complementary proteomic results aims to authenticate the 
protein induction responses observed. Figure 4.40 demonstrates some of the proteins that 
have featured in the previous chapters in the format of an iTRAQ ratio response graph as seen 
in Figure 4.22a/b.
iTRAQ ratios showing response relative to the control, normalised to the average of 1.
■  Control
PLECTIN Elongation factor 1- HB alpha HB beta-1 HB beta-2 Hbepsilon-Y2
alpha 1
Protein
Figure 4. 43: Bar graph showing protein response relative to the control (113) normalised to 
an average of 1, using fibrosarcoma 188 tissue. The responses shown here depict a decreased 
expression if values are below 1 and increased expression if values are above 1 on the bar 
graph.
Figures 4.44 and 4.45 show MALDI-MSI images which are in agreement to the iTRAQ responses 
of Plectin and Hb subunit alpha seen in in Figure 4.34.
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The time course images shown here in Figure 4.44 and Figure 4.45 match the response 
exhibited in the iTRAQ results graph (Figure 4.22a/ 4.22b) and label free quantitative LC- ESI- 
MS/MS results for plectin in Chapter 3.
P lectin  m / z 9 7 7 Control/
saline
.850.5C
24 hours CA-4-P
72 hours CA-4-P
0.5 hours CA-4-P
L515.97
.181.44
250711 V I88 combined 678910 max (MEAN:977.320-977.370)
6 hours CA-4-P
SL 1/1
Figure 4. 44: MALDI-MSI multiple Fibrosarcoma 188 sample on tissue digest of Plectin at m/z 
977.
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Corresponding to Hb 
rrt/z 1819 Control/saline
72 hours CA-4-P
0.5 hours CA-4-P
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Figure 4. 45: MALDI-MSI multiple Fibrosarcoma 188 sample on tissue digest o f Hb subunit 
alpha at m /z 1416.
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4.5.8 Concluding Remarks
One of the basic challenges with iTRAQ is not only successful labelling but accurate 
interpretation and consistent peptide-protein identifications. Decisions regarding search 
thresholds greatly influence peptide/ protein yield and are important to reduce the false 
positives scenario. The alternative selection of search parameters to mine the iTRAQ data 
herein aimed to assess differences in peptide/ protein yield. The choice was made to use 
mainly fixed filtered search data to reduce data volume and ease interpretation/ validation for 
the purpose of this project. It would however be beneficial to perform further repeats of the 
iTRAQ experiments using the two tumour models to aid validation of proteins found using 
variable modification parameters. Over 1000 proteins were identified with the employment of 
variable database search parameters, validation of treatment response and elucidation of key 
effector molecules could be facilitated in conjunction with iTRAQ data processing packages.
The complimentary/confirmatory technique employed here in this chapter provided a 
powerful means of quantitatively assessing a treatment time course. A diverse approach to 
biomarker discovery could indeed aid validation of the temporal stability of a chosen 
experimental model. The more conventional gel based approaches i.e. difference gel 
electrophoresis could be employed in future work along with cleavable isotope-coded affinity 
tags involving the biotinylated labelling of cysteine residues (Wu et al 2006).
The experimental work described in the following chapter describes a novel method for 
MALDI-MSI image validation, employing an artificial construct as a standard which could be 
engineered to include any protein target of interest.
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Chapter 5
A novel multi-peptide recombinant 
standard used in MALDI-IMS-MSI
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5.1 Introduction
Many developments and innovations have been achieved in the field of mass spectrometry 
over the last decade. Technological advances to enhance both mass resolution and mass 
accuracy have been accomplished with various pioneering techniques.
Ion mobility has enabled observation of another dimension to mass spectrometry data with a 
further separation method of isobaric ions. Nano scale chromatographic instrumentation now 
provides a means to perform highly sensitive, high throughput proteomic analysis for both 
targeted and undirected investigations (Angel e ta l 2012).
It can now be said that electrospray ionization (ESI) and matrix assisted laserdesorption 
ionization (MALDI) are key techniques employable in all aspects of biomarker discovery and 
proteomic investigative analysis.
Work by Atkinson et al (2007) displayed overlaid MALDI images using BioMAp which showed 
the distribution of the bioreductive drug AQ4N and its active metabolite AQ4 in solid tumours. 
Here in this paper, standards where included in the MALDI-MSI using AQ4N, AQ4 and ATP. This 
enabled observation of the regional spatial distribution of the drug/ metabolite and whether 
any co-localisation was visible.
An article by Djidja et al (2009) studying GRP-78 within pancreatic adenocarcinoma ffpe tissue 
sections, reported the technique of using a digested recombinant standard for image 
validation. MALDI-MSI with the employment of ion mobility produced BioMap images which 
could be related to GRP-78 immunohistochemical staining.
Targeted proteomic MS methods aim to facilitate analyte identification and a novel method 
using a multi-peptide recombinant standard for the MALDI-MSI of on tissue tryptic digests is 
reported here.
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5.2 Materials and Methods
5.2.1 Peptide sequences chosen for a recombinant protein standard based on 
MALDI-MSI and conventional proteomic analysis of fibrosarcoma 120 and 
188 tissue.
The pET vector detailed here was supplied by MWG-biotech (Germany). Unless otherwise, 
stated the chemicals were purchased from Sigma Aldrich (UK).
The peptides listed in Table 9 were chosen based on the Mass spectrometric identifications 
reported in Chapters 2-4 (with the exception of EGFR and Epiregulin).
The design of the 12 peptide construct was undertaken by Dr David Smith of Sheffield Hallam 
University (UK). Organisation of the sequence was arranged to ensure thatthe charges were 
evenly spaced across the synthetic protein in order to prevent intra cellular aggregation during 
expression. The final protein had an expected mass of 16,667.26 Da.The DNA construct was 
then sub cloned into the expression vector pET23a(+) and E-coli BL21 DE3 was chosen for 
transformation.
Plasmid preparation, transformation and purification was performed by Dr David Smith of 
Sheffield Hallam University (UK).
GRP-78 1887.9 VTH AVVTVPAYFN DAQR
EGFR 1564.7 MHLPSPTDSNFYR
HSP- 90 beta 1513.7 GVVDSEDLELNISR
Plectin 1385.7 AQAELEAQELQR
1350.5 DSQDAGGFGPEDR
Haemoglobin beta chain 1302.6 VNSDEVGGEALGR
Tenascin 1219.6 ETFITGLD
Actin 1198.7 AVFPSIVGRPR
HSP-90 alpha 1168.5 LGIHEDSQNR
Vim entin 1093.5 FADLSEAANR
Epiregulin 983.4 CEVGYTGVR
Rho GTPase activating protein 2 844.5 RLTSLVR
Tag reporter A WLE HHH HHH
Table 9: Twelve peptides from target proteins chosen fo r positive identification.
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MHl PSP TDS NFY RVN SDE VGG EAL GRA VFP SIV GRP RRL 
TSL VRE TFI TGL DAP RGV VDS EDL ELN ISR LGI HED SQN 
RFA DLS EAA NRA QAE LEA QEL QRD SQD AGG FGP EDR CEV 
GYT GVR VTH AW TVP AYF NDA QRAWLE HHH HHH
Figure 5 .1 : pETBIue-1 vector and sequence used fo r the synthesis o f the recombinant protein 
standard.
MHLPSPTDSNFYRVNSDEVGGEALGRAVFPSIVGRPRRLTSLVR 
ETFITGLDAPRGWDSEDLELNISRLGIHEDSQNRFADLSEAANR 
AQAELEAQELQRDSQDAGGFGPEDRCEVGYTGVRVTHAVVTVP 
AYFNDAQRA IWlLE iHHHHHHl\  \
Tryptophan His Tag
Figure 5. 2: The final sequence of the recombinant standard.
5.2.2 Bacterial culture
Bacterium - BL21(DE3) HsdS gal (llts 857 ind l Sam7 nin5 lacUV5-T7genel)
Growth Media - Lurnia-Bertani (LB) media, Bacto-tryptone (lOg/L), Yeast extract (5g/L), NaCI 
(10g/L).
The above materials were dissolved in 900 ml deionised water and made up to 1 L. LB media 
was sterilised by autoclaving for 20 min at 15 Ib/sq inch. After cooling filter-sterilised 
carbenicillin (final concentration of 250 mg/ml) was added as appropriate.
1.5 g of bacto-agar was added to 100 ml of LB media before autoclaving. Antibiotics were 
added (carbenicillin, final concentration of 250 mg/ml), to the cooling agar and mixed
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thoroughly. 15-20 ml of molten agar mixture was added per 100 mm diameter Petri dish and 
allowed to set, before storage at 4 °C.
Cultures were inoculated from freshly transformed bacteria (Section 2.2.7) grown on agar 
plates (Section 2.2.3) or directly from existing glycerol stocks (15 % v/v glycerol). Liquid 
cultures of less than 100 ml were inoculated directly, whereas for larger scale cultures (1 L), 
overnight starter cultures of 5 ml were used for inoculation. Cultures were incubated at 37 °C 
in an orbital incubator with shaking at 200 rpm.
5.2.3 Plasmid preparation
Plasmid DNA was isolated from fresh overnight liquid cultures of E. coli BL21(DE3) with 
carbenicillin selection using a Qiagen plasmid midi kit as described in the manufacturer's 
instructions. Isolated DNA was deemed of suitable purity if the observed ratio of the 
absorbance at 260 nm (A260) to that at 280 nm (A280) w as3 1.8. An A260 of 1.0 was assumed 
equivalent to 35 mg/ml of single stranded (ss) and 50 mg/ml of double stranded (ds) DNA.
5.2.4 E. coli- transformation
Tubes containing 200 ml aliquots of competent cells were thawed at 4 °C and 20 ng or 200 ng 
of plasmid DNA were added to separate 14 ml round bottom Falcon tubes.
A negative control lacking DNA was also included. Cells /  DNA mixtures were incubated on ice 
for 30 min and then heat shocked at 42 °C for 90 sec with mixing every 10 min. Cells where 
then put on ice for 2 min and 800 ml of liquid LB media was added to each tube. These cultures 
were incubated at 37 °C for 45 min to allow the cells to express antibiotic resistance. 
Transformed cells were spread onto LB /  agar plates containing carbenecillin (250mg/ml) and 
incubated at 37 °C for 12 h.
A 20 ml starter culture was grown overnight at 37 °C in liquid LB media (Section 2.2.2) with 
antibiotic selection (carbenecillin, 250 mg/ml). This culture was used to inoculate 10 x 2 L 
flasks each containing 1 L of LB liquid media and carbenecillin (100 mg/ml). Cultures were 
grown at 37 °C with shaking until the OD600 reached 0.6, protein expression was induced with 
1 mM (IPTG). The cells were then incubated at 37 °C overnight and harvested by continuous- 
flow centrifugation at 15,000 rpm at 4 °C (Heraus Contifuge 17RS ). The cell paste was frozen 
and stored at -80 °C until required.
5.2.5 Protein Purification
The required DNA sequence was synthesised by MWG-biotech (Germany), and sub cloned into 
the bacterial expression vector pET23a(+) (Novagen). The plasmid was then transformed into
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the E-coli strain BL21 DE3 (Promega Corporation). All bacterial cultures were grown in Luria 
Broth(LB) media with 100 jag/ml ampicillin for selection. 10 ml of a 100 ml overnight starter 
culture was used to inoculate a 1 L of LB media. Cultures were grown at 37 °C with shaking 
until the OD600 reached 0.5, protein expression was induced with 1 mMisopropyl-(3-D- 
thiogalactoside (IPTG). The culture was incubated for a further 2.5 h before the bacterial cells 
where harvested by centrifugation at 10,000g for 20 min using a Sorvall RC G+.
Bacterial pellets where resuspended in binding buffer (20mM Sodium Phosphate + 20mM 
imidazole pH 7.4)3ml per lg  of cells before being lysed by sonication (lOx 20sec pulses ata 35% 
duty cycle) using a Vibra Cell VCX 750 (750 Watts). Phenylmethylsulphonyl fluoride (PMSF) (50 
|ng/ml), DNase (20 jug/ml), RNase (20 |ig/ml) to the lysate which was then cleared of insoluble 
material by centrifugation at 8,000 g for lh  using an Eppendorf5804R centrifuge. The clear 
lysate was filtered through a 0.2 jam syringe filter and load onto a 1 ml Histrap FF column (GE) 
at a flow rate of 1 ml/min. The protein was eluted over 20 column volumes using a 0 to 100% 
gradient into elution buffer (20mM Sodium Phosphate + 500mM imidazole pH 7.4). Fractions 
containing the recombinant protein where then desalted into 50mM ammonium bicarbonate 
using PD10 column (GE). Trypsin digestion was performed on a 50 |al sample of desalted 
protein using 1 j l x I  of trypsin (lm g/m l) added for lh  plus a further 1 j j . 1  of trypsin overnight.
Samples were stored at -80C until further use.
5.4.6 Digestion
Trypsin was added (lul) (20ug/ml) for lh  plus a further lu l of trypsin for overnight incubation 
37°C and 5% C02.
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5.4.7 MALDI-MSI - Chemicals and Materials
a-Cyano-4-hydroxycinnamic acid (CHCA), aniline (ANI), ethanol (EtOH), chloroform (CHCI3), 
acetonitrile (ACN), octyl-a/b-glucoside (OcGIc), tri-fluoroacetic acid (TFA), ammonium 
bicarbonate, were from Sigma- Aldrich (Dorset, UK). Modified sequence grade trypsin (20 pg 
lyophilised) was obtained from Promega (Southampton, UK).
Tissue samples
Mice were injected sub-cutaneously in the flank with a 50 pi tumour cell suspension containing 
1 x 106 cells in serum-free medium. The cells employed in this study were from the mouse 
fibrosarcoma cell line, VEGF188. This has been engineered to express only the VEGF188 
isoform. Tumours were allowed to grow to approximately 500 mm3, before CA-4-P treatment 
(a single dose of 100 mg/kg i.p). The dosage for CA-4-P are consistent with animal studies 
performed at clinically relevant doses (Galbraith 2003., Prise 2002). Mice were killed and 
tumours excised at various times after treatment. All animal work carried out documented 
herein was performed by Dr. J. E. Bluff, Tumour Microcirculation Group, University of Sheffield, 
UK. Samples were provided as frozen excised tumours and stored at -80°C.
Experimental sections for on tissue trytic digestion and MALDI-MSI
6_2 Control (no treatment, saline i.p), 8_1 (6 h after treatment with CA-4-P) and 10_1 (72 h 
after treatment with CA-4-P).
Tissue preparation
Frozen tissue sections were cut to give approximately 10pm sections, using a Leica CM3050 
cryostat (Leica Microsystems, Milton Keynes, UK) (Djidja et al 2009). The sections were then 
freeze thaw mounted on poly-lysine glass slides. Mounted slides were either used 
immediatelyor stored in an airtight tube at -80 °C for subsequent use.
In situ tissue digestion and trypsin deposition
The tissue samples were washed initially with 70% and then 90% ethanol for 1 min then left to 
dry, subsequently slides were immersed in chloroform for 10 s. Prior to matrix application,in 
situ tissue digestion was performed with trypsin solution prepared (from lyophilised trypsin) at 
20 pg/ml by addition of 50 mM ammonium bicarbonate (NH4HC03) pH 8, containing 0.5%octyl- 
a/b-glucoside (OcGIc) based on a protocol by Djidja et al (2009).
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The "Suncollect" (SunChrom, Friedrichsdorf, Germany) automatic pneumatic sprayer was used 
to spray trypsin in a series of layers. The sections for MALDI-MS and MALDI- MSI were 
incubated overnight in a humidity chamber containing H20  50%: methanol 50% overnight at 
37°C and 5% C02.
5.4.8 Methods and instrumentation 
Matrix deposition
The matrix, a-cyano-4-hydroxycinnamic acid (CHCA) and aniline in acetonitrile:water:TFA 
(1:1:0.1 by volume), was applied using either the Suncollect (at 5 mg/ml). Identical coordinate 
settings were used as with the trypsin deposition, to ensure sample uniformity. Equimolar 
amounts of aniline were added to the CHCA solution, i.e. 1 ml of 5 mg/ml CHCA solution 
contained 2.4 pi of aniline. These matrix deposition parameters were based on methods from 
Djidja et al (2009).
Instrumentation
MALDI- IMS/MS and MALDI- IMS/MSI were performed using a HDMS SYNAPT™ G2 system 
(Waters Corporation, Manchester, UK) and Mass Lynx software (Waters Corporation, UK). 
Image acquisition was performed using raster imaging mode at 100 pm spatial resolution, 
Biomap 3.7.5.5 software (http://www.maldi-msi.org/) and HDI 1.1 software was used for 
image generation. Instrument calibration was performed using standards consisting of a 
mixture of 217 polyethylene glycol (Sigma-Aldrich, Gillingham, UK) ranging between m/z 100 
to 218 3000 Da prior to MALDI-IMS-MSI analysis. HDI 1.1 parameters were set to the following; 
specificity type -  IMS MS, MS, Number of most intense peaks -1 0 0 0 , resolution -1 0 ,0 0 0 , Low 
energy intensity threshold -  50. The low intensity threshold was to allow low abundant species 
to be potentially included. HDI images were chosen for analysis based on the highlighted 
recombinant standard and m/z ratio listed in the software displaying the peak intensity and 
corresponding drift time. HDI correlation filter tool was set to R1 minimum 0.5 and R 
maximum 1.0 for peaks analysed at m/z 1350 and m/z 1032.
To enable simple visual comparison between images, BioMap data were normalised to m/z 
877/ m/z 1066 (peaks arising from the aCHCA matrix).
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5.3 Results and Discussion
5.3.1 MALDI-IMS-MS Peptide mass fingerprint of the digested recombinant 
DNA construct
The following MALDI-IMS peptide mass fingerprint is from a tryptic digest of the recombinant 
synthetic DNA construct, used as a protein standard for MALDI-IMS image peptide validation.
The PMF in Figure 5.3 displayed a clean tryptic digest spectra with chosen peptides easily 
observable showing excellent spectrum intensity.
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5.3.2 MALDI-IMS-MSI of fibrosarcoma 188 tumour tissue, Control and post 
CA-4-P treatm ent
The follow ing MALDI-MSI was acquired at 100pm resolution using various fibrosarcoma 188 
treatment time points to investigation this novel multi-peptide recombinant standard.
The images featured in Figures 5.4- 5.7, display an assortment of peptides from the digested 
construct visualised by BioMap imaging software, therefore there is no ion mobility 
component to ion selection here. Such images feature further on within this Chapter.
CHCA m /z  8 7 7 -
post 72h post CA- .
4-P ■
* (P_291D.C
170113 10 1 recomb max (MEAN :S77.015-877.055 ) SL 1/1
A c tin  m /z  1198 -  
post 72h post CA-
4-p f .  i
1-4.33
170113 10 1 recomb max div (MEAH:1198.70-1198.731 SL 1/1
T e n a s c in C m /z  H  H is tone  2A m /z
1 2 1 9 - p o s t  72h 
post CA -4-P
9 4 4 -  post 72h 
post CA -4-P
170113_ 10_ 1 _recomb_ma_div (ME*N: 1213.57-1213.70) SL 1/1 170113_10_1 _recomb_ma* (MEAN:944.535-944.575) SL 1/1
Figure 5. 4: MALDI-MSI of on tissue tryptic digests and digested recombinant standard in 72h 
treated tissue. The spatial distribution o f peptides; Actin (m/z 1198) with arrow indicating 
position of the spotted recombinant standard, Tenascin (m /z 1219), Histon 2A (m /z 944) with 
bracket showing the absence o f the standard and CHCA peak at 877 to show inverse image 
correlation.
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Figure 5.5 - The spatial distribution of peptides; Rho GTPase activating protein 2 (N- 
chimaerin m /z 844), GRP-78 (m /z 1887), HSP-90 a (m /z 1168), Histone H4 (m /z 1325) 
displaying absence o f the standard to validate recombinant signal and Plectin (m /z 1385).
CHCA m /z  1066 -  post 6h post CA -4-P
190113_8_1_recomb_ma>: (JulEAN: 1066.21-1066.33) SL 1/1
A c tin  m /z  1198 -  post 6h post CA -4-P
190113_8_1 _recomb_maK (MEAN: 1198.78-1198.90) SL 1/1
H istone H3 m /z  1032 -  post 6h post CA -4-P
Figure 5. 6: MALDI-MS images displaying peptides distribution in fibrosarcoma 188 6h 
treated tissue, employing a DNA artificial construct for image validation. The spatial 
distribution o f peptides; Actin (m/z 1198) with arrow indicating position o f the spotted 
recombinant standard, Histone H3 (m/z 1032)showing the absence of the standard and CHCA 
peak at 1066 to show inverse image correlation.
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Figure 5.7 - The spatial distribution of peptides; Actin (m/z 1198) with arrow indicating 
position of the spotted recombinant standard, GRP-78 (m/z 1887) displaying apparent low 
intensity as seen in Chapter 3 Figure 3.31 also usingFibrosarcoma 188 time course results 
post CA-4-P treatment except via LC-ESI-MS/MS., Vimentin (m/z 1093), Histone 2A (m/z 944) 
showing the absence of the standard and CHCA peak at 877 to show inverse image 
correlation.
The MALDI-MSI in Figures 5.4 - 5.7 all display good validation of the multi-peptide standard 
due to the absence in signal intensity of peptides; Histone 2A, Histone H3 and Histone H4 
which are typically high abundant within on tissue tryptic digests. These peptides were not 
chosen for the construct and therefore co-validate the MALDI images in conjunction with the 
recombinant standard.
Interestingly, there is a signal for Rho GTPase activating protein 2 in the fibrosarcoma 188 
tissue here (Figure 5.5), albeit low intensity. Some of the proteins identified by ESI-LC-MS/MS 
and iTRAQ LC-MALDI are highlighted in the tumour tissue images which again are of low 
intensity. This reiterates the apparent ion suppression discussed in previous Chapters, a factor 
typical of high abundant species in MALDI digest spectra. It has to be considered what ions of 
interest are present within the so called 'spectral grass' and in future experiments how this 
data can be amplified for analysis.
279
5.3.3 Recombinant MALDI-IMS-MSI visualised through HDI 1.1 software
HDI 1.1 imaging software is a useful tool for the processing and visualisation of MALDI-IMS-MSI.
Interactive spectra and drift time plots enable further confirmation of species of interest.
The HDI analysis that follows has the capacity for the user to preset threshold and peak picking 
parameters to facilitate the analysis of low abundant species.
The peptides Actin, HSP-90 and Histone H3 are featured in the following HDI analysis using the 
identical recombinant standard MALDI-MSI results in Figures 5.4 - 5.7.
The HDI images here are shown as superimposed images on top of the original histological 
section used for on tissue tryptic digestion and CHCA deposition.
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Figure 5.11: HSP-90 a at m/z 1168.5 after exportation to Mass Lynx software from the selected ROI in HDI 1.1.
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Figure 5.13: HDI visualisation of Actin at m/z 1198.7. The arrow indicates the ion of interest separated by drift time.
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The MALDI-IMS-MSI visualised by HDI 1.1 software in Figures 5.7 and 5.9 gives a good 
conceptual illustration of separation by drift time. Furthermore how this unique technology 
can benefit MALDI image analysis and validation due to the vast dissimilarity in the 
corresponding images for m/z 1198.7 and m/z 1198.6.
Another useful tool of the HDI software is the image correlation filter as shown in Figures 5.15 
and 5.16. After selection of a particular ion of interest, running the image correlation filter 
option displays the peaks within the spectrum that have the same spatial distribution pattern 
as the peak picked. Therefore peaks that co-exist are observable. The following HDI screen 
images are by using this option and show examples of Plectin m/z 1350 and Histone H3 m/z 
1032. The correlation peak lists generated by selecting m/z 1032 mostly contained other 
histones i.e. Histone 2A m/z 944.5, which confirms the correlation between the spatial 
distribution of other Histones. However this was unsuccessful for Plectin m/z 1350 as fellow 
Plectin peaks were not selected. This was thought to be due to the strong peptide signals from 
the spotted recombinant standard which where all listed in the peak list correlation results. In 
order to discriminate between each peak when using a recombinant standard in future work, 
the standard could be sprayed directly to the tissue when using the HDI correlation filter tool.
Teamed with the recombinant digested construct, the MALDI-IMS images reported here 
therefore propose a novel for methodology for inclusion into the MALDI-MSI workflow.
The potential for this dynamic recombinant standard is very promising and could be 
engineered to include any prospective biomarkers for both research and diagnostic screening 
applications in the clinical workplace. This concept alone is in accordance with the forward 
momentum of MS applications.
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5.3.4 Cross validation of Plectin and HSP-90 response in fibrosarcoma 188 
tissue employing a multimodal proteomic strategy.
The confirmation and validation of any scientific hypothesis is regarded a challenge, a range of 
complementary techniques could indeed affirm marked responses seen in data generated.
The changes in the levels of Plectin throughout the treatment time course displayed a high 
percentage of co-variance in the LC-ESI-MS/MS, with the same trend visible in the iTRAQ and 
immunohistochemical results of the fibrosarcoma 188 data set.
The MALDI-IMS-MSI of plectin that follow include images from the Control fibrosarcoma 188 
tissue and the 72h post CA-4-P time point with recombinant digested standard.
Plectin m /z 1385 -  
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Figure 5 .17: MALDI-MSI o f fibrosarcoma 188 on tissue tryptic digests fo r the spatial 
distribution o f Plectin at m /z 1385.
The spatial distribution of Plectin in Figure 5.17 is in good agreement with the anti-Plectin 
immunohistochemical staining featured previously in Chapter 3.
Figures 5.18 and 5.19 use Plectin and HSP-90 to show some of the cross validation that the 
techniques in this project aimed to achieve. The samples used for ESI-LC-MS/MS and iTRAQ 
were performed on different biological sample time course sets but are still in good agreement.
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Figure 5.18: MALDI-MSI and conventional proteomic techniques to asses a dose relationship in Plectin.
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Figure 5.19: MALDI-MSI and conventional proteomic techniques to asses a dose relationship in HSP-90.
5.4 Concluding Remarks
Prediction of the future requirements to progress MS experimental analysis could focus on 
further technological advancement of ion mobility for proteins. In scientific publications, much 
of the subject matter has focused on pharmaceutical and metabolomic analysis (Thelen and 
Miernyk 2012).
Future progression in the separating capacity of ion mobility could improve peptide resolution 
thus peptide identification in MALDI-MS, during the acquisition of complex tryptic digest 
samples. This could potentially result in a peptide yield comparable to high throughput 
shotgun LC chromatographic systems.
If such advancements in ion mobility separation come into fruition, this technology along with 
many other additional components could reveal numerous concealed biological molecules.
Optimisation in sample preparation, solution chemistry and enzymology could also result in 
prevention of lost proteins to minimise the suppression and spectral dominance by 
haemoglobin, structural proteins and such like (Lapthorn et al 2013).
The chart in Figure 5.20 contains points to consider when performing on tissue enzymatic 
digestion for MALDI-MSI. The issues and factors included are mainly based on personal 
experience throughout the project reported herein. Insights were also gained from an oral 
presentation by Hamzah Neil Freeman during a worshop entitled 'On-Tissue Enzymatic 
Digestion for MALDi MS Imaging' (H Freeman 2012).
The recombinant protein reported here could hold great potential for quantification 
techniques; N15 labelling is one such method for relative quantification. Labelled and 
unlabelled samples can be combined and analysed using LC-MS/MS. The only difference 
between the two samples being their mass, this then will be used to quantify the peptides 
within the sample. The latter is a novel method that could also be applied to MALDI-MSI where 
the N15 labelled recombinant could be applied as an internal standard directly to tissue 
section and used for peptide quantification analysis.
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Figure 5. 20: Issues and factors to consider when performing on tissue digestion for MALDI imaging experiments.
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Chapter 6
Conclusion and Future Work
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The aims of the study reported in this thesis were to develop and utilise mass spectrometry 
imaging techniques (MALDI-MSI), in combination with conventional proteomic methodologies, 
to investigate protein induction in vascular-targeted strategies.
Proteins thought to be involved in tumourigenesis and drug treatment resistance and were 
observed along with the responses from proteins identified via the techniques used, in this 
global analysis study.
The collaboration between the techniques used; MALDI-MSI, ESI-LC-MS/MS, LC-MALDI-MS/MS 
with iTRAQ labelling was intended to provide cross validation of the effects post 
administration of vascular disrupting agent CA-4-P.
During the initial experimental work reported in Chapter 2 using MALDI-MSI, one of the major 
challenges was the management and analysis of the large amounts of data generated. The 
latter especially applicable to ion mobility MALDI-MSI.
The gross haemorrhagic pharmacological response elicited by CA-4-P was visible by MALDI-MSI 
throughout the fibrosarcoma 120 time course. The latter encouraged the prospect that other 
proteins could potentially be observed induced via a dose response relationship.
It was hoped that the use of PCA-DA, PCA and PLSDA would reveal more subtle changes taking 
place in the tumour samples however at present these are masked by the dominance of the 
changes in the haemoglobin signals and other proteins of high abundance. MALDI-MS of the 
fibrosarcoma 120 tissue in Chapter 2 was one such example, most likely to be due to the CA-4- 
P susceptible nature of this tumour model.
The manually performed MALDI-IMS-MS/MS in Chapter 2 contained numerous signals which 
may had been post translationally modified in ways other than what was pre-selected for 
searching, thus hampering peptide identifications. Many of the MS/MS spectra studied clearly 
contained overlapping MS/MS fragmentation patterns.
The Fibrosarcoma 188, a CA-4-P resistant experimental was introduced in Chapter 3. The use 
of immunohistochemistry and label free LC-ESI-MS/MS shotgun proteomics aimed to 
compliment and aid interpretation of the MALDI-MSI data.
The experimental work carried out using LC-ESI-MS/MS and label free quantitation revealed 
many proteins connected with necrosis, cell structural reorganisation, polymerisation, tumour 
survival and stress induced molecular chaperones. The inverse correlation of structural 
proteins, haemoglobin and heat shock molecular chaperones gave the required validation and 
identification to relate these responses to those seen in MALDI-MSI.
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In addition to this the striking differences between HSp-90 and Plectin showed the distinct 
regional differences in the MALDI-MSI, immunohistochemistry and LC-ESI-MS/MS results.
The haemoglobin time course using the resistant 188 tumour model gave quite different 
results to those previously seen in the MALDI-MSI of the fibrosarcoma 120 data set. The first 
indication of the 'switch back to viability' concept was revealed. This regenerative attempt by 
the tumour could also be correlated to the HSp-90 and Plectin responses recently discussed.
The relationship pathways generated by using STRING 9.0 proteomic network software gave 
an invaluable insight into the activity of the active tumour milieu and provided a means of 
linking the identified proteins to their functional partners. Protein-protein interactions could 
be observed to help interpretation of the MALDI-MSI and LC-ESI-MS/MS response graphs.
One such pathway revealed a link incorporating Ras GTPase-activating-like protein (IQGAP1), a 
protein thought to be involved with tumour progression and metastasis. The decreased 
response from IQGAP1 over the time course suggests an inhibitory effect by CA-4P. Similar 
responses to treatment were exhibited by Plectin and Transforming growth factor-beta- 
induced protein ig-h3 (Tgfbi). Future anti-IQGAPl/ anti-Tgfbi immunohistochemistry of the 
fibrosarcoma 188 tissue could determine whether the staining of these two proteins reveals 
co-localisation with Plectin, potential implicated in the 'viable tissue switch'.
Another protein that would be expected to show an inverse correlation to Plectin/ 
IQGAPl/Tgfbi, is the protein Alpha-enolase. Increased expression of Alpha-enolase is said to be 
indicative of aggressive tumour progression as claimed of Plectin. However in these data 
Alpha-enolase showed an increase in abundance overtime whereas Plectin quite markedly 
decreases.
Over a thousand proteins were present in the LC-ESI-MS/MS results but only a fraction were 
selected by Scaffold 3 proteomic software for analysis. Conclusions were made that further 
optimisation not only during sample preparation but throughout data-dependent acquisition 
mode could prove invaluable to advance proteome analysis and coverage. This would result in 
a greater number of unique peptides per protein.
An opportunity to analyse the fibrosarcoma 120 samples with LC-ESI-MS/MS could serve to 
complete the comparison between the susceptible and resistant tumour models
iTRAQ. quantitation of both fibrosarcoma 120 and 188 samples was performed in Chapter 5. 
Similarly to the LC-ESI-MS/MS results, numerous proteins were identified and various PTM 
parameters were employed in order to reduce and affirm the relative responses observed.
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Different biological tumour samples were used compared to those of the ESI study with an aim 
to validate overall responses previously seen.
The main differences in the responses observed between the two tumour models employed 
(120 and 188) here were that of Elongation factor 1-alpha 1 and Vimentin.
In the fibrosarcoma 188 samples Elongation factor 1-alpha 1 levels are elevated throughout 
the time points relative to the control. In contrast to this, levels in the fibrosarcoma 120 iTRAQ 
results are all decreased relative to the control. It was thought that elevated levels seen in the 
fibrosarcoma 188 samples maybe due to some form of pharmacological conflict elicited by this 
CA-4-P resistant tumour model.
Vimentin levels decrease overtime in the fibrosarcoma 120 iTRAQ response results with a 
more erratic response leading to an increase seen by the 188 results.
Overall the dose relationships observed in the iTRAQ data by the proteins involved in 
haemorrhaging, structural remodelling, tumour survival and the stress response were in good 
agreement with the other techniques employed here. Further optimisation and/or more 
experimental repeats could both ascertain the relative responses seen and achieve optimum 
percentage of iTRAQ labelling.
Although a widely practised technique, it was concluded that MALDI on tissue digestion 
imaging still has many potential courses for optimisation. The chart in Chapter 5 aimed to 
summarise points and issues for consideration. The requirement for the best buffer, enzyme, 
solvent and matrix could indeed reveal numerous concealed biological molecules, essential in 
the understanding of cancer. Additionally, another consideration in the assesment of 
proteomic dose response relationships using MALDI-MSI is the effect of post translational 
modifications. The apparent disappearance of a protein within an image time course could be 
due to such alteration i.e. phosphorylation of peptides due to having a serine/ 
threonine/tyrosine present in the sequence or having undergone methylation/acetylation.
MALDI-MSI has the potential to forge a place in the workflow of clinical diagnostics. Targeted 
approaches for the observation of disease biomarkers could be visualised using MALDI-MSI 
and serve as a complimentary technique to standard clinical imaging.
The novel method reported here using a multi-peptide recombinant standard could prove an 
important diagnostic tool for the analysis of patient biopsies and tissue micro-arrays. The 
exciting prospect is the diversity of a multi-peptide recombinant standard. As mentioned
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earlier in Chapter 5, the artificial construct can be engineered to include any prospective 
biomarkers for both research and diagnostic screening applications.
This initiative could indeed further the impetus of MS applications in cancer research.
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